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Abstract
Gene therapy is increasingly critical in the treatment of different types of maladies. The
approach of gene therapy can be fundamental in dealing with many kinds of tumors, viral
infections (e.g., HIV, HSV), and disturbs linked to genetic anomalies. However, the use of
nucleic acids is limited by their ability to reach their action site—the target cell and, often,
the inside of its nucleus.
Dendrimers, on the other hand, are an interesting kind of polymers, the general synthetic
scheme of which is relatively of recent development (∼1980). Among the many possible uses
of these polymers, they revealed themselves as great nanocarriers for drugs in general, and
particularly for genetic material. Many of the properties of these molecules are directly linked
to their structure, and this in turn is critically influenced by their molecular composition.
Exploiting in silico techniques, we can reveal many informations about the atomistic structure
of dendrimers, some of which are otherwise difficult to gather.
The interactions between the carrier and its cargo, and also with all the biological systems
that are interposed between the administration and the reaching of the target (e.g., serum
proteins, lipid membranes. . . ) are of critical importance in the development of new dendrimers
for gene therapy. These interactions can be described and studied at a detail once unthinkable,
thanks to the in silico simulation of these systems.
In this thesis many different molecular simulation techniques will be employed to give
a characterization as precise as possible of the structure and interactions of new families of
dendrimers. In particular two new families of dendrimers (viologen and carbosilane) will be
structurally characterized, and their interactions with albumin and two oligodeoxynucleotide,
respectively, will be described. Then, the point of view of these interactions will be changed:
the interactions between a fifth generation triethanolamine-core poly(amidoamine) dendrimer
(G5 TEA-core PAMAM) and a sticky siRNA will be studied, varying the length and chemical
compositions of the overhangs of the siRNA.
Studying dendrimers the use of new molecular simulations techniques were deepened, and
such techniques will be employed in other parallel projects. We’ll see the steered molecular
dynamic method applied in the study of one mutation of the SMO receptor. The development
iii
of biological membranes models (that will be used in future to study the interactions of
dendrimers with such membranes) was also used to refine and better characterize the σ1
receptor 3D model, previously developed by our research group. A detailed characterization
of the putative binding site of this receptor will be given, employing this refined model.
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Sommario (italian abstract)
La terapia genica si sta rivelando sempre più importante nel trattamento di diversi tipi di
malattie. Da diversi tipi di tumori alle infezioni virali, quale ad esempio da HIV, fino anche a
malattie legate ad anomalie genetiche sono tutti disturbi in cui l’approccio della terapia genica
può rivelarsi fondamentale. L’utilizzo di acidi nucleici quali agenti terapeutici è fortemente
limitato dalla possibilità di portare queste molecole al loro sito d’azione—la cellula bersaglio
e, spesso, l’interno del nucleo di quest’ultima.
I dendrimeri d’altro canto sono un interessante tipo di polimero, di cui lo schema generale
di sintesi è relativamente recente (∼1980). Tra i diversi loro utilizzi, questi polimeri si sono
rivelati anche ottimi agenti di trasporto per farmaci, ed in particolare per materiale genetico.
Molte delle proprietà di queste molecole derivano direttamente dalla loro struttura, e questa è
influenzata criticamente dalla loro composizione. Mediante tecniche in silico è possibile avere
molte informazioni riguardo la struttura dei dendrimeri, alcune delle quali sono altrimenti
difficilmente ottenibili.
L’interazione tra il trasportatore ed il suo “carico”, come anche con tutti i diversi sistemi
biologici che si frappongono tra la somministrazione ed il raggiungimento dell’obbiettivo (ad
es. proteine seriche, membrane lipidiche. . . ) è un parametro chiave nello sviluppo di nuovi
dendrimeri per la terapia genica. Queste interazioni possono essere descritte e studiate con
un dettaglio un tempo impossibile, mediante la simulazione in silico di tali sistemi.
In questo lavoro di tesi diverse tecniche di simulazione molecolare saranno utilizzate al
fine di dare una caratterizzazione quanto più precisa possibile della struttura e delle intera-
zioni di nuove classi di dendrimeri. In particolare sarà data una descrizione strutturale di due
nuove famiglie di dendrimeri viologeni e carbosilani, e delle loro interazioni rispettivamente
con albumina e due diversi oligodeossinucleotidi. Si alternerà poi il punto di vista da cui
studiare tale interazione: sarà data una descrizione dell’interazione tra un dendrimero po-
liammidoamminico a nucleo trietanolamminico (TEA-core PAMAM) di generazione 5 e uno
sticky siRNA, al variare della lunghezza e tipo di “braccia” del siRNA.
Nello studio di dendrimeri alcune nuove tecniche di simulazione molecolare sono state
approfondite, e tali tecniche sono state utilizzate anche in altri progetti paralleli. Vedremo
v
la steered molecular dynamic applicata allo studio di una mutazione del recettore SMO. Lo
sviluppo di modelli di membrane biologiche (utile in futuro per lo studio dell’interazione di
dendrimeri con tali membrane) è stato utilizzato per perfezionare e meglio caratterizzare il
modello tridimensionale del recettore σ1, precedentemente sviluppato dal nostro gruppo di
ricerca. Una caratterizzazione dettagliata del sito di binding putativo di questo recettore sarà
descritta, usando tale perfezionato modello.
vi
“Music has no effect on research work,
but both are born of the same source
and complement each other
through the satisfaction they bestow.”
Albert Einstein
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Part I
Introduction
G4 PAMAM dendrimer in complex with a siRNA molecule.

1
Gene therapy
Cancer and genetic disorders are only the main serious diseases that can be addressed by
gene therapy. To succeed with this strategy, it’s of vital importance the creation of safe and
efficient delivery vehicles. This is necessary because the main limitation of these therapy in
vivo is the difficulty of transporting large and negatively charged molecules like nucleic acids
(NAs) inside the nucleus of a cell, obviously without degradation. Most NAs as such not only
experience transport problems across the cell membranes but also are subjected to rapid
recognition and enzymatic digestion by nucleases. Therefore, appropriate nanovectors able
to efficiently and safety allow genetic material to reach the desired population of cells, cross
their membranes, discharge the exogenous nucleic acid bringing out maximum therapeutic
effects are highly needed.
To ensure the delivering to the right target, the vehicle-NA complex must be able to
remain in the bloodstream for the needed time, avoiding the uptake by the mononuclear
phagocyte system. The complex must be able to enter the cell and, once inside the cytoplasm,
avoid lysosomal degradation.
Taking inspiration from nature, the most commonly used carriers for delivering NA nowa-
days are of viral origin. As expected these molecules can trigger immunological responses, so
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it’s needed the development of safer and cheaper alternatives.
Dendrimers currently play the leading role as premiere nanocarriers in general, and espe-
cially in gene delivery. These macromolecules provide great gene loading capacity, well-defined
physicochemical properties, and a high degree of molecular diversity that allows extensive
modification to help overcome extracellular and intracellular barriers.
1.1 Protein therapy and gene therapy
Proteins have been used for treating various kinds of diseases, an approach named protein
therapy.1, 2 The bioavailability of therapeutic proteins in the body is not surprisingly low, the
rate of hepatic and renal clearance is high, and they are unstable in vivo. The simpler answer
of increasing the doses is non available, as this operation increases also their toxic effects,
and this molecules are expensive to produce industrially.3 A simple in concept, but hard to
realize, idea is that we can efficiently insert the gene which encodes the protein, that will be
efficiently produced directly by the cells of the patient. The production of the therapeutic
protein, once the gene has correctly reached his target, is long lasting and stable in quantity.
Moreover unwanted effects produced by the systematic presence of a introduced protein are
avoided.
1.2 Classification of gene therapy
The broad name of “gene therapy” collects many different methods of using NA to treat
diseases. The common goal is to insert a NA that repair a dysfunction or interfere in the
production of malign proteins. The first use of the term is referred to the insertion of a gene
into the patient’s cells, that can alter the number and kind of proteins produced. Targeting
germ (reproductive) cells as sperm or zygotes, the gene inserted will be integrated into the
genome and can be inherited.4 This type of gene therapy can raise ethical resistance; however,
the US Food and Drug Administration (FDA) has allowed the research in the field of germ
line gene therapy in the United States of America, but does not allow federal funds to be used
for this research in people. If the targeted cells are somatic (non-reproductive), the effect will
be restricted to the individual and thus will not be inherited.
In a broader sense, is possible to transfer genetic material to cells infected by a virus, like
Human Immunodeficiency Virus (HIV), to block the transcription of genes of the virus itself,
but not interfering with the patient’s genome. Another possibility is the insertion in a cell of
small interfering RNA (siRNA), specific nucleic acid-targeting reagents for gene expression
modulation. In this methodology, the goal is not to insert a gene into the target cell genome,
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but to block the production of proteins interfering with the messenger ribonucleic acid (RNA)
produced by the cell.
1.3 HIV fight
Drug resistance and toxicity are the main obstacles for the development of new anti-viral
drugs against HIV infection.5 Moreover is a fundamental property of new drugs to be able to
reach the latently infected cells. Short oligodeoxynucleotides (ODNs) are a class of antisense
therapy drugs, promising in HIV control and also in the treatment of cancer, metabolic
disfunction and other infections.6 Two ODNs are promising in the fight against HIV: GEM91,
and SREV.
GEM91 is a 25-base long ODN that binds to the translation initiation site of the gag
gene of the HIV-1 pathogen of acquired immunodeficiency, inhibiting virus entry/reverse
transcription and reducing steady state viral RNA levels.
SREV is of sufficient length to inhibit the expression of the rev gene and halt viral
replication. The rev gene regulates the expression of HIV structural genes; rev mutants are
incapable of synthesize structural proteins gag, pol, and env.
1.3.1 Cationic carbosilane dendrimers
Cationic carbosilane dendrimers containing ammonium (or amine) groups in their molecular
architecture (and particularly at their surface) could be used as internalizing agents for
gene therapy. Muñoz-Fernandez et al. have recently shown that generation 2 (G2) cationic
carbosilane dendrimers present low toxicity and also retain and internalize genetic material as
ODNs or siRNAs. Particularly four dendrimers ( Figure 14.1 on page 97) were characterized
for their capacity of binding to different ODNs and serum proteins and, most importantly,
for their ability to transfect blood cells and inhibit HIV-1 replication in the presence of
serum.7–11 An important property of this family of dendrimers is that they can form complexes
with ODNs or even with plasmids at biocompatible doses, even at a low generation as G2.
The presence of Si−O bonds in their structure is also another important feature of these
dendrimers, by exploiting the corresponding hydrolytic process.
1.4 siRNA
RNA-based therapeutics can be classified by the mechanism of activity, and include inhibitors
of messenger RNA (mRNA) translation (antisense), the agents of RNA interference (RNAi),
catalytically active RNA molecules (ribozymes), and RNAs that bind proteins and other
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molecular ligands (aptamers). siRNAs target specifically NAs to modulate gene expression,
and are developed from the discovery of the RNAi process (late 1990s).12 The cellular process
of RNAi uses small RNAs to silence gene expression through post-transcriptional or transcrip-
tional gene silencing. Post-transcriptional gene silencing (PTGS) is regulated by translational
repression and degradation of mRNAs with imperfect complementarity, and sequence specific
cleavage of perfectly complementary mRNAs. An endogenous microRNA (miRNA) repress
translation of a perfectly complementary mRNA, while if the complementarity is limited, it
can induce its degradation.
Figure 1.1 gives a brief overview of the mechanisms involved in PTGS. In general, primary
miRNAs (pri-miRNAs) are processed by a complex into the nucleus, and then incorporated
into the pre-RNA-Induced Silencing Complex (RISC) complex.13 Similarly, the same pre-
RISC complex directs the processing of short hairpin RNA (shRNA) and double-stranded
RNA (dsRNA) molecules into ~21–23 nucleotides siRNAs.14 One strand of the siRNA is
loaded into RISC and can direct sequence-specific cleavage of mRNA.15 While protected in-
side RISC, the guide siRNA strand can be repeatedly used to target many complementary
mRNAs, needing a low concentration of siRNA molecules to achieve therapeutic knockdown
of endogenous and viral mRNA. This is a main advantage with respect to some antisense ther-
apies, which act stoichiometrically on the mRNA target. Therapeutic siRNAs and shRNAs
utilize many of the same endogenous factors of natural miRNAs, so artificial siRNA/shRNA
therapeutics may compete with the endogenous miRNA mechanisms.
A common approach to induce PTGS is the delivery of siRNA molecules to cells in
dsRNA form. This method transiently knock down gene expression after each successful drug
treatment; also, siRNAs are fragile molecules, and enough concentration of siRNA needs to
reach the target cells.
shRNA, on the contrary, are constitutively expressed from promoters and can induce
long-term gene silencing for the duration of their transcription and biogenesis. It has to be
kept in mind that an over-expression of shRNAs can saturate the natural miRNA machinery,
resulting in severe toxicity.16, 17
Similar to other RNA-based therapeutics, the efficacy of siRNA/shRNA drugs relies on
maximizing targeted delivery while minimizing off-target toxicity and degradation: functional
and effective delivery methods are crucial for this highly promising approach to therapy.
1.4.1 Sticky siRNA
Conventional artificial siRNA molecules bear (dT)2/(dT)2 overhangs at the 3´-ends, which
protect the fragments from RNase degradation and exert a beneficial effect on the RNAi
machinery.18
6
Figure 1.1: Mammalian PTGS pathway for miRNAs, shRNAs, and siRNAs.
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A further improvement was performed by Behr and co-workers, which demonstrated that
“sticky” siRNA, siRNA with complementary sequence overhangs such as (dA)n/(dT)n (n
≥ 5) exhibit better gene silencing efficiency compared to their (dT)2/(dT)2 analogous.19
This behavior was observed when polyethyleneimine (PEI) is used as the delivery agent, but
has to be noted that PEI is not efficient in delivering conventional siRNA with standard
overhangs—although is a good vector for gene delivery.20
A possible explanation of these observation could be the self-assembly of sticky siRNA
into “gene-like” long double-stranded RNA ( Figure 12.3 on page 74). This mechanism allows
stronger cooperativity and multivalency in interactions with the PEI vector.
An additional contributing factor might also be the overhangs of the sticky siRNA. Thanks
to the inherent flexibility of single strand nucleic acid fragment, the overhangs could behave
as a sort of clamps to hold the nanovector just like protruding molecular arms.
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Dendrimers
Dendrimers are polymeric macromolecules with a highly branched 3D structure, hence their
name from the greek δενδρoν (dendron, tree). The first conceptualization of such treelike
structures is dated back to 1941, by Flory21–23. He proposed that highly branched molecules
could be constructed by using a trifunctional monomer possessing two different functional
groups, A and B, where A and B can react with one another. The first successful laboratory
synthesis of something similar to this dendritic complexity did not occur until the late 1970s24,
developing the concept of repetitive growth with branching applied to the construction of low
molecular weight amines. The first article using the term “dendrimer” and describing in great
detail the preparation of poly(amidoamine) (PAMAM) dendrimers was presented in 1984 at
the First International Polymer Conference, Society of Polymer Science, Japan (SPSJ).25
In contrast to linear polymers, dendrimers have precisely controlled architecture with tailor-
made surface groups, which could be finely tuned. These pioneering works demonstrated that
polymers could be constructed possessing discrete sizes, shapes and molecular weights.
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Figure 2.1: (A) 2D representation of a dendrimer, demonstrating its different component and
(B) an example of the structure of a G2 carbosilane dendrimer; the Si atoms are the branching
points, while the central Si atom is the core.
2.1 Of structure and generation
In the simpler scenario dendrimers are produced adding to a central core molecular groups.
Repeating the process, successive layers are added and the structure can be expanded to the
required size. To schematize, a dendrimer consists of (Figure 2.1):
• an initiative central core, that can be a single atom (e.g., Si) or a simple group (e.g.,
phenyl, triethanolamine (TEA)) with at least two identical chemical functions;
• many branches, emanating from the core, constituted of repeat units, organized in a
geometrical progression that results in a series of radially concentric layers;
– the branching (or focal) units, where the dendrimer branch is divided into two or
more branches, that can also be a single atom or a simple group;
– the homostructural spatial segments between the focal points (dendrimer shell),
or between the last outer branching point and the surface (dendrimer outer shell);
• the terminal (or end, surface) groups, in other words the outer chemical moiety.
The number of focal points going from the core towards the dendrimer surface is often referred
as the generation number of that dendrimer. This is useful to discriminate between different
dendrimers of the same family (with the same core, branching, spatial and terminal groups).
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So a dendrimer having four focal points is a 5th generation dendrimer, or G5 (letter G plus
the number of generation). The smaller member of a family is the G0 dendrimer, that is the
functionalized central core.
The branched topology confers dendrimers their important properties. For example a
molecular architecture with chemically distinct interior and surface can be used to encap-
sulate and release molecules chemically incompatible with the environment external to the
dendrimer (e.g., catalysts, drugs, or chromophores).26 Another property that stems from
the chemical structure of these objects is their multivalency. The number of surface groups
increase with dendrimer generation and it’s possible to have a dense presentation of multi-
ple terminal groups on the dendrimer surface. Multivalency can be exploited as a means to
achieve concentrated payloads of drugs or imaging labels chemically grafted to the dendrimer
surface.
Similar to dendrimers are dendrons, monodisperse wedge-shaped dendrimer sections with
multiple terminal groups and a single, different, reactive function at the core. In addition to
the properties of dendrimers, this function gives an option of orthogonal reactions utilizing
the distinct reactive point at the core and surface groups. For example, one can graft dendrons
to a surface, to another dendron27 or another macromolecule.28
2.2 Of synthesis
From the first successful laboratory synthesis of a dendrimer in 1978, many attempted were
made to simplify and speed up the process. Different methods can have different advantages
in creating a dendrimer with multifunctional terminal groups for example, or in reaching an
higher generation number.
2.2.1 Divergent approach
In this approach, the core is reacted with at least twice of reagent containing at least two
protected branching sties.29 The reactions is followed by removal of the protecting groups,
leading to the formation of first generation dendrimer, and this process can be repeated
several times, until the dendrimer of the desired size is formed. This is the simplest scheme
of synthesis, and PAMAM dendrimers are often prepared by this method. One advantage of
this approach is that the end groups can be different from the inside groups, modifying the
surface of the molecule.
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or  impossible purification procedures. As a result, the need for chemistries with 
high  efficiency  is  a  crucial  requirement  for  dendrimer  synthesis. Nevertheless, 
dendrimers are still seen as tedious, time consuming and expensive materials to 
construct. 
   
 
 
Figure 3. Basic architectural components of a dendrimer. 
 
2.1.1.1 Divergent growth approach 
  The  synthesis of dendrimers using  the divergent growth  approach was 
first discussed by Vögtle6  in 1978 but  it was  the  independent work  reported by 
Tomalia7  and  Newkome8  in  1985  that  pioneered  the  strategy.  Here,  ABx 
monomers  are  added  to  a  multifunctional  core  allowing  dendrimers  to  grow 
radially  layer by  layer outwards,  resulting  in approximately doubled molecular 
weight if compared to the previous generation scaffold, Figure 4.  
 
   
 
Figure 4. Divergent growth approach. Figure 2.2: Scheme of the divergent growth appr for the synthesis of dendrimers.
2.2.2 Convergent approach
One of the main limitations of the divergent approach is that the terminal group is the same
in all dendrimer’s branches. To overcome this limit, the convergent method was proposed in
1990 by Hawker and Fréchet.30 Firstly is synthesized a focal point functionalized dendron,
that secondly will be anchored to a chore with other dendrons, to produce a hetero-dendron
dendrimer.
However a common limitation to both these methods is the difficulty to synthesize the
dendrimer in large quantities: repeated reactions are occurring while the active site needs to
be protected.
2.2.3 Other approaches
The simplest methods previously described are both boring and time-consuming, while pro-
ducing lots of waste products. Many other methods were developed in the last years, like
the “double-stage”,31 “double-exponential growth”,32 “orthogonal coupling”33 methods. The
first methods that drastically reduces the number of passages needed, and also produces less
waste products, uses the “lego” chemistry and was introduced by the group of J.P. Majoral.34
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of  benzyl  ether  dendrimers  and  resulted  in  a  strategy,  different  from  the 
divergent  growth  approach,  which  provided  easier  removal  of  by‐products. 
Using  the  convergent  growth  approach,  dendrons  are  pre‐synthesized  starting 
from the periphery and successively growing inwards by continuous activation of 
the focal point, Figure 5.  
   
 
 
Figure 5. Convergent growth approach. 
 
  The elegance in this strategy is minimization of reaction sites, since there 
are never more coupling reactions that need to occur to form the next generation 
than  the  number  of  B´‐functionalies  of  the  branching  monomer.  This  since 
dendrons of the previous generation  is coupled to one branching unit. The final 
dendrimer  is  formed when dendrons are coupled  to a multifunctional core  that 
terminates further activation. Furthermore, the large difference in molar mass and 
polarity between the fully substituted dendron/dendrimer and by‐products result 
in  facile  purifications  procedures.  However,  disadvantages  exists  since  high 
generation dendrons sometimes shields the focal point by wrapping its dendritic 
structure around it, making the coupling reaction to a multifunctional core slow 
and sometimes even impossible due to steric hindrance of bulky groups. 
  A  well  known  dendrimer  that  is  synthesized  using  the  convergent 
growth approach is the aromatic poly(benzyl ether) dendrimer,22 or Fréchet‐type 
dendrimer.  Convergent  growth  is  obtained  through  initial  Williamson 
etherification reaction between benzyl bromide and 3,5‐dihydroxy benzyl alcohol 
using  K2CO3.  The  deactivated  focal  point  of  the  first  generation  dendron  is 
activated using carbon tetra bromide (CBr4) and triphenyl phosphine (TPP) and is 
then  coupled  to  3,5‐dihydroxy  benzyl  alcohol  to  yield  the  second  generation 
deactivated dendron. This is repeated until the desired dendron size is obtained. 
Dendrimers are formed as dendrons are coupled to a multifunctional phenol core.  
Figure 2.3: Scheme of the convergent growth approach for the synthesis of dendrimers.
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2.3 Of properties
Dendritic architecture holds great potential over other carrier systems, particularly in the
field of drug delivery, because of the unique properties compared to linear polymers.
2.3.1 Shape and size
The high level of control over dendrimers’ architecture makes them an ideal carrier. The size
of dendrimers increases proportionally to the generation number, ranging from several to
tens of nanometers in diameter. The size of common dendrimers is similar to many biological
structures (as example, a G5 PAMAM dendrimer is approximately the size of human serum
albumin (HSA)—5.5 nM diameter).35
The size of a dendrimer influences also its shape; lower generation dendrimers tend to be
open and amorphous whereas higher generations can adopt a spherical conformation. This
parameter is obviously highly influenced by the internal chemical structure of the branches
and the core.
2.3.2 Monodispersity
Dendrimers are monodisperse, unlike linear polymers. This property offers the advantage of
working with a tool of well-defined and reproducible scalable size.36 The convergent method
generally produces the most isomolecular dendrimers, thanks to the purification at each step
of synthesis. Dendrimer bridging and incomplete removal of protection blocks at each of the
generation sequences may effect the degree of monodispersivity.37
2.3.3 Peripheral charge
An important property of the terminal units of a dendrimer is their charge. End groups may
possess positive, negative or neutral charges, which are vital for the resulting properties of
the final dendrimer. Cationic dendrimers (e.g., PAMAM) can form complexes with negatively
charged NAs. The positive charges facilitates also the interaction with negatively charged
biological membranes.
The polyvalency of dendrimers can also lead to their toxicities, mainly cytotoxicity and
hemolysis.38–46 One of the main effort in the development of new dendrimers is the engineering
of their surface to overcome these toxicities.
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2.3.4 End groups and toxicity
The interaction of dendrimers with many cells and cellular compartments is highly impor-
tant, possibly leading to toxic effects for the patient. The main parameter that influences
the toxicity of dendrimers is the number of terminal groups and surface charges. It has been
reported an higher, dose-dependent, toxicity with positively charged dendrimers than neu-
tral or negatively charged molecules. In light of these reports, modification of surface groups
of cationic dendrimers with neutral molecules is preferred to possibly prevent toxicity.47–50
The positive charge improve the permeability of biological membranes, facilitating the in-
tracellular delivery of bioactive molecules. At higher generation, however, the disruption of
the membrane integrity may be an outcome of the dendrimer-membrane interaction. This
lead to the leakage of important intracellular components, which finally can cause cell death,
hence the toxicity. This kind of toxicity is attached to higher generations of positively charged
dendrimers, attributed to the high charge density of these molecules.
2.3.5 Dendrimer-membrane interactions
As seen, the interaction of higher generation dendrimers having positively charged surface
groups with negatively charged biological membrane results in alteration in the membrane
and cell lysis. In a study was observed the interaction between cationic phosphorus-containing
dendrimers (CPDs, G3 and G4) and a bilayer consisting of 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) as a model lipid membrane. Presence of dendrimers was observed
to lead significant changes in the main transition enthalpy and phase transition temperature
values. Rate of alteration of thermotropic behavior was found to be concentration-dependent.
The fluidity rate of the lipid-dendrimer complexes was proportional to the dendrimer/lipid
molar ratios.49
In another study were employed G1 and G4 PAMAM dendrimers with model lipid mem-
branes. It was inferred that at this low generation PAMAM dendrimers interact electrostat-
ically with membrane by inducing aggregation of lipid vesicles without affecting integrity of
membrane significantly. This interaction was affected by two parameters; membrane fluidity
and surface pressure with preferential interaction at subphysiologic surface pressure in liquid
crystalline state, particularly evident in case of rapidly dividing cells.50
2.3.6 Biocompatibility
As stated before, the main drawback of dendrimers with cationic terminal ends is a pro-
nounced cytotoxicity at high generations. This phenomena is less observed for neutral or
negatively charged dendrimers. Fortunately the toxicity of cationic dendrimers can be over-
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came by partial or complete modification of their periphery with negatively charged or neutral
groups.38, 39, 42 While for PAMAM this toxicity increase with generation number, the pattern
is different for poly (propylene imine) (PPI) dendrimers, although both the families have ter-
minal positively charged amino groups. Development in the filed have resulted in dendrimers
with decreased toxicity or even non-toxic dendrimers in both in vitro and in vivo studies
as observed in case of neutral dendrimers like polyester, polyether and surface engineered
dendrimers (for example glycosylated, PEGylated dendrimers).40, 46
Thiagarajan et al. evaluated the in vivo toxicity of PAMAM dendrimers including effect
of surface charge and size of dendrimers on the permeability through epithelial barrier and
acute toxicity, on oral administration in CD-1 mice. The scientists investigated the positively
charged as well as anionic dendrimers for toxicity and determined the maximum tolerated dose
(MTD). The MTD for anionic dendrimers was found to be 10 folds higher than for cationic
dendrimers. For cationic dendrimers MTD was found to be in the range of 10–200 mg/kg,
while anionic dendrimers were found to be tolerable at doses as high 500 mg/kg.51 Also, they
assessed oral drug delivery aptitude of G6.5 PAMAM dendrimers via in vivo oral translocation
in CD-1 mice with evaluation of acute oral toxicity and physicochemical disposition, and
concluded that dendrimers have the potential to permeate gut epithelial barrier.52
2.3.7 Pharmacokinetics
In case of intravenous administration, macromolecules are instantly introduced into the blood
stream with restricted diffusion to the extravascular space. Subsequent elimination of these
circulating macromolecules occurs followed by distribution to particular organs for disposi-
tion. Capillary permeability, organ blood flow and nature of the macromolecules are factors
that play a major role in the specific tissue-macromolecules uptake. In case of dendrimers,
effect of surface charge on excretion profile of non-biodegradable G5 PAMAM dendrimers
was studied. As compared to cationic dendrimer, about twice as much of the uncharged den-
drimer was excreted via the urine and feces over seven days, suggesting enhanced cellular
uptake of the cationic dendrimers.53
Although enough reports are available on the pharmacokinetics of dendrimers yet sys-
tematic investigation on the in vivo fate of dendrimers is needed to certify their clinical
utility.
2.4 Of the characterization
An important result of a controlled—per step—synthesis of these molecules is a well defined
nanomeric architecture. Characterization of dendrimers is therefore a vital step in the de-
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signing and engineering of these versatile carriers. Various methods are used to differentiate
generations of dendrimers having different surface groups, like high performance liquid chro-
matography (HPLC), ultra performance liquid chromatography (UPLC), NMR, UV-visible
spectroscopy, and X-ray diffraction. The presence of tailor-made surface groups facilitates
surface modification of dendrimers, which could be further confirmed by reliable analyti-
cal methods including infrared spectroscopy (IR), NMR, AFM, X-ray photoelectron spec-
troscopy, scanning electron microscopy (SEM), transmission electron microscopy (TEM),
matrix-associated laser desorption ionization-time of flight (MALDI-TOF) mass spectrom-
etry, size exclusion chromatography, electrospray ionization-mass spectrometry (ESI-MS),
vapor phase osmometry (VPO), laser light scattering (LLS) and sodium dodecyl sulfate-poly
acrylamide gel electrophoresis (SDS-PAGE).54–59
Various methods of characterization of dendrimers along with description of respective
parameters are summarized in Table 2.1.
2.5 Of the applications
Dendrimers have many possible interaction sites, both on their surface and in their internal
layers. The potential of dendrimers as vessels or hosts for other molecules was strikingly
demonstrated by Jansen et al.60 All the three architectural components of a dendrimer (core,
internal branching units and surface groups) can be tailored to fulfill different goals.
Their multivalency structure might allow researchers to attach both targeting and drug
molecules to the same dendrimer, reducing negative side effects of medications on healthy
cells. Conjugation of poor-bioavailable drugs with dendrimer may also increase their bioavail-
ability, decrease the dose frequency, and so increase the patient compliance.
2.5.1 Therapeutic activity of dendrimers per se
Poly-lysine dendrimers against Herpes Simplex Virus (HSV) are currently under Phase II
clinical trials for their efficacy against vaginal infection. SPL7013 Gel (VivaGel®) developed
by Starpharma Pty Ltd (Melbourne, Australia) is a vaginal microbicide for the prevention
of HIV and HSV infections.61 The active ingredient of this carbopol-based aqueous gel is a
dendrimer with a divalent benzhydrylamine (BHA) core, four generations of lysine branches
with the outermost branches capped with a total of 32 naphthalene disulfonic acid groups
that impart hydrophobicity, and a high anionic charge to the dendrimer surface.62
PAMAM dendrimers were studied for antimicrobial activity against Escherichia coli, their
activity being attributed mainly to the interaction with polyanionic lipopolysaccharide.63
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Analytical method Characterized parameter
Nuclear magnetic resonance (NMR) Helps in determining chemical transformation undergone by end groups;
applicable to structural analysis and step-by-step characterization of
synthesis
Infrared and Raman spectroscopy Ascertains the chemical transformation taking place during the synthesis or
surface engineering
UV-visible spectroscopy Helps in determining the change in chemical structure and synthesis method
by detecting chromophores and auxochromes. Also used to test the purity
Fluorescence Used to characterize the structure and synthesis of dendrimers having
photochemical groups and to quantify defects occurred during the synthesis
Circular dichroism Characterization of structure of dendrimers having optical activity
Atomic force microscopy Characterization of size, shape and structure
Transmission electron microscopy (TEM),
electron paramagnetic resonance
Characterization of surface structure
X-ray diffraction Gives information about chemical composition, size and shape
X-ray photoelectron spectroscopy Gives information about chemical composition and size
Electrochemistry Gives information about the structure
Electrophoresis Assess purity and homogeneity of water-soluble dendrimers
Small-angle X-ray scattering (SAXS) Gives average radius of gyration (Rg) in solution; used for determination of
average particle size, shape, distribution, and surface-to-volume ratio
Small-angle neutron scattering (SANS) Gives average radius of gyration (Rg) in solution as well as detailed
information about the internal structure
Laser light scattering (LLS) Gives the hydrodynamic radius
Mass spectrometry (FAB-MS, ESI-MS,
FT-ICR MS, MALDI-TOF MS)
For the determination of molecular mass and some structure information
Size exclusion (or Gel permeation)
chromatography (SEC, GPC)
Gives molecular weight and size
Intrinsic viscosity Gives physical characterization and morphological structure
Differential scanning calorimetry (DSC) Gives the glass transition temperature (Tg), which is affected by the
molecular weight, entanglement and chain-end composition of polymers
Dielectric spectroscopy For studies of molecular dynamics
Table 2.1: Methods of characterization of dendrimers.
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2.5.2 Solubilization and improvement in delivery
Many drug molecules are limited in their applications by their hydrophobicity, and so poor wa-
ter solubility. Dendrimers are a promising candidate for solubilization of bioactive molecules.
The main mechanisms that are involved in this regard are micellar solubilization, ionic in-
teractions, hydrophobic interactions as well as hydrogen bonding. All of these properties
are affected by various tunable factors as dendrimer size, generation, surface groups, inter-
nal branching, and also pH and temperature. A study performed with nonsteroidal anti-
inflammatory drugs (NSAIDs) including ketoprofen, ibuprofen and diflunisal concluded that
PAMAM dendrimers are effective solubility enhancer for these drugs.64
PAMAM dendrimers with amino and hydroxyl terminal were also tested for transdermal
delivery of a model drug, indomethacin. In the in vivo pharmacokinetic and pharmacody-
namic studies with Wistar rats, a significant increase in concentration of indomethacin in
blood was observed in case of PAMAM dendrimers-mediated delivery of the molecule, in
comparison to that observed with pure drug suspension.65
Dendrimers can also increase the retention of pilocarpine within the eyes, showing a
possible application of dendrimers in ocular delivery of bioactives.66
PAMAM dendrimers of generation 2, 2.5 and 3 were assessed for pulmonary absorption
of enoxaparin, a low molecular weight heparin. The increase of the relative bioavailability
of enoxaparin was of about 40 % without any adverse effect on mucocilliary transport rate,
and without producing severe damage to lung tissues for G2 and G3 dendrimers. Negatively
charged dendrimers with carboxyl end groups (2.5G) did not influence the bioavailability, so
dendrimer with surface cationic charge can serve as promising vehicle for pulmonary delivery
of bioactives.67
2.5.3 Targeted delivery and reduction of toxicity
Fatal disorders like cancer and diseases caused by parasitic infections have a well-defined
target site, and hence is possible to design a site-specific carrier to treat these disorders.
One of the most explored examples in this context is folate conjugated dendrimer for tar-
geting anti-cancer bioactives to tumor. Since the folate receptors are over-expressed on the
surface of different types of cancer cells, hence folate conjugated dendrimers can efficiently
target anticancer bioactives to the altered cells.68, 69 In a study with the anticancer drug
methotrexate coupled with PAMAM dendrimers and folic-conjugated PAMAM dendrimers,
biodistribution of folic acid conjugated dendrimers showed three times higher accumulation
in the tumor cells after 24 h compared to those conjugated without folic acid.70
The degree of functionalization of a dendrimer can be deeper, and was obtained a PA-
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MAM dendrimer functionalized both with folic acid and fluorescein isothiocyanate (FITC),
for tumor targeting and imaging, respectively. The obtained dendrimer was linked with com-
plementary oligonucleotides for cell specific binding and internalization.71 Is clear from this
example that it is possible a multifunctional engineering of these macromolecules.
2.5.4 Diagnostic applications
Dendrimers have been used efficiently as imaging agent, in radiotherapy, as X-ray contrast
agent as well as molecular probes. Dendrimers linked to various ligands have been used for
molecular detection, separation, radiotherapy and as imaging agent. As an example, FITC
tagged PAMAM dendrimers has been investigated for determining the cellular uptake.72 The
spectrum of the diagnostic applications of dendrimers is likely to broaden in near future,
thanks to their multivalency and tunable surfaces.
Figure 2.4: Model of gene transfection process with dendrimers.
2.5.5 Gene Delivery
Dendrimers with structural flexibility and hyperbranched architectures are suitable candi-
dates for gene delivery operations owing to formation of compact complexes with DNA (den-
driplexes), attributed to enhanced flexibility of dendrimers. Figure 2.4 shows a possible route
for the use of dendrimers as delivery vectors. DNA is assembled with the dendrimers (form-
ing a complex called dendriplex), and is transported to the specific target cell via the blood
stream. Here the self-assembled complex encounter many types of proteins. Once reached its
19
target, the dendriplex should bind to the cell membrane and wait for endosomial uptake, al-
lowing internalization inside the cytoplasm. The endosome escape should happen once inside
the cell, and the DNA should be released from the dendriplex. The last critical step is the
transfer of the genetic material from the cytoplasm to the nucleus, that is still not completely
clear.73
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The broadened use of MD techniques
Molecular simulations are often an attempt to reproduce at the computer the evolution in
time of a system of interest. Many detail levels are available to the researcher, and many tools
can be used to derive different informations from the trajectories obtained. The, so to speak,
simple and plain molecular dynamic can be enriched with different techniques and, once the
method is validated, can be used, with due care, on different systems. In this thesis two main
different simulations procedures were examined for the use on dendrimers and were applied
also in other side projects on which our laboratory was involved. Primarily, I familiarized
with the simulation of lipid membrane models, to study the interaction of dendrimers with
biological membranes. These models were used to refine the σ1 receptor 3D homology model
developed by our group, and also in the study of two mutations of the smoothened receptor
(SMO). In this second work I used also the steered molecular dynamic (SMD) technique to
shed light on the mechanism of resistance to vismodegib in one of these two mutations.
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Figure 3.1: Hedgehog pathway scheme, in absence (left) and presence (right) of a PTCH
ligand.
3.1 Basal cell carcinoma and SMO receptor
Basal cell carcinoma (BCC) accounts for approximately 70% of all malignant diseases of the
skin. The incidence of BCC is strongly associated with exposure to UV radiation, and has
increased dramatically over the last 30 years.74, 75
Current treatments are mainly surgical approaches, which are the most effective strat-
egy. Radiation therapy is employed to eliminate surgical residual not otherwise curable, or
in patients that aren’t surgical candidates.76 There is although a significant rate of recur-
rence, often associated with increased aggressiveness, and also there is a poor prognosis upon
metastatic spread.
3.1.1 The Hedgehog pathway
The pathogenesis of BCC involves the Hedgehog (Hh) pathway, that plays a critical role in
embryonic development and is not active in most adult tissues. An exception are stem cells,
hair follicles, and skin cells, for which the Hh pathway is important.77 The “Hedgehog” terms
comes from the description of Drosophila melanogaster larvae, which took the appearance of
an hedgehog when the relevant gene was mutated.78 The pathway activation starts with the
Hh ligand binding to a 12-pass transmembrane receptor known as PTCH. This receptor acts
as a tumor suppressor in the absence of its ligand, inhibiting the SMO protein, a G-protein-
coupled receptor. So, it is the SMO receptor that is responsible for the propagation of the
signal, once a ligand binds to PTCH and the inhibition on SMO is released. The subsequent
mechanism is not completely clear, but certainly there is the release of the inhibition of
glioma-associated (Gli) protein, a transcription factor linked to oncogenic effects on the cells.
Gli transcriptional activation upregulate the expression of PTCH1 (negative feedback), Gli-1
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Figure 3.2: Chemical structure of vismodegib.
(positive feedback) and other factor important for the survival of the cell, involved in the cell
cycle regulation and angiogenesis, as well as antiapoptosis mechanisms.
The Hh pathway interacts also with many other pathways, and a variety of diseases
have been linked to abnormal Hh pathway signaling, including medulloblastoma, hematologic
malignancies, and other solid tumors.
As was briefly described, there are many possible alterations in the Hh pathway that
can alter it’s functionalities. Mutations that inhibit the PTCH receptor, or that constitu-
tively activate the SMO or Gli proteins can produce a ligand independent activation of the
pathway.79
3.1.2 Drug-based therapeutic approach. . .
The ingestion of corn lilies (Veratrum californicum) during the gestation of sheep was ob-
served to lead to cyclopia in the offspring. From the plant was isolated cyclopamine, a SMO
antagonists. From this molecule more potent e selective SMO antagonists were developed
and are used for a variety of cancer types, including advanced BCC cases.
A promising molecule is the orally administered SMO inhibitor GDC-0449 (vismodegib,
Figure 3.2), currently in a trial of patients with locally advanced or metastatic BCC.80, 81 At
a dose of 150 mg once daily received FDA approval in 2012 for the treatment of adults with
BCC that has recurred following surgery, or patients unsuitable for surgery or radiation.
3.1.3 . . . and drug resistance
The response to vismodegib treatment, and similar drugs, is usually dramatic. Unfortunately,
as often is the case, resistance to SMO inhibition can occur: previously responding tumors
restart their growth, or new tumors are developed by the patient. The mechanism of such
resistance is complex, and only recently we are shedding light on it. An important observation
was made comparing samples of before-treatment and vismodegib-resistant tumor of the same
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Figure 3.3: Chemical structure of (+)-pentazocine.
patient, in treatment with vismodegib. The pre-existing PTCH mutation found in the pre-
treatment tumor was still present in the resistant tumor, but a new mutation in SMO was
observed (D473). This mutation was found to affect vismodegib binding to SMO, conferring
the drug-resistance.82
3.2 The σ1 receptor
Discovered in 1976, the σ receptor was initially described as a subtype of opioid receptor.
It was identified using the compound SKF 10,047 (N-allylnormetazocine), hence the name
from the greek letter for “s”. Unfortunately, SKF 10,047 is now recognized as a non-selective
ligand, and years later it was recognized that the σ are a distinct class of receptors, widely
distributed in the central nervous system, as well as in the rest of the body.83, 84
To date, at least two subtype, σ1 and σ2, have been identified, with different pharmacology
and molecular mass.85, 86 Since their discovery, many studies have linked the σ receptors to
different human disease; from cancer to central nervous system maladies and substance abuse.
Unfortunately our knowledge on these elusive receptors is limited: we haven’t identified an
endogenous ligand (Fontanilla et al. identified as probable N,N,dimethyltryptamine87), and
also their 3D structure is unknown.
Only the σ1 receptor subtype has been cloned: a single polypeptide of 25 kDa, that shares
no sequence homology with any known mammalian protein.88 Another characteristic that
makes harder the study of this receptor is that the σ1 receptor is promiscuous in its binding;
one of the most used radioligand is (+)-pentazocine (PTZ) (Figure 3.3), with an high affinity
for the σ1 subtype and low for the σ2. A strong binder for σ2 receptor that also can select
between the two subtypes is currently missing.
The σ1 receptor is localized in the plasma membrane and subcellular membranes; this is
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Figure 3.4: Cross section of the 3D structure of the σ1 receptor embedded in a membrane
model (POPC/POPE/CHL, 2:2:1). Water oxygens are shown in light cyan, while Na+ and Cl–
ions are visible as green and purple spheres, respectively. Lipids are portrayed in different shades
of green. The σ1 receptor receptor protein is shown as red solvent accessible surface.
one of the reasons that makes it difficult to obtain a 3D crystal of this protein. Particularly,
the σ1 receptor is found in the endoplasmic reticulum, where it plays a modulatory role in
intracellular Ca2+ signaling.89 From the data available, our research group was able to built
a 3D homology model of the σ1 receptor, to date the only model of this protein (Figure 3.4).
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Part II
Material & Methods
First demonstration of the Pilot ACE computer, 1950.

The gap between the nanoscale, referred as size and time, and the macroscopic world has
been reduced exponentially in recent years, thanks to computer simulations. Using computa-
tional techniques increasingly “exact” prediction of molecular interactions and bulk proper-
ties can be obtained, the main limitation being the available computational power. Nowadays
with affordable machines it’s possible to have a precision at atomistic detail, with an accu-
rate description of physical interactions. Molecular simulations are divided mainly in two
branches: the study of equilibrium conditions (molecular mechanic (MM)) and the evolving
of the system with time (molecular dynamics (MD)). In a typical MD simulation, the atomic
trajectories of a system of N particles are generated by numerical integration of Newton’s
equation of motion, for a specific interatomic potential, with certain initial and boundary
conditions. Post-processing the trajectory, it’s possible to complement experimental data
with energetic and structural informations. The precision obtained today in simulations on
the order of hundreds of nanoseconds, thanks to modern and ad-hoc force fields, is incom-
mensurable with what was achievable ten years ago; the main effort today is to extend the
timescales of these simulations.
In this part, we will introduce and describe the molecular modeling techniques used in
this thesis. Since the basis of the computational methods used are common for all the cases
of interest, in this section we will present the common procedure, while the single exceptions
will be described in the appropriate section of the results and discussion part. The presented
procedures have been used for the publications related to this thesis.90–96
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4
Molecular simulation in life sciences
The solution of the Schrödinger equation97 should be carried out for a rigorous treatment
of interatomic interactions, using quantum calculation methods. Unfortunately, nowadays
it’s impossible to apply these techniques to biological important systems like proteins or
nucleic acids (NAs). Remembering the Born-Oppenheimer approximation98 we can sacrifice
the explicit description of electrons; every atom can be treated as a classical particle. The
description of the system in this way is dependent only on nucleuses position and velocity,
following Newton’s second law in the form
−dEpot(R)
dR
= md
2R
dt2
. At the atomistic scale the atoms of a molecule are represented as a balls, centered on their
nucleus, with a precise mass and charge. Every bonds is represented as a string with a certain
force constant and resting length.
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To precisely describe a system at the atomistic level, we need to be able to approximate
its potential energy. The definition of force field by Otto Ermer is:
“the analytical expression that describes the potential energy of the studied molecular
complex and all the parameters needed to describe it”
so, as we’ll see in more detail in the next chapter, the term force field refers to both an
interatomic potential functional form and its relative parameters. Once a system is correctly
described with a force field the reaching of the equilibrium is described by
dEpot
dri
= 0
where the potential energy is function of the coordinates ri of the atoms of the system. A
simply MM is useful to reduce bad energetic configurations that typically occur in the early
steps of the simulation, but is only a preliminary step for complex systems, since it does not
take care of the temperature, and kinetic energy
Ekin =
3
2kbT
for which we have to consider the time evolution of the system.
4.1 Molecular dynamics
MD is simply an iteration in time of MM—at each time step of the simulation the system
moves toward the equilibrium. The concept at the basis of this technique is rather simple:
given a starting configuration for the molecular system of interest, corresponding to the
position and connections of atoms, the forces that are acting on each atom are calculated,
and thus trajectories can be computed as the evolution at each time step of the system toward
the equilibrium. Differently form the MM, in MD an initial set of random velocities need to
be calculated from the starting temperature: new positions and velocities for all the atom
of the system are then calculated at each dynamic step. Obviously, the system fluctuates
toward the equilibrium maintaining the total energy (Etot) constant. If the new velocities
are too low or too high to maintain the constancy, at each step they need to be rescaled in
order to be consistent with the temperature of the system and with the Etot. For this purpose
thermostats and velocity scaling algorithms had been developed.
During a MD simulation we have to solve at each dynamic time step (across time) an
equation like
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Fi(t) = miai(t)
. It is thus necessary to calculate the force F (t), dependent on the position of each atom in
space, from the potential V (R) defined by the force field. This will be done for all the atoms
that constitute the system.
Fi = −∇Vi(R1, . . . , Rn)
Once the force is calculated—and thus the acceleration is known—by integration it is
possible to calculate the new coordinates for all the atoms of the system with the so-called
Verlet algorithm, represented by the equations
Ri(t+ ∆t) = Ri(t) + vi(t)∆t+
1
2ai(t)d∆t
2
Ri(t−∆t) = Ri(t)− vi(t)∆t+ 12ai(t)d∆t
2
, that summed together give
Ri(t+ ∆t) = 2Ri(t)−Ri(t−∆t) + ai(t)d∆t2
. With this algorithm it is possible to compute the new positions of each atom of the system
and thus to calculate the new potential energy (Epot,i), as sum of the potential energetic
contribution given by each atom, and the new velocities of all the atoms
v′i(t) =
Ri(t+ ∆t)−Ri(t−∆t)
2∆t
. From the velocities it’s possible to calculate the new values of the kinetic energy as
Ekin,i =
1
2mi[v
′
i(t)]2
and the constancy of the total energy (Etot,i) is checked.
Etot,i = Epot,i + Ekin,i
All this procedure is iteratively repeated at each time step for the whole length of MD
simulation.
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5
Force field & software
As we highlighted in previous chapter, the choice and usage of the proper force filed is
of primary importance for the reliability of the modeling. For instance, a force field that
is dedicated to general material science could give completely wrong results for proteins
simulations, or in most cases could be unable even to start the calculation. Transferability is
an indispensable property to choose a force field, indeed it allows to use a set of parameters
tested on a small number of cases and apply it in very different situations.
The studies presented in this work were all carried out exploiting amber (version 12
and 14)99, that is both a set of molecular mechanics force fields for molecular dynamics
of biomolecules—originally developed by the Peter Kollman’s group at the University of
California (San Francisco)—and a simulation package that implements these force fields.
The form of the amber force field is
V (RN) =
∑
bonds
1
2kb(l − l0)
2 +
∑
angles
ka(θ − θ0)2 +
∑
torsions
1
2Vn[1 + cos(nω − γ)] +
+
N−1∑
j=1
N∑
i=j+1
{εi,j[( σij
Rij
)12 − 2( σij
Rij
)6] + qiqj4piε0Rij
} (5.1)
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where:
• the first term represents the harmonic force (ideal spring) linked to the energy between
covalently bonded atoms. This is a good approximation near the equilibrium bond
length, but becomes increasingly poor as atoms separate. Kb is a constant, and it’s
determined by the kind of atoms involved;
• the second term is associated to the variations in the angle term respect to the ideal
value. It represents the energy due to the geometry of electron orbitals involved in
covalent bonding. Ka is a constant, and it’s determined by the kind of atoms involved;
• the third term is the potential function associated with the torsional angles. It represents
the energy for twisting a bond, and depends on bond order (e.g., double bonds) and
neighboring bonds or lone pairs of electrons;
• the last term involves the non-bonded energy between all atom pairs as decomposed
by van der Waals (vdW) (first term) and electrostatic (second term of summation)
energies.
All the constant (Kb , Ka, etc. . . ) are unknown, a priori. In order to use the force field, it
is necessary to have values for all the parameters (e.g., force constants, equilibrium bond
lengths and angles, charges. . . ). The amber software contains a fairly large number of these
parameter sets. Each parameter set has a name, and provides parameters dedicated to certain
types of molecules:
• “ff ” followed by the year of creation (i.e. 95): peptide, protein and nucleic acid param-
eters;
• GAFF (Generalized amber force field)100: parameters for small organic molecules to
facilitate simulations of drugs and small molecule ligands in complex with biomolecules
(e.g., proteins);
• GLYCAM: parameters for simulating carbohydrates;
• LIPID: parameters for simulating lipid molecules (e.g., phospholipids, cholesterol. . . ).
In all the calculations presented in this thesis, the ff12 was used for proteins and NAs
(and the updated ff14 ), being the most widely used in this studies. The lipid11101 and
lipid14SB102 force field where used to parametrize lipid molecules, while GAFF was used for
all unconventional organic molecules, as dendrimers and drugs.
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5.1 The Amber package
As said, amber refers also to the simulation package that implements these force fields. This
is a list of the modules exploited in this work:
• antechamber103 recognizes atom type and bond type, and also assigns partial charges
to unconventional molecules using the GAFF force field;
• parmchk calculates the missing parameters for small organic molecules parametrized
with GAFF;
• leap prepares files necessary to start the simulation, including adding ions and solvent
and the parametrization of the system. It’s also able to create initial structures of simple
NA fragments;
• parmed is a program used to edit parameter-files;
• sander (Simulated Annealing with NMR-Derived Energy Restraints) is the central
simulation program and provides facilities for energy minimization and molecular dy-
namics with a wide variety of options;
– pmemd (Particle mesh Ewald molecular dynamics) is a newer version of sander
by Bob Duke. It is optimized to improve the performance of the simulations in
parallel;
– pmemd.cuda104, 105 is a recent porting of many pmemd functionalities on GPU
architecture, considerably speeding up the calculations;
• nmode (Normal Mode analysis) calculates the entropy of the system;
• MMPBSA.py106 performs free energy of binding calculations on snapshots from MD
trajectories;
• cpptraj107 is an analysis program for simulation results.
In all the studies described in this thesis, missing GAFF parameters for drugs molecules were
calculated with semiempirical Austin model (AM1) calculation method with the antechamber
module, corrected with an ab initio term for bonds (BCC bond term)108–110. This calculation
method can guarantee results with precision comparable to the one of pure quantum-mechanic
calculations allowing a consistent reduction in the computational time. For dendrimers, par-
tial charges were derived using a more precise RESP methodology, using the R.E.D. server
capabilities.111–113
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The most used visualization tools were UCSF Chimera114 and VMD (visual molecular
dynamics)115 programs. With these tools is possible to analyze trajectories, sequence align-
ments, docking results, conformational changes; also, both programs are able to export high
quality images and movies.
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Pharmacophore models
Pharmacophore mapping was one of the major elements of drug design in the past, and also
today is really helpful, especially in the absence of structural data of the target receptor.
A pharmacophore may be defined as the ensemble of steric and electronic features that is
necessary to ensure the optimal supramolecular interactions with a specific biological target
structure, and to trigger its biological response. The tool was initially applied to the discovery
of lead molecules, and now is extended to lead optimization. Pharmacophores can be used
for retrieving potential leads from structural databases (lead discovery), or for designing
molecules with specific desired attributes (lead optimization), but also for assessing similarity
and diversity of molecules using pharmacophore fingerprints.
The model structures of all compounds were built using the 2D-3D sketcher of Discovery
Studio Catalyst (DS v. 2.5, Accelrys, San Diego, CA, USA); we employed an ad hoc procedure
to derive molecular conformations, instead of using those automatically generated by DS
Catalyst, for a better quality in covering the low-energy conformational space. Each molecular
structure was subjected to energy minimization using the generalized CHARMM force field
until the gradient dropped below 0.05. The minimized structures are used as the starting
point for subsequent conformational searches. A 10000 step Monte Carlo torsional sampling
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conformational search was conducted for each compound. Unique low energy conformations
within 20 kcal mol−1 of the corresponding global energy minimum were collected for each
molecule. A conformation is considered unique only when the maximum displacement of at
least one heavy atom is greater than 0.5Å, and a maximum of 250 unique conformations were
recovered for each compound. The classical conformational search was also carried out using
the Poling algorithm and the CHARMM force field as implemented in DS Catalyst program
for comparison. The “best quality” generation option was adopted to select representative
conformers over a 0–20 kcal mol−1 interval above the computed global energy minimum in
the conformational space, and again the number of conformers generated for each compound
was limited to a maximum of 250.
Based on the conformations for each compound, the DS Catalyst Hypothesis module was
used to generate three-dimensional pharmacophore models. During hypotheses generation,
the software attempts to minimize a cost function containing two main terms: the first pe-
nalizes the deviation between the estimated affinities of the training set molecules and their
experimental values, whilst the second penalizes the complexity of the hypothesis. The un-
certainty factor for each compound represents the ratio range of uncertainty in the affinity
value based on the expected statistical irregularity of biological data collection. Uncertainty
influences the first step—also called the constructive phase—of the hypothesis generating
process. An uncertainty value of 3.0 is the default factor, but sometimes if the experimental
affinities of compounds barely span the required four orders of magnitude an uncertainty of
1.1 was preferred.
The overall costs of a model consist of three cost components, namely, the weight cost,
the error cost and the configuration cost. The weight cost component is a value that increases
in a Gaussian form as this function weights in a model deviate from the ideal value of 2. The
error cost represents the difference between estimated and measured activities of the training
set. The configuration cost quantifies the entropy of the hypothesis space.
In addition the following three cost values are calculated during the generation of phar-
macophore models: the fixed cost, the total cost and the null cost. The fixed cost is the lowest
possible cost representing an hypothetical simplest model that fits all data perfectly. The
null cost represents the maximum cost of a pharmacophore with no features and estimates
activity to be the average of activity data of training set molecules. The null cost value is
equal to the maximum occurring error cost. For every pharmacophore generation 10 total
cost values and each of fixed cost and null cost values are calculated by the pharmacophore
generation protocol in the unit of bits. For a meaningful pharmacophore model, the fixed cost
should be lower and the null cost should be higher and the total cost value should be closer
to the fixed cost and away from the null cost value.
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Figure 6.1: Example of a 3D pharmacophore hypothesis: the features are portrayed as meshed
spheres, color-coded as follows: red, positive ionizable (PI); light blue, hydrophobic aromatic
(HYAr); pink, hydrophobic (HY); light green, hydrogen bond acceptor (HBA).
6.1 Validation procedures
Three validation procedures are, usually, used to determine the statistical relevance and
the validity of the proposed 3D pharmacophore models: the test set prediction method,
the CatScramble method, and the leave-one-out procedure. A larger difference between the
fixed costs and null costs than that between the fixed costs and total costs signifies the
quality of a pharmacophore model. In this work, the first procedure consisted of the collection
of further, different compounds into a test set, and in performing a regression analysis by
mapping the test set molecules onto the best pharmacophore hypothesis. The high correlation
coefficients obtained using the test set compounds revealed the good correlation between the
actual and estimated affinities and, hence, the predictive validity of the corresponding 3D
hypothesis. The CatScramble validation procedure is based on Fisher’s randomization test.
The goal of this type of validation is to check whether there is a strong correlation between the
chemical structures and the biological activity. This is done by randomizing the affinity data
associated with the training set compounds, generating pharmacophore hypotheses using the
same features and parameters employed to develop the original pharmacophore model.
The statistical significance is calculated according to the following formula:
significance = 100× [1− (1 + x/y)]
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where x is the total number of hypotheses having a total cost lower than the original (best)
hypothesis, and y is the total number of DS Catalyst Hypothesis runs (initial plus random
runs). Thus, 49 random spreadsheets (i.e., 49 DS Catalyst Hypothesis) have to be generated
to obtain a 98 % confidence level. Should any randomized data set result in the generation
of a 3D pharmacophore with similar or even better cost values, root-mean-square deviations,
and correlation coefficients, then it is likely that the original hypothesis does reflect a chance
correlation.
Finally, the leave-one-out test checks if the correlation between experimental and com-
puted affinities is heavily dependent on one particular molecule of the training set by re-
computing the pharmacophore model with the exclusion of one molecule at a time. For each
run, the hypothesis characterized by the lowest total cost was employed to predict the affinity
of the excluded compound and to estimate the new correlation coefficient.
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7
Creation of the systems
The procedure described in this section will be maintained as general as possible, since most of
the steps that will follow are common for all the cases studied. Variations from this template
will be eventually highlighted when needed.
It is worth noting that, since we want to simulate every system as close as possible to
the real conditions, it is fundamental to mimic these conditions. In these studies, the main
characters are molecules that are naturally inserted in physiological condition of the human
body, so to obtain an accurate simulation we will recreate the correct salt concentration
corresponding to the human ionic strength (NaCl 0.15 M) in a water environment (using
TIP3P116 water molecules).
As default starting files, amber is able to read a series of different formats (.pdb, .xyz,
etc.). Typically, for protein and NA structures, the format that is most widely used is the
.pdb file. The extension .pdb stats for, and is downloadable from, the Protein Data Bank
(www.rcsb.org/pdb/home/home.do)—a free on line data base containing the pdb files for the
most studied protein and organic structures. The file pdb is a simple coordinate file, often
obtained by X-ray techniques—it contains only the atom numbers and names (Figure 7.1,
columns 2 and 3), the name and number of the residues to whom these atoms belong (columns
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ATOM      1  N   SER     1       0.839 -17.879  51.844  1.00  0.00     
ATOM      2  HT1 SER     1       1.155 -17.060  52.402  1.00  0.00     
ATOM      3  HT2 SER     1       1.622 -18.556  51.748  1.00  0.00     
ATOM      4  HT3 SER     1       0.040 -18.339  52.325  1.00  0.00     
ATOM      5  CA  SER     1       0.398 -17.412  50.459  1.00  0.00     
ATOM      6  HA  SER     1       1.175 -16.786  50.045  1.00  0.00     
ATOM      7  CB  SER     1       0.172 -18.628  49.604  1.00  0.00     
ATOM      8  HB1 SER     1      -0.225 -18.330  48.610  1.00  0.00     
ATOM      9  HB2 SER     1      -0.547 -19.316  50.098  1.00  0.00     
ATOM     10  OG  SER     1       1.407 -19.287  49.434  1.00  0.00     
ATOM     11  HG1 SER     1       1.260 -19.957  48.763  1.00  0.00     
ATOM     12  C   SER     1      -0.942 -16.513  50.483  1.00  0.00     
ATOM     13  O   SER     1      -1.751 -16.674  51.382  1.00  0.00     
ATOM     14  N   GLY     2      -1.056 -15.639  49.479  1.00  0.00     
ATOM     15  HN  GLY     2      -0.333 -15.640  48.801  1.00  0.00     
ATOM     16  CA  GLY     2      -2.052 -14.652  49.161  1.00  0.00     
ATOM     17  HA1 GLY     2      -1.801 -13.758  49.712  1.00  0.00     
ATOM     18  HA2 GLY     2      -3.003 -15.041  49.494  1.00  0.00     
ATOM     19  C   GLY     2      -2.178 -14.280  47.661  1.00  0.00     
ATOM     20  O   GLY     2      -1.596 -15.036  46.877  1.00  0.00     
ATOM     21  N   GLN     3      -2.980 -13.213  47.281  1.00  0.00     
ATOM     22  HN  GLN     3      -3.378 -12.599  47.958  1.00  0.00     
ATOM     23  CA  GLN     3      -3.309 -12.897  45.874  1.00  0.00   
Figure 7.1: Extract from a pdb file.
4 and 5) and the coordinates of each atom within the structure (Figure 7.1, columns 6, 7 and
8).
7.1 System parametrization
To run a simulation both sander and pmemd need three starting files:
• a mdin file, that is a file containing all the instructions to run the calculations;
• a parameter file (usually called .prmtop), that is the parametrization file for the system.
It contains all the values of the constants to put into Equation 5.1 on page 35, taken
from the force field that was chosen for calculations;
• a coordinates file (usually called. inpcrd), that contains the coordinates of all the atoms
of the system.
The parameter and coordinate files are separated, because the same parameter files will
be used also in all the other programs in association with every MD trajectory file of the
same system. The leap module of amber is able to create this files starting from simple
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coordinates files like pdb, for standard biological molecules like proteins and NAs. Also, it can
create simple starting structures for NA fragments, needing only the sequence of nucleotides.
Unconventional molecules, like drugs and dendrimers, are not automatically recognized by
leap, so some preliminary steps are needed.
For small and simple molecules, like drugs, we used the antechamber module, that is able
to assign GAFF atom types to simple molecules starting from their coordinates files. Partial
charges were assigned with the semiempirical AM1-BCC method, and missing parameters
were added successfully with the parmchk module. Once typed with GAFF atom types, leap
is able to recognize the molecule.
7.2 Dendrimers parametrization
For dendrimers, that are quite big molecules, we used a quite different approach, conceptually
similar to what is used for protein and aminoacids. Firstly every dendrimer was divided in
smaller units: a central unit, a repeated branching unit and a terminal unit. Every unit
was parametrized alone (with small fragments of adjacent units, to recreate it’s molecular
environment), creating a library file that was given to leap to parametrize the whole molecule.
To parametrize each units we employed a procedure similar to what was used for drugs,
but we choose a more accurate RESP procedure for the partial charges assignment. Eventually
missing force field terms (for Si atom) were derived from quantum mechanical calculations
using the GAMESS software117, 118 and the paramfit module of AMBER. For QM calculations,
the MP2/HF/6-31G level of theory was used. vdW parameters for Si were taken from the
MM3 force field.119
7.3 System finalization
All the simulations were performed in explicit solvent and under periodic boundary conditions
(PBC)—the replication in the three dimension of the same box (Figure 7.2). This, from the
calculation point of view, is carried out with the condition that all the atoms and molecules
that get off the original box from one side, come in again from the opposite. In this way it is
guaranteed that the content of the periodic box is always the same. With this model we avoid
any boundary effect, during the simulation only one of the particles is represented but the
effects are reproduced over all the image particles. Each particle not only interacts with the
other particles but also with their images in neighboring boxes. Upon initial inspection such
a method would appear to be very computationally intensive requiring the evaluation of an
infinite number of interacting pairs. However, by employing a technique known as the Ewald
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Figure 7.2: Representation of PBC. The central box is replicated in the three dimensions.
sum, or its more modern equivalent the Particle Mesh Ewald (PME)120 method it is possible
to obtain the infinite electrostatics. This involves dividing the calculation up between a real
space component and a reciprocal space component. The PBC interactions still need to be
computed though, which means we have to use a cut-off. For production calculations the
ideal range is between 8 and 10Å.
Leap can parametrize pdb files already containing water and ions, as the case of pdb files
for lipid membranes built with the CHARMM-GUI interface121–123, or can create a solvated
box starting from a “dry” solute.
7.3.1 Box geometry
Basically, there are two geometries for the water box that are used for PBC in amber:
the tetrahedric and octahedric. The geometry of the water box is chosen dependently on
the geometry of the solute, in order to reduce as much as possible the presence of water
molecules in the system. In fact, if the solute presents a spherical symmetry, to choose an
octahedric water box allows a consistent saving of “useless” atoms in the system. On the
other hand, if the solute is strongly un-spherical and present a geometry that is not isotropic
(e.g., deoxyribonucleic acid (DNA) strands), the tetrahedric geometry is more indicated and
guarantees more flexibility.
Leap is able to create a box of water molecules of a given dimension and shape, with the
solute on its center. One important rule in MD is that solute molecules shouldn’t directly
interact with their self images: box dimensions so are dependent on the cut-off used for vdW
interactions and on the mobility of the solute. In all the works done we choose a box with a
radius at least of 10–15Å from the solute.
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7.3.2 Water model
The most abundant molecule in an explicit solvent simulation is water. There are many differ-
ent models of water that can be used, some more precise in recreating dipole effects—adding
more than three interaction sites—and other that sacrifice a little of precision—fixing some
parameter—speeding up calculations. In all our simulations we used the TIP3P water model.
This model uses a total of three sites for the electrostatic interactions; the partial positive
charges on the hydrogen atoms are exactly balanced by an appropriate negative charge lo-
cated on the oxygen atom. The vdW interaction between two water molecules is computed
using a Lennard-Jones (LJ) function, and no vdW interactions involving the hydrogen atoms
are calculated. The angle between the two hydrogen atoms is constant, so this water model
has a rigid geometry; this simplification decreases notably the CPU time required to simulate
the systems.
This water model needs the use of the SHAKE124 algorithm to constrain all the bonds
involving hydrogen atoms on subsequent MD simulations. This is a further approximation
that allow to speed up the calculations. Since the time step of MD should be faster than
the highest frequency motion in the system, a standard MD simulation can’t use a time step
higher than 1 fs. Constraining the highest frequency motion given by the hydrogen atoms,
we are able to enlarge the time step to 2 fs, and so sample more conformational space in the
same simulation time.
7.3.3 Ions
Once we “immersed” the complex into the water, it is necessary to add the counterions in the
system. In fact, ions can affect consistently the ability to move of the solute, influencing the
final dynamic trajectories. The correct amount of ions to add to the system depends on the
charges present in the solute and on the volume of the water box, in order to reproduce the
physiological 0.15 M [NaCl] condition. The Na+ and Cl– ions can be added by leap, and are
inserted in the system following the electrostatic potential surface of the solute. If during the
addition of counterions positional conflict (superposition) with water molecules constituting
the box are verified, the entire water molecule is substitute with the ion that is placed in the
water molecule centre of mass. Since the number of water molecules in the box is rather high,
usually almost all the counterions substitute a water molecule. This create a non-uniformity
in the box, since one single atom (Na+ or Cl–) is replacing three atoms. That is one of the
motivations why, for instance, during the first period of constant pressure and temperature
(NPT) dynamic (which allows the volume of the water box to change) the box reduces its
dimensions in order to adjust the density.
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Figure 7.3: Example of a box prepared with leap. Water is represented as transparent balls,
while Na+ and Cl– ions are portrayed in purple and green, respectively. In cyan is represented
a viologen dendrimer SASA, while human serum albumin is portrayed in red ribbon.
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7.4 Creation of mutated complexes
During the carcinogenesis process, it is very frequent to find mutations in important proteins.
That could lead to drug resistance, if the protein was a drug-target, but could also be a new
objective for the therapy. Changes in the DNA sequence can occur at the level of the chro-
mosome, in which large segments of chromosomes are altered (deleted, duplicated, inverted,
translocated to different chromosomes, or otherwise rearranged). This results in changes such
as modification of gene dosage, the complete absence of genes, or the alteration of gene se-
quence. The type of variation that occurs when entire areas of chromosomes are duplicated or
lost, called copy number variation (CNV), has especially important implications for human
disease and evolution.
While a mutation is defined as any alteration in the DNA sequence, biologists use the term
single nucleotide polymorphism (SNP) to refer to a single base pair alteration that is common
in the population. Specifically, a polymorphism is any genetic location at which at least two
different sequences are found, with each sequence present in at least 1 % of the population.
Note that the term “polymorphism” is generally used to refer to a normal variation, one that
does not directly cause disease. Moreover, the cutoff of at least 1 % prevalence for a variation
to be classified as a polymorphism is somewhat arbitrary; if the frequency is lower than this,
the allele is typically regarded as a mutation.
SNPs are important as markers, for scientists to use in an attempt to find genetic changes
that predispose individuals to certain traits, including disease. On average, SNPs are found
every 1000–2000 nucleotides in the human genome, and scientists participating in the In-
ternational HapMap Consortium have mapped millions of these alterations (International
Human Genome Sequencing Consortium, 2001).
• Point mutations:
– substitution: one base is incorrectly added during replication and replaces the pair
in the corresponding position on the complementary strand;
– insertion: one or more extra nucleotides are inserted into replicating DNA, often
resulting in a frameshift;
– deletion: one or more nucleotides is “skipped” during replication or otherwise
excised, often resulting in a frameshift.
• Chromosomal mutation:
– inversion: one region of a chromosome is flipped and reinserted;
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– deletion: a region of a chromosome is lost, resulting in the absence of all the genes
in that area;
– duplication: a region of a chromosome is repeated, resulting in an increase in
dosage from the genes in that region;
– translocation: a region from one chromosome is aberrantly attached to another
chromosome.
So, it is important to be able to build the “mutated” complex in order to compare the results
obtained between wild type (wt) and mutates complex. Particularly is important to analyze
the effects in the protein/protein or protein/drug interaction occurred following the mutation.
We will briefly describe how we introduced point mutations or amino acid deletions inside
the protein chain.
All the computational mutagenesis procedure has been carried out exploiting the Ro-
tamers module of UCSF Chimera114 . Each mutated complex was then subjected to the same
procedure as the wt protein, and a particularly long time was spent on the equilibration
phase.
For the aminoacids that have several possible rotamers (for instance aspartic and glutamic
acids), each rotamer structure is generated and minimize separately. We proceed with a
systematic conformational search for 100 different conformations for the mutated residue.
For each conformation obtained, a check of the steric bump is planned to avoid sterical clash
between all the residue in the protein and the mutant. In particular, the conformation of the
mutated residue is not taken in account if the new residue is closer than 1Å to any aminoacid
in the protein.
Looking at the final structure, while a point mutation provokes only adjustments in the
secondary structure of the protein, a consistent deletion can provoke drastic distortions and
final configurations that are considerably distant from the wt protein. Thus, it is perfectly
clear that the huger the deletion, the more consistent the simplification and the risk that the
final mutated protein conformation in the model could be completely different from the real
one.
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8
Simulation procedure
Pmemd is the module of amber that best scale up in parallel calculations, and nowadays
has almost all the capabilities of the older sander module. For all the simulations performed
we used pmemd and particularly, for calculations that are ported to the GPU version of
the software, we used the GPU implementation pmemd.cuda every time it was possible. A
standard procedure it’s described in the following sections. It is worth noting that besides
all kind of parameters that have to be monitored, a human eye on the trajectory obtained
and on the minimized structure is mandatory to quickly catch many problems and anomalies
that can arise during molecular simulations.
8.1 Minimization
It is always a good idea to minimize the structure before starting molecular dynamics, since
the default geometry that was obtained building our system could result in conflict and small
overlap with atom in different residues. A preliminary minimization is always performed, to
eliminate bad contact and to relax the system to the force field used.
We performed 500 steps of Steepest Descent, followed by 500 steps of Conjugated Gradient
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minimization with 5.0 kcal mol−1 Å−2 restraint on the solute (solvent relaxation). Another
round of 1000 steps of Conjugated Gradient minimization without restraints was done in
order to eliminate all bad contacts.
8.2 Heating and density relaxation
From the minimized structures we started the proper MD simulations. For this first phases
the time step used was 1.0 fs in order to avoid too large deviations due to the rising of
temperature and to the high fluctuations of the molecules belonging to the solvent. The
resulting structures were consequentially heated to the target temperature (usually 300 K).
In this process was applied a restraint of 5.0 kcal mol−1 Å−2 on the solute. The heating phase
took 50 ps and was performed in the canonical ensemble (constant volume and temperature
(NVT)). Langevin thermostat125 was used for temperature regulation (collision frequency =
2.0 ps−1). In the next 50 ps we maintained the restraint on the solute and switched to the
isothermal-isobaric ensemble (NPT), to equilibrate the density of the water box. Pressure
control was exerted by coupling the system to a Berendsen barostat126 (with a pressure
relaxation time 1.0 ps).
8.3 Equilibration
All the restraint were then removed (gradually in subsequent steps if needed) and the systems
were equilibrated in the NPT ensemble with a time step of 2.0 fs. This phase can take from
few to tens of nanoseconds, depending on the conformation of the solute. Some values could
be checked to verify the status of the equilibrium of the system. The quantities that usually
are checked to monitor the status of the system are temperature (T), pressure (P), volume
(V), potential energy (Epot) and the root-mean-square deviation (RMSD) of structural atoms
(for an explanation see Figure 8.1).
The first parameters monitor the energetic equilibrium, while we can say that the RMSD
represent the vibrational one. Usually our systems attained the energetic equilibrium in
correspondence of the reaching of the target temperature, in the first tens of picoseconds,
while there are strong vibrations to maintain the constancy of the energy. The vibrational
equilibrium takes much longer, from two to tens of nanoseconds for a drug-protein complex
that is quite stable. In the case of NA and dendrimer complexes we performed at least 50 ns
of equilibration, being these molecules fairly flexible. After the RMSD plot had reached a
plateaux, as seen in Figure 8.1, we started the so called production phase, from which the
data collection can be considered as reliable.
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Figure 8.1: RMSD plot example. In blue is plotted the RMSD during the equilibration phase,
while in red for the production phase.
8.3.1 Equilibrium for lipid membrane systems
Lipid membrane systems have a particular parameter that is very important to monitor their
equilibrium: the area per lipid (APL). This is the average area that a single phospholipid
occupies in an interface and is usually reported in Angstroms. Since this systems are built
assembling together hundreds of equilibrated lipid molecules, in the first 50–100 ns they have
to equilibrate their position in the membrane. As can be seen in Figure 8.2 the value of
APL decrease highly in the first 50 ns of simulation, and can take up to 100 ns to reach an
equilibrium.
Å
ns
Figure 8.2: APL plot example.
8.4 Production
The production phase is where data for further analysis is collected. If high fluctuations in
the density are not expected, it is possible to switch to the NVT ensemble to speed up the
calculations. In this case the first 2 ns of simulations were discarded, to account for possible
minimal perturbations due to the change of ensemble. Also this phase hadn’t a fixed duration;
we continued the simulation until we reached the convergence of the property on which we
were interested. Usually that translates in 10–100 ns of simulation.
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9
Binding energy analysis
The Molecular Mechanics/Poisson Boltzmann Surface Area (MM/PBSA) and the Molec-
ular Mechanics/Generalized Born Surface Area (MM/GBSA) approaches can be used to
estimate the binding free energies of a complex from snapshots obtained from an equili-
brated MD trajectory (usually 200 snapshots were used). Both methods are scripted in the
MMPBSA.py module of amber, and allow to calculate the affinity energy for the associa-
tion of two molecules, represented in Figure 9.1 (e.g., dendrimer/NA and drug/protein) or
to compare the free energy of two different solvated conformations of the same molecule.
By calculating the absolute free energy directly between the two “end points” instead
of calculating the relative free energy along a mapping coordinate, we are avoiding com-
putations on less interesting intermediate states. Nonetheless, it is clear that applications
of this methodology will have intrinsically much larger errors than free energy perturba-
tion/thermodynamic integration calculations. However, despite the larger uncertainties, we
can most of the times, calculate ∆Gbind in respectable agreement with experiment. Especially,
relative free energies of macromolecules and ligand-receptor interactions, ∆∆G, are in very
good agreement with experiment and can be computed relatively quickly.
In the simulation of these solvated states, the majority of the energy contributions would
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∆Gbind
Figure 9.1: The two states, “bound” and “unbound”, of ligand (yellow) and receptor (green)
in solution (blue).
come from solvent-solvent interactions and the fluctuations in total energy would be an
order of magnitude larger than binding energy of the two molecules of interest. Thus the
calculation would take an enormous amount of CPU time to converge. So explicit solvent
and ions are stripped from the trajectory file to hasten convergence by preventing solvent-
solvent interactions from dominating the energy terms.
9.1 The MM/PB(GB)SA thermodynamic cycle
In order to simplify, the MM/PBSA methodology127 is based on the thermodynamic cycle
reported in Figure 9.2.
From the scheme in Figure 9.2, we derive
∆Gbind,solv = ∆Gbind,vacuum + ∆Gsolv,comp − (∆Gsolv,lig + ∆Gsolv,rec) (9.1)
that could be simplified in the addition of a corrective factor to the free energy of binding
computed in vacuum
∆Gbind,solv = ∆Gbind,vacuum + ∆Gsolv (9.2)
and ∆Gsolv is computed as
∆Gsolv = ∆GPOLAR + ∆GNP (9.3)
. The electrostatic contribution ∆GPOLAR is calculated with a numerical solver for the
Poisson-Boltzmann method as implemented in the pbsa program in amber (∆GPB, MM/PBSA
) or with generalized Born methods implemented in sander (∆GGB, MM/GBSA). The hy-
drophobic contribution, ∆GNP , instead is determined using the relationship
∆GNP = γ(SASA) + β (9.4)
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∆Gbind,solv
∆Gbind,vacuum
∆Gsolv,comp∆Gsolv,rec∆Gsolv,lig
Figure 9.2: Thermodynamic cycle used to exploit ∆Gbind,vacuum, vacuum to solve ∆Gbind,solv.
where the surface tension parameter γ = 0.005 42 kcal mol−1 Å−2, β = 0.92 kcal mol−1, and
solvent accessible surface area (SASA) is obtained with the LCPO method128 implemented
within sander or the molsurf method as implemented in cpptraj.
The gas phase free energy contributions, EMM , are calculated by sander or mmpbsa_py_energy
in AMBER, according to the force field with which the topology files were created.
EMM = Eint + EvdW + Eele (9.5)
Eint = Ebond + Eangle + Etors (9.6)
∆EMM = EMM,complex − (EMM,receptor + EMM,ligand) (9.7)
∆Gbind,vacuum = ∆EMM − T∆S (9.8)
Entropy contributions to the total free energy were added as a further refinement, and
were computed performing a normal mode analysis in the gas phase using the nmode pro-
gram called by MMBPSA.py. The normal mode analysis calculations are computationally
expensive, so were performed on a subset made of 15 of the snapshots used in the calculation
of ∆Gbind.
The final result from MMBPSA.py is the value of ∆Gbind expressed as
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∆Gbind,solv = ∆EMM + ∆Gsolv − T∆Sbind = ∆Hbind − T∆Sbind (9.9)
. The more negative the value of ∆Hbind—meaning the complex has a lower energy than the
two molecules taken separately—the more stable is the complex, and thus its formation is
favored.
9.2 Single(multi) trajectory technique
MM/PB(GB)SA typically employs the approximation that the configurational space explored
by the systems is very similar between the bound and unbound states, so every snapshot for
each species is usually extracted from the same trajectory file, avoiding the need of producing
three different MD trajectories. This is the so called “single trajectory” technique, and is a
fairly good approximation for standard rigid systems like drug-protein complexes. When
flexible molecules were involved, as the case for dendrimers and NAs, we used the “multi
trajectory” techniques; one separated MD trajectory was generated for each macromolecule
involved. This choice was dictated by the necessity for effectively sampling the unbound state
of the dendrimer and the NAs, that reasonably is quite different from their bond state.
9.3 A link with experimental datas
The effectiveness of a certain inhibitor drug is defined by the half maximal inhibitory con-
centration (IC50) that is defined as the amount of drug to put into the solution in order to
inhibit the activity of the specific biological target of the 50. The correspondence between
IC50 and the free energy of binding is defined as
∆Gbind = −RTln(IC50) (9.10)
. Thus, it is possible to compare the ∆Gbind obtained from our MD simulations with exper-
imental values. If the values coming from our simulations are consistent with experimental
measurement, the procedures and the molecular models used for the cases faced in this thesis
can be considered reliable.
9.4 Per residue decomposition analysis
While the MM/PBSA approach usually gives results in better agreement with the experi-
ments, and thus was used for all the calculations of ∆Gbind in this thesis, the MM/GBSA
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have the capability to make a per residue binding free energy decomposition.
∆H =
i=N∑
i=1
∆Hi (9.11)
where N is the total number of residues of the complex. This can be used to evaluate the role
of each residue in the stabilization of a receptor-ligand complex.
9.4.1 Protein-ligand complexes
The more negative is the value of ∆Hi, the stronger is the favorable action of the ith residue
in stabilizing the complex. This could help to identify a particular residue important for
the binding site, or to understand a “domino effect” that rearrange all the structure of the
complex.
Also, is important to evaluate the ∆∆Hi, the difference in ∆Hi between a mutated and
a wild type protein. This value can help understand if a residue tends to stabilize more the
binding in the native conformation of the protein than in the presence of a given mutation
along the amino acid chain.
This energetic analysis can be rather useful because it is able to provide unique details in
the binding between protein and inhibitor drugs. Such details are impossible to obtain with
other experimental techniques, and evidence this approach and the modeling in general as
an extremely powerful instrument for the exploration and the analysis of the potentiality of
different small inhibitor molecules.
9.4.2 Dendrimer-target complexes
One of the consequences of subdividing each dendrimer in smaller residues is that we can
apply the per residue energy decomposition to identify the branches of the dendrimer that
are effectively contributing to the binding. This was done summing together the values of
∆Hi for residues that are in the same branch, yielding the effective free energy of binding
∆Gbind,eff , the contribution to binding yielded by the dendrimer branches in constant and
productive contact with the nucleic acid fragment. The number of branches effectively con-
tributing to the binding (Neff ) was important to normalize the values of ∆Gbind,eff obtained
with different dendrimers of the same family. With this technique we were able to identify
a critical molecular design parameter for carbosilane dendrimers: the normalized effective
binding energy ∆Gbind,eff/Neff , i.e., the performance of each active individual dendrimer
branch directly involved in a binding interaction.
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10
Steered Molecular Dynamics
In steered molecular dynamic (SMD) simulations we increment or decrement the distance
between the center of mass (COM) of one molecule (the ligand) and the COM of another
molecule (or a part of another molecule, i.e., the binding site); all the atoms can adjust to
the forced change in the structure so that conformations may be sampled along a particular
pathway. In theory the unbinding/binding should happen spontaneously during the simu-
lation, but its kinetic is often well beyond the maximum length of a simulation. Thus, we
accelerate the process in order to understand how the systems energy changes.
10.1 SMD for binding studies
In the discovery and study of safe and effective drugs and nanocarriers, it is important to
determine the binding affinity of the studied molecule with its targets. A good affinity allow
the use of a drug at low doses, limiting it’s side effects and reaching only the target, and is
important for a nanocarrier to take around the body its cargo.
As explained in the previous chapter, the most used technique employs the MM/PBSA
approach. This methods take into consideration only the end-points of the binding process.
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However a direct calculation of the change in free energy in some complexes is difficult for
the intrinsic flexibility and natural change in conformation upon binding. An alternative
approach is to use SMD to compute the force that is required to separate the two molecules
in a complex.129, 130
By integrating the force used over time, a generalized work (W ) can be computed and
used to calculate ∆G using the so called Jarzynski relationship131–133
exp(−∆G/kBT ) = 〈exp(−W/kBT )〉A (10.1)
where kB is the Boltzmann constant, T is the temperature of the system at the equilibrium
state A (bound complex). The bracket means that a configurational average is to be carried
out. In practice we will run 10 simulations and average them to obtain the effect of the
bracket.
10.2 SMD for unbinding studies
Another use of SMD is for the study of the kinetic of binding. Two different complexes can
have a similar, low, ∆Gbind, thus the bound state is preferred than the unbound state from
the energetical point of view. But sometimes a drug can have some difficulties in reaching
its binding site in a mutated protein, although once inside the binding pocket the complex
is stable.
Using SMD to force the entrance of the drug in its binding pocket we were able to observe
this process, and this is another tool in the study of drug resistance.
10.3 SMD as a “docking” substitute
One of the problem in the creation of complexes with dendrimers is the laking of ad-hoc
docking methods. The same is true if we want to put together two different proteins to form
a dimer. Also in this situation SMD can be really helpful.
In our works with dendrimers and NAs we started with an equilibrated structure of the two
macromolecules about 50Å away from each others. Next, the dendrimer was pulled close to its
target using a force of 50 kcal mol−1 Å−2 and a velocity of 5Å ns−1. The phosphorous atoms of
the NA were forced in their position by applying a weak restraint of 0.5 kcal mol−1 Å−2. This
allowed avoiding substantial deformation of the NA during the dendrimer pulling process.
Once the dendrimer reached the proximity of the NA (i.e., a distance between the dendrimer
and the NA COMs of approximately 12Å), this restraint was released and both molecules
were allowed to move to reach the final complex configuration. With this procedure the
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dendrimer was able to adapt its conformation approaching the NA, and that was impossible
with other methods.
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11
Structural analysis
The structural analysis of all the MD trajectories obtained was performed using the cpptraj
program of amber. All the automatizations and further calculations were carried out using
in-house developed python scripts.
11.1 Root-mean-square deviation
The root-mean-square deviation (RMSD) is defined as
RMSD =
√√√√ 1
N
i=N∑
i=1
δ2i (11.1)
where δ is the distance between N pairs of equivalent heavy atoms from a reference starting
position.
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11.2 Radius of gyration
A parameter that provides a quantitative characterization of the size of a molecule is the
radius of gyration Rg. For a given molecule of N atoms, the mean-square radius of gyration
is defined as 〈
R2g
〉
=
( 1
M
)〈[ N∑
i=1
mi[ri −R]2
]〉
(11.2)
where R is the center of mass of the molecule, ri and mi are the position and mass of the ith
atom, and M is the total mass of the molecule.
11.3 Shape tensor
The shape tensor S describe the molecular mass distribution as
S =
N∑
i=1
mi[(rjri)13 − (rjrTi )] (11.3)
where ri is the position of the ithatom with respect to the center of mass of the molecule
and 13 is the unitary matrix of dimension 3. Transformation to the principal axis system
diagonalizes S (S = diag(Ix, Iy, Iz)), and the three eigenvalues of S (Iz, Iy, and Ix, sorted in
the descending order) are the principal moments of inertia of the equivalent ellipsoid.
The first invariant of S gives the squared radius of gyration (Tr S = Ix + Iy + Iz = R2g)
while the second invariant shape descriptor, or the asphericity δ, reflects the deviation from
a spherical shape of a molecular conformation:134
δ = 1− 3 〈I2〉〈I21 〉
(11.4)
where I1 and I2 refer to the first and second invariants of the shape tensor:
I1 = Ix + Iy + Iz (11.5)
I2 = IxIy + IyIz + IxIz (11.6)
11.4 Monomer density distribution
The average radial monomer density ρ(r) can provide information about the internal structure
of the simulated molecule. ρ(r) can be defined as the number of atoms whose center of mass
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is located within a spherical shell of radius r and thickness ∆r. Accordingly, integration over
r yields the total number of atoms N(r) as
N(r) = 4pi
R∫
0
r2ρ(r)dr (11.7)
. For dendrimers we used the center of mass of the whole molecule as the reference point.
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σ1 receptor in a lipid membrane model.

12
Impact of siRNA overhangs for dendrimer-mediated
siRNA delivery and gene silencing1
Small interfering RNA (siRNA) are increasingly interesting therapeutics, but as all the nucleic
acids (NAs) they need an efficient nanocarrier to reach their target. Dendrimers are among
the most promising nanovectors developed in the last years, and Ling Peng et al. recently pro-
posed a structurally flexible fifth-generation triethanolamine (TEA)-core poly(amidoamine)
(PAMAM) dendrimer (G5) as an effective nanocarrier for delivery of sticky siRNA bearing
long complementary sequence overhangs (dA)n/(dT)n (n = 5 or 7).135, 136 The impact of
different siRNA overhangs on the delivery potency and the underlying mechanism of inter-
action between the G5 dendrimer and siRNA molecules bearing either complementary or
noncomplementary sequence overhangs (of different length and composition) were the main
objectives of the work presented in this chapter. With a computational approach, combined
with experimental datas, we showed that complementary overhangs offer the best gene si-
lencing profile, through the formation of concatemers—supramolecular structures resulting
from synergistic and cooperative binding via (dA)n/(dT)n (n = 5 or 7) bridges.
1The matherial presented in this chapter was published at: Posocco, P., Liu, X., Laurini, E., Marson, D.,
Chen, C., Liu, C., et al. (2013). Molecular Pharmaceutics, 10(8), 3262−3273. doi:10.1021/mp400329g
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Figure 12.1: siRNA molecules studied, bearing overhangs of different lengths and sequences.
An interesting observation is that also siRNA with longer but noncomplementary over-
hangs [(dX)n/(dX)n, with X = T or A and n = 5 or 7] have a considerably higher gene
silencing potency than normal siRNA with only 2-thymine long overhangs, although they
are less effective than their complementary counterparts. Flexibility of the overhangs is a
fundamental property of these systems, highly impacting siRNA delivery performance, and
than gene silencing. The overhangs behave as a sort of clamps that hold the nanovectors.
12.1 Design of siRNA molecules with different overhangs
To test whether the interaction of the siRNA overhangs with dendrimeric vectors effec-
tively contributes toward improving siRNA delivery (in addition to self-assembly of sticky
siRNA), we designed siRNA molecules carrying noncomplementary sequence overhangs, com-
plementary sequence overhangs, and conventional (dT)2 overhangs (Figure 12.1). All siRNA
molecules share common sequences that target the heat shock protein 27 (Hsp27) and the
translationally controlled tumor protein (TCTP), respectively. Hsp27 is a molecular chaper-
one, which plays an important role in resistance to anticancer drugs and has been recently
considered as a novel target for treating drug-resistant prostate tumors and other cancer
forms.137, 138 TCTP, a highly conserved protein present in all eukaryotic organisms, has been
lately reported to regulate cell survival in many human cancers; accordingly, it constitutes
an interesting target in cancer therapy, especially in breast and prostate malignancies.139, 140
While the classical siRNA bear (dT)2 overhangs, our sticky siRNA feature complementary
sequence overhangs of two different lengths: (dA)5/(dT)5 and (dA)7/(dT)7. The correspond-
ing siRNA with noncomplementary sequence overhangs were decorated with (dT)5/(dT)5,
(dA)5/(dA)5, (dT)7/(dT)7, and (dA)7/(dA)7, respectively (Figure 12.1). Accordingly, in what
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Figure 12.2: Dendrimer G5-mediated siRNA delivery and gene silencing of Hsp27 and TCTP in
human prostate cancer PC-3 cells (A and E) and C4-2 cells (B and F) as well as in human breast
cancer MDA-MB-231 cells (C) and MCF-7 cells (D) with siRNA carrying various overhangs at
a N/P ratio of 10, respectively. The siRNA dose-dependent silencing of TCTP in PC-3 cells
(G) and C4-2 cells (H) and of Hsp27 in MCF-7 cells (I). The vinculin protein was used as a
reference protein. All of the transfections were done in triplicate. *, **, and *** differ from
control (p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001, respectively) by Student’s t test.
follows all of these siRNA molecules are denoted as siRNA(T2/T2) and, with n = 5 or 7,
siRNA(An/Tn), siRNA(Tn/Tn), siRNA(An/An), for the sake of simplicity and convenience.
It is to note here that we chose not to work with siRNA molecules bearing even longer
overhangs for fear of such long oligonucleotides inducing undesired immune responses.141
12.2 Gene silencing using siRNA with different overhangs
The ability of our designed siRNA molecules to down-regulate Hsp27 and TCTP was assessed
in human prostate cancer PC-3 and C4-2 cells, and in human breast cancer MDA-MB-231
and MCF-7 cells, respectively.142, 143 The fifth generation TEA-core PAMAM dendrimer (G5)
was chosen as nanovector for these siRNA molecules given its proven capacity to effectively
deliver sticky siRNA in lieu of normal siRNA.136 As expected, no gene silencing was observed
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Figure 12.3: Self-assembly of sticky siRNA into “gene-like” longer double-stranded RNA.
with normal siRNA delivered by G5, while gene silencing up to 90 % was attained with
siRNA molecules bearing complementary sequence overhangs of both lengths [(dA)5/(dT)5
and (dA)7/(dT)7, Figure 12.2]. This result is in agreement with our previous observations136
and can be mainly ascribed to the sticky overhangs (dA)n/(dT)n (n = 5 or 7): these comple-
mentary single-strand sequences induce siRNA self-assembly into “gene-like” longer double-
stranded RNA (Figure 12.3), providing significantly enhanced cooperativity and multivalency
when binding toward the nanovectors. This, in turn, endows a low generation dendrimer such
as G5 with greater delivery capacity.
What was surprising was the considerably potent gene silencing (up to 70 %) observed
with siRNA bearing noncomplementary overhangs (dT)5/(dT)5, (dA)5/(dA)5, (dT)7/(dT)7,
and (dA)7/(dA)7. Namely, siRNA with noncomplementary overhangs could also substantially
enhance gene silencing compared to normal siRNA, although they remained less effective than
their complementary sticky counterparts (Figure 12.2), whereas no activity was observed with
any scramble siRNA molecules. The observed gene silencing potency depended on the length
and sequence of the overhangs as well as the concentration of siRNA. Compared with conven-
tional siRNA bearing only the two nucleotide-long overhangs (dT)2/(dT)2, siRNA molecules
with longer overhangs (n > 2) were much more effective in inducing gene silencing. In ad-
dition, siRNA with (dT)n/(dT)n overhangs were slightly more efficient than those bearing
(dA)n/(dA)n overhangs of equal length (n = 5 or 7).
12.3 Nanoscale and stable siRNA/dendrimer complexes
Spurred on by these results, we next endeavored to investigate the reasons why siRNA
molecules with longer overhangs of both complementary and noncomplementary sequences
were more efficient in inducing gene silencing than the standard siRNA with (dT)2/(dT)2
overhangs. As the formation of stable complexes between siRNA and delivery nanovectors is
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size [nm] polydispersity [PDI] zeta potential [mV]
siRNA(A5/T5)/G5 108 0.18 +35
siRNA(T5/T5)/G5 124 0.12 +42
siRNA(A5/A5)/G5 118 0.14 +43
siRNA(A7/T7)/G5 117 0.19 +44
siRNA(T7/T7)/G5 114 0.18 +43
siRNA(A7/A7)/G5 124 0.12 +33
Table 12.1: DLS Measurement of size and zeta potential of the dendrimer G5 complexes with
various siRNA molecules bearing different overhangs
one of the most important prerequisites for effective cell uptake and delivery of siRNA, we
first examined the size and size distribution of various siRNA/G5 dendrimer complexes by
dynamic light scattering (DLS). Also, the surface zeta potential of complexes was assessed
by laser Doppler microelectrophoresis, a technique that derives the value of a surface zeta
potential based on electro-osmosis measurements close to the sample surface. For the clas-
sical siRNA with (dT)2/(dT)2 overhangs, its complexes with G5 generated nanoparticles of
various sizes ranging from 7 to 400 nm with large polydispersity, implying that G5 could not
form stable neither uniform nanoparticles with these siRNA. With siRNA harboring both
complementary and noncomplementary long overhangs, however, G5 readily formed stable
and uniform nanoparticles with an average size of 100 nm in diameter at N/P = 10 and a
polydispersity index around 0.15 (Table 12.1). Moreover, zeta-potential measurements gave
positive values for the dendrimer complexes with siRNA bearing longer overhangs (n = 5 or 7)
(Table 12.1), implying that these siRNA/G5 nanoparticles are stable colloids. A size around
100 nm and a positive surface potential are two requisites for successful delivery of nanopar-
ticles into cells. Hence, these data for siRNA/dendrimer complexes further corroborate our
experimental observation that G5 permits effective gene silencing with siRNA bearing longer
overhangs, whether complementary or not, whereas no significant gene silencing is achieved
with conventional siRNA/G5 complexes.
12.4 Insight into siRNA binding to G5 by molecular simula-
tions
To understand if and how different siRNA overhangs could impact dendrimer-mediated de-
livery, we next performed molecular dynamics (MD) simulations to assess the binding of
the tested siRNA molecules to the G5 dendrimer. We commenced our in silico study by
considering a situation in which monomeric siRNA form a complex with their dendrimeric
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Figure 12.4: Total effective free energy (∆Geffbind = ∆H
eff
bind − T∆Seffbind), enthalpic (∆Heffbind),
and entropic (T∆Seffbind) components of binding of the siRNA molecules with different overhangs
toward the G5 dendrimer as well as effective positive charges (Neff ) with G5 involved in siRNA
binding.
nanocarrier. The relevant results are shown in Figure 12.4. According to our calculations,
binding of siRNA toward the G5 dendrimer is affected both by the nature and length of the
siRNA overhangs in the following interesting manner:
• for the two homologous siRNA series, the siRNA with (dA)n/(dA)n overhangs are
characterized by the most favorable ∆Gbind values, followed by the complementary
overhangs (dA)n/(dT)n and, last, by the siRNA bearing (dT)n/(dT)n overhangs which
show the lowest affinity for the G5 dendrimer;
• longer overhangs (n = 7) are more beneficial to dendrimer binding;
• the lowest affinity value for the G5 dendrimer pertains to the siRNA carrying the
shortest overhangs (dT)2/(dT)2.
For a more rigorous and thorough understanding of the interaction between the different
siRNAs and G5, we then assessed the effective free energy of binding (∆Geffbind), that is, the
contribution to binding yielded by the dendrimer branches in constant and productive in-
teraction with the NA fragment. To estimate ∆Geffbind for each siRNA/G5 complex, all G5
branches involved in nucleic acid binding (Neff ) were precisely identified, and their individ-
ual contribution toward the overall binding energy estimated by a per-residue free energy
decomposition technique.
The cumulative results of this analysis are reported in Figure 12.4, showing the values
of Neff , the effective total free energy of binding ∆Geffbind, and its enthalpic ∆H
eff
bind and
entropic T∆Seffbind components for all complexes. The first important finding from this study
76
Figure 12.5: Selected equilibrated MD snapshots of the complexes between the G5 dendrimer
and the siRNA molecules with 5-nucleotide long (upper panel) and 7-nucleotide long (lower
panel) overhangs. These overhangs are respectively, (a) (dA)5/(dA)5; (b) (dT)5/(dT)5; (c)
(dA)5/(dT)5; (d) (dA)7/(dA)7; (e) (dT)7/(dT)7, and (f) (dA)7/(dT)7. In the panels, the den-
drimer is depicted as forest green sticks, the terminal charged amine groups as light green
sticks-and-balls, the siRNA as an orange ribbon, and the two overhangs (dA)n and (dT)n are
highlighted in red and navy blue, respectively. Some Cl– and Na+ and counterions are shown
as big light gray and small dark gray spheres, respectively. Water molecules have been omitted
for clarity.
concerns the number of dendrimer branches efficiently involved in siRNA binding, Neff . As
expected, Neff is the smallest (38) for the siRNA with the shortest overhangs [(dT)2/(dT)2],
while a net trend is observed with Neff increasing from siRNA(Tn/Tn) to siRNA(An/Tn) to
siRNA(An/An) for the two homologous siRNA series (Figure 12.4). Contextually, the ∆Geffbind
increases (i.e., became more negative and hence more favorable) in the same order.
Further examination of the main components of ∆Geffbind for all monomeric siRNA systems
revealed that, although the binding process is essentially enthalpy-driven, entropy also plays
a substantial role in modulating the ultimate, individual affinity of each siRNA toward the
dendrimer nanovector G5. For example, the system with siRNA bearing (dA)5/(dA)5 over-
hangs has the most favorable effective enthalpic component (∆Heffbind = −592.0 kcal mol−1)
among the three homologous assemblies with (dA)5/(dA)5, (dA)5/(dT)5, and (dT)5/(dT)5
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overhangs (Figure 12.4). This can be ascribed to the high number of favorable electrostatic
interactions, characterized by the value of Neff (46), alongside other nonbonded interactions
between the charged G5 residues and this specific siRNA molecule, including its overhangs. At
the same time, the siRNA (A5/A5) complex with G5 presents the lowest unfavorable entropic
contribution (T∆Seffbind = +227.2 kcal mol−1), by virtue of the rigid nature and aggregation
propensity of the (dA)5 overhangs; this allows for more permanent contacts between the
entire siRNA (including its overhangs) and the G5 peripheral positively charged terminal
groups (Figure 12.5a). The cumulative effect of these two contributing factors results in the
most favorable value of the effective free energy of binding ∆Geffbind = −364.8 kcal mol−1. By
contrast, the siRNA (T5/T5) in complex with G5 is characterized by the smallest Neff value
(41) in the series. Accordingly, this system presents the least favorable enthalpic contribution
(∆Heffbind = −503.1 kcal mol−1) and the highest entropic loss (T∆Seffbind = +241.1 kcal mol−1)
which, when combined, give the lowest ∆Geffbind value (−262.0 kcal mol−1). The analysis of the
entire MD trajectory reveals that the (dT)5 overhangs are endowed with higher flexibility
with respect to their (dA)5 counterparts, and the flexibility of the Tn-overhangs is quantified
by the highest loss of entropy upon their binding with siRNA and well-qualified by the higher
fluctuations (higher degree of freedom) of these overhangs in the solvent, hence leading to a
less optimized siRNA /dendrimer opposite-charge contacts (Figure 12.5b). Lastly, the siRNA
with the complementary over-hangs (dA)5/(dT)5 displays a somewhat intermediate behavior
(Figure 12.5c), both in terms of Neff and ∆Geffbind values, suggesting a possible compensatory
effect between a more rigid and hence more efficient (dA)5 overhang on one side and a more
flexible and less efficient (dT)5 overhang on the other.
Analogous situation is found for the 27-mer siRNA/G5 complexes for which, in line with
the 25-mer siRNA series, the affinity of the siRNA for the G5 dendritic vector (∆Geffbind)
increases according to the nature of the overhangs in the following order: (dT)7/(dT)7 <
(dA)7/(dT)7 < (dA)7/(dA)7. Once again, the relevant simulations highlights the higher flex-
ibility of the (dT)7 overhang and its role in dendrimer binding. Thus, in the case of the
siRNA (T7/T7)/G5 complex, this property ultimately results in the smallest value of Neff
(45), the least favorable enthalpic contribution (∆Heffbind = =626.7 kcal mol−1), the most unfa-
vorable entropic term (T∆Seffbind = +258.9 kcal mol−1) and, correspondingly, the lowest value
of ∆Geffbind (=− 367.8 kcal mol−1) (Figure 12.5e). On the contrary, the siRNA featuring the
(dA)7/(dA)7 overhangs show the highest affinity for G5, the binding being driven by the most
favorable enthalpic term (∆Heffbind = −669.1 kcal mol−1) and the lowest unfavorable entropic
loss (T∆Seffbind = +243.1 kcal mol−1), in agreement with the highest value of Neff (53) and
the higher rigidity (and hence, binding efficiency) of the (dA)7 overhangs (Figure 12.5d),
respectively. Also in this case, the siRNA(A7/T7) shows an intermediate behavior between
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the two other members of the series (Figure 12.5f), confirming an overall balance between
two opposing effects exerted by the two different (dA)n and (dT)n overhangs.
While these results should be considered with due care given all approximations assumed
in the formulations of the molecular systems involved, they do allow for the following general
considerations:
• the presence of longer overhangs on a siRNA duplex appears more advantageous for
dendrimer binding when compared to shorter ones, due to the higher number of effective
dendrimer charges in active and permanent contact with the nucleic acid;
• for siRNA with noncomplementary overhangs of a given length, the presence of less
flexible [i.e., (dA)n] overhangs affords a more favorable enthalpic contribution, a less
unfavorable entropic penalty, and ultimately, a higher affinity of the siRNA for binding
to its dendrimeric nano-carrier;
• in the case of very long overhangs (e.g., n = 7), the presence of more flexible nucleotides
(e.g., (dT)7/(dT)7) might be of little benefit in dendrimer complexation with respect to
shorter overhangs populated by more rigid counterparts (e.g., (dA)5/(dA)5) by virtue
of an enthalpy/entropy compensation effect.
12.5 Concatemerization of sticky siRNA favors binding with
dendrimer vector G5
Sticky siRNA can self-assemble into “gene-like” longer double-stranded RNA via hybrid
bridges formed by the complementary sequence overhangs (Figure 12.3). This “oligomeriza-
tion” or “concatemerization” may, in turn, permit stronger cooperativity and multivalency
which would assist their interaction with the vectors and, eventually, lead to better delivery
efficiency. So far, the stoichiometry and structure of these “gene-like” siRNA are unknown.
Nevertheless, Behr et al.19 clearly demonstrated that:
• sticky siRNA capable of forming noncovalent concatemers via (dA)8/(dT)8 bridges in-
creased siRNA/vector complex stability and hence protected them from RNase degra-
dation;
• since concatemers were not detected in the absence of vectors (e.g., polyethyleneimine
(PEI)) mainly because of the low stability of the overhang duplex, the presence of poly-
cationic vectors may favor encounters of siRNA/nanovector intercomplexes by shielding
their repulsive forces, thus favoring sticky siRNA concatemerization.
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Figure 12.6: Total effective free energy (∆Geffbind = ∆H
eff
bind−T∆Seffbind), enthalpic (∆Heffbind), and
entropic (T∆Seffbind) components of binding of dimeric sticky siRNA toward the G5 dendrimer
as well as effective positive charges (Neff ) with G5 involved in dimeric sticky siRNA binding.
To investigate these concepts, we carried out MD simulations and the appropriate ∆Gbind
calculations for dendrimer G5 in complex with two dimeric sticky siRNAs, hereafter referred
to as [siRNA (A5/T5)]2 and [siRNA (A7/T7)]2, respectively. The results obtained are shown
in Figure 12.6. When the values of the dimeric complexes are compared with those of the cor-
responding monomeric assemblies multiplied by two (see Figure 12.4), we see that the ∆Gbind
for the dimeric cases are substantially more favorable than those obtained for two monomeric
systems (i.e., −975.4 kcal mol−1 for [siRNA (A5/T5)]2 vs 2 × (−387.4) = −774.8 kcal mol−1
for two siRNAs (A5/T5) and −1024.5 kcal mol−1 for [siRNA (A7/T7)]2 vs 2 × (−422.9) =
−845.8 kcal mol−1 for two siRNAs (A7/T7), respectively). Although the models considered
here likely represent a much simplified vision of the real systems, the results obtained not
only support the hypothesis proposed by Behr et al.—namely, preformed sticky siRNA /vec-
tor complexes favor the subsequent concatemerization of the siRNA complementary sticky
ends—but also indicate a synergistic and cooperative binding mechanism between sticky
siRNA and dendrimer.
Further supportive evidence comes from the analysis of the effective free energy of bind-
ing (∆Geffbind) of the dimeric complexes of the sticky siRNA , [siRNA (A5/T5)]2, and [siRNA
(A7/T7)]2 (Figure 12.6). Indeed, in the systems containing dimeric complexes of siRNA , the
number Neff of effective G5 positive charges constantly in contact with the longer siRNA
strand is more than two times that estimated for each corresponding monomeric complex
{96 for the [siRNA (A5/T5)]2/G5 vs 44 for the siRNA (A5/T5)/G5 complex, and 105 for the
[siRNA -(A7/T7)]2/G5 vs 47 for the siRNA (A7/T7)/G5 complex, respectively; Figure 12.6}.
An inspection of the MD trajectories for these two systems reveals that the presence of
the “hybridized” (dA)5/(dT)5 and (dA)7/(dT)7 double-stranded portions of these siRNAs,
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Figure 12.7: Selected equilibrated
MD snapshots of the complexes be-
tween dendrimer G5 and the sticky
siRNA dimers [siRNA(A5/T5)]2 (a) and
[siRNA(A7/T7)]2 (b). The dendrimer
is depicted as forest green sticks, the
terminal charged amine groups as light
green sticks-and-balls, the siRNA as an
orange ribbon, and the two overhangs
(dA)n and (dT)n are highlighted in red
and navy blue, respectively. Some Cl–
and Na+ are shown as big light gray and
small dark gray spheres, respectively.
Water has been omitted for clarity.
which are more rigid and globally more charged compared to each of their corresponding
single-stranded overhangs, allows for a small but significant conformational rearrangement
of the dendrimer outer branches which, in turn, leads to the augmented number of favor-
able, stabilizing electrostatic interactions (Figure 12.7). In addition to the total ∆Gbind, evi-
dence of the beneficial action of the “concatemerization” of two siRNAs with complementary
overhangs can also be found in the corresponding values of the effective quantities ∆Geffbind,
∆Heffbind, and T∆S
eff
bind (Figure 12.6). In particular, it is interesting to note the concomitant
synergistic enhancement in the enthalpic driving force toward binding {−1260.3 kcal mol−1
for [siRNA (A5/T5)]2 vs 2 × (−554.9) = −1109.8 kcal mol−1 for two siRNAs (A5/T5) and
−1441.2 kcal mol−1 for [siRNA (A7/T7)]2 vs 2× (−637.3) = −1274.6 kcal mol−1 for two siR-
NAs (A7/T7)} and the decrease in the entropic contribution disfavoring siRNA/G5 com-
plexation {+372.2 kcal mol−1 for [siRNA (A5/T5)]2 vs 2 × (+233.4) = +446.8 kcal mol−1
for two siRNAs (A5/T5) and +437.2 kcal mol−1 for [siRNA (A7/T7)]2 vs 2 × (+248.2) =
+496.4 kcal mol−1 for two siRNAs (A7/T7)}.
These results demonstrate that the presence of a dimeric sticky siRNA constituted by two
complementary overhangs and a central “(dA)n/(dT)n hybridized double-stranded” tract syn-
ergistically enhances dendrimer binding, ultimately underlying the cooperative and multiva-
lent nature of the dendrimeric nanovector/nucleic acid interactions. These in silico predictions
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Figure 12.8: Binding of the dendrimer G5 toward siRNA bearing 5-nucleotide long (a) and
7-nucleotide long (b) overhangs was assessed by an ethidium bromide displacement assay.
are further confirmed by experimental results aimed at assessing the binding between siRNA
and the G5 dendrimer using ethidium bromide (EB) displacement fluorescence spectroscopy
(Figure 12.8). According to these tests, the siRNA carrying the complementary overhangs
(dA)n/(dT)n exhibited the strongest binding toward the G5 dendrimer, the affinity of the
siRNA for G5 decreasing in the order (dA)n/(dT)n > (dA)n/(dA)n > (dT)n/(dT)n (n = 5 or
7).
12.6 Dissociation process of siRNA/G5 complexes
Importantly, once siRNA/dendrimer complexes are internalized into cells, siRNA molecules
need to be released from their corresponding supramolecular ensembles to reach the RNA
interference (RNAi) machinery to start the gene silencing process. Therefore, siRNA release
from its nanovector is also a crucial step for effective siRNA delivery and gene silencing.
With the purpose of investigating in more detail the process of siRNA release from its den-
drimer complex, we decided to explore the siRNA/dendrimer unbinding process using steered
molecular dynamic (SMD). Accordingly, during our SMD simulation, the siRNA duplex was
forcedly pulled away from its vector using a pulling force given by F (t) = k[vt − (r − r0)n]
where k is the force constant, v is the pulling velocity, n is the pulling direction normal, and r0
and r are the position of the siRNA at the beginning and at time t of the pulling experiment,
respectively. We note here that SMD simulations were not attempted on the siRNA bearing
complementary overhangs (dA)n/(dT)n (n = 5 or 7) as even the simplest siRNA “dimeric
concatemer” currently poses considerable technical computational problems.
Figure 12.9a presents the time profiles of the pulling forces during the SMD simulations of
the dissociation of the standard siRNA (siRNA(T2/T2)) and four siRNA bearing noncomple-
mentary overhangs—siRNA(T5/T5), siRNA(A5/A5), siRNA(T7/T7), and siRNA(A7/A7)—
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Figure 12.9: (a) Average force profile of siRNA unbinding from their G5 dendrimer com-
plexes. Color legend: blue, siRNA(T5/T5); green, siRNA(T7/T7); yellow, siRNA(A7/A7); red,
siRNA(A5/A5); black, siRNA(T2/T2). (b) Correlation between the SMD peak force and the
effective binding free energy ∆Geffbind for the corresponding siRNA and the G5 dendrimer. The
linear fit has a correlation level of R2 = 0.95. (c) Dissociation of siRNA from the dendrimer
complexes as revealed by heparin-coupled ethidium bromide assay.
from their respective G5 complexes. Clearly, an increased level of force is required to initiate
movement of the siRNA double-strand away from the dendrimer, which implies that the
nucleic acid encounters energy barriers to dissociation. The maximum pulling forces F are
730 pN for the siRNA(T2/T2), 753 pN for the siRNA(T5/T5), 794 pN for the siRNA(A5/A5),
842 pN for the siRNA(T7/T7), and 862 pN for the siRNA(A7/A7). After passing this peak,
the force drops rapidly. In Figure 12.9b, these rupture forces are plotted as a function of the
effective binding energies ∆Geffbind obtained from the classical MD simulations (Figure 12.4).
As can be seen, a very strong correlation is found between these two quantities (R2 = 0.95):
the larger the rupture force, the more favorable (i.e., more negative) the effective binding
free energy, and hence the more reluctant the release of siRNA from their corresponding
dendrimer ensembles.
More interestingly, however, is the finding that, for the two siRNA with the most flexible
overhangs, (dT)5/(dT)5 and (dT)7/(dT)7, the force reaches a maximum almost at the same,
shortest time (≈150 ps), while the force peaks for siRNA(A7/A7) and siRNA(A5/A5) follow at
≈2.1 ns and ≈2.4 ns, respectively (Figure 12.9a). For the siRNA with the shortest overhangs
(dT)2/(dT)2, the rupture force maximum occurs after a considerably longer time, ≈3.2 ns
(Figure 12.9a). Notwithstanding the fact that longer overhangs enhance the binding of the
siRNA carrying noncomplementary overhangs with the dendrimer vector, they also possess
increased flexibility which, in turn, facilitates their detachment from the dendrimer. Thus, the
siRNA with the most flexible overhangs, (dT)7/(dT)7 and (dT)5/(dT)5, are able to unbind
at earlier time points, while those featuring more rigid and/or shorter overhangs such as
(dA)5/(dA)5 require longer times to dissociate from their complex.
We further experimentally assessed siRNA release from their corresponding dendrimer
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complexes using the heparin-coupled EB assay. In this method heparin (a highly negatively
charged polysaccharide) is employed in competing with siRNA for dendrimer binding. Upon
addition of heparin, siRNA is gradually displaced from the dendrimer complexes by heparin,
and the released siRNA is ready to intercalate the fluorescent EB probe, which hence emits
a strong fluorescence. From the intensity of the emitted EB fluorescence, the corresponding
siRNA release from its nanocarrier can be estimated. As revealed in Figure 12.9c, in agreement
with our computational predictions, the siRNA with short and flexible overhangs (dT)5/(dT)5
are most easily displaced by heparin from their dendrimer complexes, followed in order by
(dA)5/(dA)5, (dT)7/(dT)7, and (dA)7/(dA)7.
Altogether, the above results show that, among the siRNA molecules with noncomple-
mentary overhangs, those characterized by (dT)n/(dT)n overhangs appear to offer the best
compromise in terms of dendrimer affinity and release. These conclusions greatly correlate
with the experimental evidence, according to which siRNA(T7/T7) molecules are endowed
with the best G5-mediated siRNA delivery and gene silencing among all investigated siRNA
molecules carrying noncomplementary overhangs.
12.7 Conclusions
In our quest for safe and efficient vectors for the delivery of siRNA therapeutics, we discov-
ered that the structurally flexible, fifth generation TEA-core PAMAM dendrimer G5 is an
effective nanovector for delivering sticky siRNAs.136 With the help of combined experimental
and computational approaches, we have successfully identified the underlying mechanisms
of interaction between the overhangs of the sticky siRNA with this dendrimeric nanovector
and the contribution of siRNA overhangs to the observed improved delivery potency. siRNA
molecules with complementary overhangs offer the best action in term of gene silencing. On
the other hand, while siRNAs bearing noncomplementary long overhangs show considerably
higher gene silencing potency than normal siRNAs, they are nevertheless still less effective
than sticky siRNAs bearing complementary overhangs. The observed gene silencing potency,
however, depends on the length and nature of the overhangs.
Overall, our results allowed us to formulate a sensible molecular rationale explaining
the importance of the different siRNA overhangs in dendrimer-mediated siRNA delivery
and gene silencing. Long and complementary overhangs on siRNA duplexes offer the best
action in terms of dendrimer binding via concatemerization of the complementary over-
hang nucleotides. The formation of such concatemers via (dA)n/(dT)n bridges is fostered
by preformed siRNA/dendrimer complexes, and the effective free energy of binding of the
“gene-like” RNA/dendrimer complex is the result of a synergistic and cooperative mecha-
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nism. Once decomplexed in the cytoplasm, the sticky siRNA concatemers fall apart to deliver
siRNA molecules for effective gene silencing.19 For siRNAs bearing noncomplementary over-
hangs, the sum of effects of overhang length, nature, and flexibility plays a major role in
determining their ultimate performance in siRNA delivery and the resulting gene silencing.
Thus, although higher overhang rigidity increases the siRNA binding capacity toward the G5
dendrimer, a higher overhang length—and hence higher flexibility—is more beneficial for the
subsequent nucleic acid release process. Results from computer modeling show that, among
the siRNAs with noncomplementary overhangs considered in the present work, those charac-
terized by (dT)n/(dT)n overhangs appear to offer the best compromise in terms of dendrimer
binding and unbinding characteristics. These conclusions greatly correlate with experimental
findings according to which siRNAs with (dT)n/(dT)n overhangs are endowed with the best
G5-mediated siRNA delivery and gene silencing, as discussed above. Collectively the results
presented here demonstrate that the adoption of this kind of multi-disciplinary approach can
yield fundamental insight into the importance of siRNA overhangs for dendrimer-mediated
siRNA delivery. This will offer a new perspective on siRNA therapeutics and be of instru-
mental use in the future translational implementation of siRNAs in the treatment of various
diseases.
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Viologen-phosphorus dendrimers1
Viologen phosphorus-containing dendrimers are relatively new compounds which have been
seldom investigated in terms of their biological and structural properties.144, 145 These types
of compounds exhibit antimicrobial properties and their behavior depends on their size, the
number of viologen units and the nature of the surface groups.144 Quite recently, Erik De
Clercq and collaborators146 proved the antiviral activity of dendrimers containing a viologen
against the Human Immunodeficiency Virus (HIV) and, to a lesser extent, against other
viruses such as the Herpes Simplex Virus (HSV), the Reovirus (RV), and the Respiratory
Syncytial Virus (RSV).
Accordingly, I embarked in a computational study to determine the main structural char-
acteristics of some representative members of the viologen-based dendrimers, and their bind-
ing to albumin. In particular, I focused on two different families of new viologen dendrimers
bearing phosphorus groups as additional units incorporated either at the focal point or at
the periphery, or both of these key structural positions of the dendritic backbone.144, 145
This choice of strategy was aimed by the fact that we already demonstrated the key role
1The matherial presented in this chapter was published at: Posocco, P., Laurini, E., Marson, D., Peng,
L., Smith, D. K., Klajnert, B., et al. (2013), In B. Klajnert, L. Peng, V. Cena, Dendrimers in Biomedical
Applications. Cambridge: Royal Society of Chemistry.
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charge G Rg [Å] asphericity
D1 +6 0 9.25 0.078
D2 +6 0 10.76 0.063
D3 +12 0 12.32 0.020
D4 +6 0 12.19 0.081
D5 +12 0 13.07 0.023
D6 +18 1 16.59 0.069
D7 +36 1 18.82 0.026
Table 13.1: Main structural parameters for viologen dendrimers D1–D7
played by phosphorus dendrimers in biology and for biomedical applications due to several
specificities.147
Accordingly, the two viologen-phosphorus dendrimers were built from a trifunctionalized
P(S)(NCH3NH2)3 (D2, D4, and D6) or hexafunctionalized core (P3N3)(NCH3NH2)6 (D3,
D5, andD7), and decorated on their surface either with aldehyde groups or with phosphonate
groups, the latter being well-known for their biological properties. A dendron structurally
similar to D2 but stemming from a phenyl core (D1) was also considered for comparison.
Figure 13.1 illustrates the chemical structures of the viologen dendrimers D1–D7, while
Figure 13.2 shows the MD equilibrated snapshots of D4 and D7 at neutral pH and in the
presence of a physiological ionic strength (0.15 M) in solution.
13.1 Dimensions and shape of viologen-phosphorus dendrimers
The Rg values, Equation 11.2 on page 66, estimated by molecular dynamics (MD) simulations
for all viologen dendrimer generations at pH = 7.4 and 0.15 M NaCl are listed in the fourth
column of Table 13.1. As shown in Figure 13.3a, the dimensions of the viologen dendrimers
linearly increase with increasing generation.
While the value of Rg yields an indication of the overall dimension of the dendrimers, it
does not inform about the real shape of the molecules, that is, if the dendrimer is adopting
a true spherical or, e.g., an oblong shape. The fifth column of Table 13.1 and the graph
in Figure 13.3b show that all viologen dendrimers studied tend to assume a spherical con-
formation; nonetheless, the dendrimers featuring the cyclotriphosphazene moiety as a core
(D3, D5, and D7) and characterized by 6 branches all present a δ value close to 0.02 and,
thus, assume a more spherical than their 3-branched trihydrazidophosphine-core or phenyl-
core counterparts (D1, D2, D4, and D6). Such a behavior can be ascribed to the presence
of regularly spaced like-charges along the dendrimer branches, whose reciprocal repulsion
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Figure 13.1: Chemical structures of the viologen dendrimers D1–D7.
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Figure 13.2: Equilibrated MD snapshots of viologen-phosphorus dendrimers D4 (left) and D7
(right) in solution at neutral pH and 0.15 M NaCl. The dendrimers are shown as atom-colored
spheres (grey, C; red, O; yellow, S; blue, N, orange, P, white, H). Water molecules are omitted
for clarity, while some counterions are shown as green (Cl–) and purple (Na+) spheres.
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Figure 13.3: (a) Plot of Rg calculated from MD simulations as a function of the viologen den-
drimers’ molecular weight at pH = 7.4 and 0.15 M NaCl. (b) Plot of the asphericity parameter
δ for viologen dendrimers D1–D7.
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(greater for those molecules with a higher number of ramifications) finds a global equilibrium
condition in the adoption of a more regular and spherical shape.
13.2 Flexibility and back-folding of viologen-phosphorous den-
drimers
From the average radial monomer density ρ(r) ( Equation 11.7 on page 67) plots reported in
Figure 13.4 we can have an idea of the flexibility and space-filling of this family of dendrimers.
In figure are reported the plots for the trihydrazidophosphine-core group of dendrimer, but
the observations hold for the cyclotriphosphazene-core dendrimers. The first two plots are
very similar, and represent the behavior of two generation 0 dendrimers. Here we see that the
terminal residues are at an higher distance from the center of mass (COM) of the dendrimer
than the external viologen groups, as is expected for an “all-open” conformation. The third
plot is rather different, with the curve of the terminal residues more broad and with a peak
much earlier than the previous plots. This explains an observation that we made analyzing the
MD trajectories for this dendrimers. In higher generation viologen-phosphorus dendrimers,
the end-groups can back-fold toward the dendrimer core. Obviously, the presence of a sub-
stantial back-folding can be detrimental to ligand binding, and can hinder the synthesis of
higher generation dendrimers, as less terminal groups are available on the dendrimer surface.
13.3 Dendrimer binding with human serum albumin
One of the most abundant proteins in the bloodstream is human serum albumin (HSA),
so it’s important to study the interaction of a new molecule with this protein. Is is shown
that viologen-phosphorus dendrimers can perturb biological membranes144, and their inter-
action with HSA can have a protective role to this aspect. To describe the binding of the
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Figure 13.5: Equilibrated MD snapshot of D6 in complex with HSA.
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viologen-phosphorus dendrimer studied with HSA, we used the effective free energy of binding
∆Gbind,eff , that is the contribution to binding yielded by the dendrimer branches in constant
and productive contact with the protein.
Observing the per-residue decomposition of the ∆Gbind (Figure 13.6) and the equilibrated
MD snapshots in Figure 13.7, we see that at higher generation the number of interactions
with HSA is only slightly increased, while the strength of the interactions is weaker than
what’s observed for generation 0 dendrimers.
13.4 Conclusions
With MD simulations we gave a morphological descriptions if this new family of viologen-
phosphorus dendrimers. We observed that these dendrimers have a spherical shape, and
we found that at higher generations the end-residues of these dendrimers tend to back-fold
toward the dendrimer core, making them less available on the dendrimer surface for binding
and further synthesis.
Studying the interactions between these dendrimers and HSA, that has an important role
for lowering the side-effects of these molecules, we showed that increasing the generation of
the dendrimer the interactions with HSA are weaker, lowering its protective effects.
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(a) (b)
(c)
Figure 13.7: Equilibrated MD snapshots of D3 (a), D5 (b), D7 (c) in complex with HSA.
In red are depicted the dendrimer’s residues not involved in the binding, while in green are
depicted the protein’s residues involved in the binding.
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Cationic carbosilane dendrimers and
oligonucleotide binding: an energetic affair1
Cationic carbosilane dendrimers of generation 2 are shown to have low toxicity profiles and
are able to internalize genetic material. In the work reported in this chapter, I performed a
complete in silico structural characterization of a set of 2G carbosilane dendrimers (1–4 in
Figure 14.1), followed by a structural and energetical characterization of their interactions
with two oligodeoxynucleotides (ODNs). In a dedicated study it was verified that while
dendrimers 2–4 could effectively bind GEM91 and SREV (two short ODNs developed as
antisense antivirals in HIV-1 treatment), dendrimer 1 showed a lower affinity for the nucleic
acids (NAs) with respect to the other dendrimers studied (precisely, affinity was shown to
decrease in the order 4 ≥ 3 > 2  1).148 Moreover, it was shown that the affinity of these
dendrimers is higher for the ODN GEM91 in respect to what was observed for the ODN
SREV.
The simulations performed predict that all the four dendrimers and their corresponding
complexes with the two ODNs are characterized by similar size and shape. The molecule-
1The matherial presented in this chapter was published at: Marson, D., Laurini, E., Posocco, P., Fermeglia,
M., Pricl, S. (2014). Nanoscale. doi:10.1039/c4nr04510f
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N Rg δ SASA
1 361 9.07± 0.21 0.0126 1910± 87
2 489 10.39± 0.13 0.0096 2699± 76
3 449 9.92± 0.28 0.0174 2288± 82
4 481 10.62± 0.25 0.0103 2555± 72
Table 14.1: Number of atoms N [–], radius of gyration Rg [Å], asphericity δ [–], and SASA
[Å2] of dendrimers 1–4.
specific ODN binding ability can be rationalized considering a critical molecular design pa-
rameter: the normalized effective binding energy ∆Gbind,eff/Neff . This parameter assess per-
formance of each active individual dendrimer branch, directly involved in a binding interac-
tion.
14.1 Structural aspects of G2 carbosilane dendrimers 1–4
To characterize the structure and properties of these dendrimers, we have selected the fol-
lowing quantities: (i) radius of gyration Rg, Equation 11.2 on page 66; (ii) solvent accessible
surface area (SASA); (iii) shape tensor S, Equation 11.3 on page 66; (iv) molecular aspheric-
ity δ, Equation 11.4 on page 66; and (v) monomer density distribution ρ(r), Equation 11.7
on page 67.
Table 14.1 lists the values of Rg obtained from equilibrated molecular dynamics (MD)
trajectories of 1–4 in water at 0.15 mM NaCl. As we see, dendrimers 1 and 3, both charac-
terized by 8 positive charges on their surface (Figure 14.1), have similar values of Rg (9.07
and 9.92Å, Table 14.1). As somewhat expected, the two other dendrimers 2 and 4 bear-
ing 16 positive charges on their scaffolds have larger dimensions with respect to their less
charged counterparts (10.39 and 10.62Å, Table 14.1). Interestingly, however, the different
molecular architecture of 2 and 4 (containing eight groups of single and doubly methylated
outer fragments, respectively, Figure 14.1) does not result in a significant difference in their
Rg values.
Considering one of the most popular dendrimers family, the ethylenediamine-core (EDA)
poly(amidoamine) (PAMAM) dendrimers, as a proof-of-concept for comparison it is interest-
ing to observe that the literature Rg values for the G1-PAMAM, with 8 positively charged
terminal groups at pH 7.4, fall in the interval 7.5–9.9Å, while those for the G2-PAMAM,
with 16 charged terminal groups at physiological pH range from 9.2 to 13.6Å.149, 150 Notwith-
standing the well-known literature controversy about Rg values for PAMAM dendrimers, we
are tempted to observe that, on average, the calculated Rg values of all G2 carbosilane den-
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Figure 14.1: Structure of the G2 carbosilane dendrimers 1–4.
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Figure 14.2: Zoomed view of equilibrated MD snapshots of G2 carbosilane dendrimers 1 (top
left), 2 (top right), 3 (bottom left), and 4 (bottom right). In all panels, the dendrimers are
shown as colored sticks (1, light blue; 2, dark sea green, 3, plum; 4, dark lavender), water is
portrayed as light gray transparent spheres, and some Na+ and Cl– ions are depicted as purple
and green spheres, respectively. Hydrogen atoms are omitted for clarity.
drimers 1–4 fall in an intermediate range of dimensions between G1- and G2-PAMAMs. The
comparison between G2 carbosilanes 2 and 4, and the G2-PAMAM is straightforward: both
G2 dendrimer families feature 16 positive charges in their outer shell and are characterized
by similar values of atom numbers (N) and SASA. Indeed, N = 489, 481, and 532 and
SASA = 2699, 2555, and 2333Å2 for 2, 4, and G2-PAMAM, respectively (Table 14.1 and
ref. 149, 150). The results for the carbosilane dendrimers 1 and 3 can be rationalized by con-
sidering that these two molecules do bear the same charge of G1-PAMAM (+8) but, being
a generation 2, they are also characterized by a number of atoms and, accordingly, a solvent
accessible surface area quite larger than those pertaining to G1-PAMAM. In fact, while N =
361 and 489 for 1 and 3, respectively (Table 14.1), the N value for a EDA-core G1 PAMAM
is 236; in line with this, the calculated SASA for G1 PAMAM is quite smaller (1341Å2)149, 150
than the corresponding SASA values obtained for 1 and 3 (1910 and 2288Å2, Table 14.1).
This evidence supports the fact that the Rg values of 1 and 3 lie in the upper limit of the
G1-PAMAM interval.
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Figure 14.3: Moment of inertia-based aspect ratios (left) and asphericity parameter δ (right)
for the G2 carbosilane dendrimers 1–4 generated from the corresponding equilibrated MD
trajectories.
Concerning the shape of G2 carbosilane dendrimers 1–4, the first, qualitative clue is pro-
vided by Figure 14.2, showing snapshots extracted from the corresponding equilibrated MD
trajectories. From these images we see that, at variance with the reference G2 PAMAMs that
are characterized by a highly asymmetrical conformation,149, 150 all 1–4 molecules are char-
acterized by a symmetrical, nearly spherical shape. A quantitative support to this qualitative
assertion is afforded by the shape tensor S.
Figure 14.3 shows the moment of inertia-based molecular aspect ratios and the asphericity
parameter δ for the G2 carbosilane dendrimers 1–4 as obtained from the corresponding
equilibrated MD trajectories. We see that for all dendrimers both aspect ratios Iz/Ix and
Iz/Iy are in the range 1.0–1.7, indicating that these molecules are strongly compact spheroids
independent of their charge (+8/+16). In keeping with this, the asphericity parameter δ
values are all quite small and close to zero (Figure 14.3 and Table 14.1 for numerical values),
confirming the spherical character of these dendrimer conformations.
At variance with EDA-core PAMAMs, for which lower generation molecules (G1–G3)
tend to assume highly asymmetrical shapes whereas higher generations (G5–G7) become
nearly spherical, G4 being a transition between the two forms,149, 150 the carbosilane den-
drimers 1–4 already attain a spherical distribution of mass at G2. Aside from eventual small
differences in their branch flexibility and/or hydrophilicity, this difference can be essentially
attributed to the geometry of the core. Indeed, we know that the size, shape, and initiator-
core multiplicity Nc exert a dramatic influence on the ultimate critical molecular design
parameters (CMDPs)151 of a dendrimer. Thus, although for both dendrimer families Nc = 4,
the initiator-core for the G2 carbosilane dendrimers consists of a single, Si atom from which
the four branches emanate directly and radially in space. In contrast, in the case of the
EDA-based PAMAMs the core consists of a small, flexible, four atom-long chain, to which
the dendrons are tethered and extend from its extremes. As the initiator-core is a dendrimer
99
Figure 14.4: Monomer density distribu-
tion ρ(r) for the G2 carbosilane den-
drimers 1–4. Color legend: 1, light blue;
2, dark sea green; 3, plum; 4, dark laven-
der.
primary template, these differences are transcribed and displayed through the dendrimer de-
velopment; thus, the carbosilane dendrimers 1–4 are already spherical at lower generations
while higher generation numbers are required for EDA-core PAMAMs to fold into a sphere.
Figure 14.4 shows the overall monomer density distribution (ρ(r)) for the G2 carbosilane
dendrimers 1–4, calculated taking the origin as the center of mass (COM) of the dendrimer.
As we see, all dendrimers are characterized by almost superimposable profiles indicative of
a rather uniform space filling: the curves spike at small R, and then almost monotonically
decrease, the width of the tail zone being again very similar for all four dendrimers. This is a
further confirmation of the fact that the same branching pattern and, above all, the presence
of a tetravalent Si atom as the common initiator-core for these G2 carbosilane dendrimers
dictate the overall, similar conformation of these molecules.
14.2 Complexation of G2 carbosilane dendrimers with ODNs
Given the similarities in size and shape shared by G2 carbosilanes 1–4, in order to explain
the difference in binding affinities of the four dendrimers for the two ODN sequences GEM91
and SREV we went on and performed MD simulations of the relevant complexes. At variance
with other studies reported in the literature, in this work we adopted an alternative approach
based on a combination of steered molecular dynamic (SMD) and classical MD experiments to
determine the initial geometries of each dendrimer/ODN complex. Specifically, starting from
a common initial configuration, each dendrimer was guided towards three different regions
of the ODN (i.e., the two ends and the center of the ODN sequence) by SMD simulations
and, once a distance of approximately 12Å was achieved, each configuration was allowed to
evolve to equilibrium by classical MD simulation runs. Figure 14.5 illustrated this procedure
taking dendrimer 4 and the ODN GEM91 as examples. As can be seen from the images
in Figure 14.5, independently of the initial binding region the ODN is completely wrapped
around the dendrimer and the resulting complexes become virtually indistinguishable at the
end of each combined MD process. Analogous results were obtained with all dendrimers and
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tstart = 0 ns
tSMD = 10 ns  
tend = 100 ns
Figure 14.5: Coupling SMD and classical MD simulations to mimic the binding process of
dendrimer 4 to the ODN GEM91. The dendrimer is portrayed as dark lavender spheres while
the ODN strand is represented as an orange ribbon. Water and oxygen atoms are shown as
transparent aqua spheres, whereas some Na+ and Cl– ions are portrayed as gray and cyan
spheres, respectively.
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Figure 14.6: (left) COM distance between dendrimer 4 and the ODN GEM91 as a function
of time for the three, different initial binding positions: light and medium lavender, dendrimer
initially bound by SMD at the ends of the ODN strand; dark lavender, dendrimer initially bound
by SMD in the middle of the ODN sequence. (right) Radial monomer distribution of dendrimer
4 and GEM91 of the three final, equilibrated complex structures. Color legend: light lavender
(4)/light orange (ODN) and medium lavender (4)/medium orange (ODN): MD equilibrated
configuration obtained from the dendrimer initially bound by SMD at the ends of the ODN
strand; dark lavender (4)/dark orange (ODN): MD equilibrated configuration obtained from
the dendrimer initially bound by SMD in the middle of the ODN strand.
with both ODN sequences.
To quantitatively substantiate the equivalence of the three final structures, we compared
the distance between the dendrimer/ODN COM and the radial monomer distributions ρ(r)
of the corresponding complexes, as illustrated in Figure 14.6 taking again the complex be-
tween 4 and GEM91 as an example. The left panel in Figure 14.6 shows that, when the
dendrimer/ODN binding process is started from a configuration where, at the end of the
SMD part, the dendrimer docks into the center of the nucleic acid single strand, a very short
time is required for the ODNs to wrap around the dendrimers; accordingly, the COM distance
of the relevant complexes readily reach their equilibrium value (7Å on average, Figure 14.6).
When the dendrimers bind to either end of the ODN sequences, the nucleic acid needs to
overcome larger energetic and entropic barriers in order to fold before it can find its wrapping
around the dendrimer surface.
This more complex folding pathway clearly requires longer times, but in the end the COM
distances between dendrimers and ODNs do converge to the same equilibrium value (Fig-
ure 14.6). Also, rather importantly, the degree of ODN strand/dendrimer compenetration,
defined as the integral of the area shared by the dendrimer and ODN ρ(r) curves (see the
right panel of Figure 14.6), is very similar in the three cases of Figure 14.5, being equal to
72.1 %, 75.5 %, and 72.9 %, respectively.
Conclusive proof of the equivalence of the dendrimer/ODN final complex structures pro-
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GEM91 SREV
Rg δ INT Nc Rg δ INT Nc
1 9.16± 0.11 0.0128 233± 32 6.1± 0.2 1 9.13± 0.12 0.0150 194± 29 5.7± 0.3
2 10.46± 0.12 0.0099 709± 46 9.7± 0.2 2 10.42± 0.10 0.0102 515± 38 7.9± 0.2
3 9.99± 0.10 0.0185 1723± 53 15.2± 0.3 3 9.87± 0.11 0.0188 1762± 51 15.5± 0.4
4 10.71± 0.11 0.0107 1953± 62 17.2± 0.3 4 10.70± 0.11 0.0108 1878± 66 15.5± 0.3
Table 14.2: Radius of gyration Rg [Å], asphericity δ [–], interface area between the dendrimer
and ODN INT [Å2], and the average number of contacts between the dendrimer positively
charged nitrogen atoms and the ODN negatively charged oxygen atoms Nc [–] for dendrimers
1–4 in complex with GEM91 and SREV ODNs.
duced by the combined SMD/MD approach can be found in the corresponding values of
the free energy of binding ∆Gbind, as calculated via the Molecular Mechanics/Poisson Boltz-
mann Surface Area (MM/PBSA) ansatz. Referring again to the GEM91/4 assembly as an
example , the ∆Gbind values calculated for the two equilibrated complex structures having
the dendrimer initial position at one extreme of the ODN strand (e.g., the bottom panel in
Figure 14.5, right and left images) are (−53.4± 4.6) kcal mol−1 and (−53.3± 5.1) kcal mol−1,
respectively, while for the complex originating from the assembly featuring the dendrimer
centrally with respect to the ODN strand (bottom panel, central in Figure 14.5 central im-
age) ∆Gbind is (−34.9± 5.0) kcal mol−1. It is evident that, also from an energetic standpoint,
the three structures are indeed comparable, the difference in the affinity between the den-
drimer and ODN being within the relevant ∆Gbind standard deviation intervals. Of note,
utterly similar results are obtained for all other dendrimers, both in complex with GEM91
and SREV.
Given the structural equivalence of the three, final equilibrated structures of each den-
drimer/ODN complex, all the remaining discussions will be focused on one single structure
only, i.e. the one generated from SMD experiments placing the dendrimer central to the
nucleic acid strand.
14.3 Structural aspects of the complexes
Figure 14.7 offers a zoomed view of the equilibrated structures of each SREV/dendrimer
conformation.
From these images we can observe how, independently of the positive charge content of
the dendrimers, the ODN not only wraps around them but we also see a significant com-
penetration of the two molecular entities. To quantify this pictorial evidence, Table 14.2
lists the values of some important structural parameters extracted from the analysis of the
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(a) (b)
(c) (d)
Figure 14.7: Equilibrated MD snapshots of dendrimers 1–4 in complex with the ODN SREV.
Dendrimers 1 (a), 2 (b), 3 (c), and 4 (d) are depicted as light sky blue, dark sea green, plum, and
dark lavender sticks and balls, respectively, with terminally charged amine groups highlighted
in green. The SREV sequence is portrayed as an red grape ribbon. Water and ions are omitted
for clarity.
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Figure 14.8: Evolution of the radius of gyration Rg of the ODN GEM91, the dendrimers 1–4,
and the relevant complexes showing the shape invariance of the dendrimers and the confor-
mational adaptation of the ODN upon binding. (top left) 1, light blue; ODN GEM91, orange,
complex, dark blue; (top right) 2, dark sea green, ODN GEM91, orange, complex, light sea
green; (bottom left) 3, plum; ODN GEM91, orange; complex, purple; (bottom right) 4, dark
lavender, ODN GEM91 orange, complex, light lavender.
equilibrated MD trajectory of all dendrimer/ODN complexes.
A swift survey of the values shown in Table 14.2 reveals that the G2 carbosilane den-
drimers 1–4 do not change the size and shape upon binding to the ODNs. Indeed, both Rg
and δ values for the dendrimers in the complexes are virtually indistinguishable from those
of the dendrimers alone (Table 14.1 and Table 14.2). In line with this, Figure 14.8 shows the
time evolution of the radius of gyration Rg of the ODN GEM91 in complex with dendrimers
1–4 as an example.
However, some differences between the dendrimer complexes with GEM91 and those in-
volving SREV begin to appear. First, the values of the dendrimer/ODN interface areas (INTs)
within the complexes (Table 14.2) are different between the 40 different dendrimers and, for a
given dendrimer, between GEM91 and SREV. Specifically, for both ODNs INT monotonically
increases in passing from 1 to 4, although the difference in INTs values progressively levels off
between dendrimers 3 and 4. Also, the INTs values are lower for all dendrimers in complex
with SREV with respect to the GEM91 complex counterparts (Table 14.2). In keeping with
this, also the number of contacts between the positively charged nitrogen atoms on the den-
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GEM91 SREV
ODN Complex ODN Complex
1 15.83± 0.55 15.44± 0.49 1 17.28± 0.28 15.69± 0.21
2 15.57± 0.36 15.00± 0.27 2 16.12± 0.23 15.50± 0.20
3 13.87± 0.25 14.34± 0.50 3 15.20± 0.19 14.44± 0.17
4 13.71± 0.50 13.98± 0.30 4 14.95± 0.25 14.20± 0.20
Table 14.3: Radius of gyration Rg [Å] of the two ODNs GEM91 and SREV wrapped around
the dendrimers 1–4 and of the relevant complexes.
drimers and the negatively charged oxygen atoms of the ODN phosphate groups Nc follows
the same trend: Nc increases from 1 to 4 and is larger (on average) for GEM91 with respect to
SREV (Table 14.2). In keeping with these results, the values of Rg for the GEM91/dendrimer
complexes are slightly lower than those of the SREV counterparts (Table 14.3), suggesting
a smaller degree of penetration and, hence, somewhat weaker interactions between the G2
carbosilane dendrimers and the SREV strand.
Considering the monomer density distribution of the dendrimer/ODN complexes yields
further information on the structural features of these supermolecular assemblies. For the
purpose of discussion, Figure 14.9 shows these distributions for dendrimer 4 in complex with
ODN GEM91.
Upon binding, the curve of the ODN single strand shows the maximum in the location
of the dendrimer terminal groups, which roughly corresponds to the radius of gyration of
the dendrimers. Also, we distinctly see a substantial penetration of the ODN within the
dendrimer structure. However, considering again the degree of compenetration of the ODN
strand and the dendrimer, differences among the diverse dendrimers and between the two
strands can be detected. In fact, not only this parameter increases in going from dendrimer
1 to dendrimer 4 for a given ODN, but it also slightly decreases in passing from GEM91 to
SREV (in the order: 37.6 % (1), 55.0 % (2), 72.0 % (3), and 75.7 % (4) for GEM91 and 32.1 %
(1), 47.5 % (2), 65.2 % (3), and 73.7 % (4) for SREV, respectively). These pieces of evidence
could be taken as the first, rough indication that the interactions of the dendrimers with
a given ODN decrease in the order 4 ≥ 3 > 2 > 1 and that, for a given dendrimer, more
favorable interactions characterize the complex with the ODN GEM91 than the assembly
with ODN SREV.
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Figure 14.9: Density distribution ρ(r) for the dendrimers 1–4 and the ODN GEM91 in the
relevant complexes. Top left, 1; top right, 2; bottom left, 3; bottom right 4. Dendrimer and
ODN curves are represented by continuous and broken lines, respectively.
14.4 Energetical aspects of ODN/dendrimer binding
To substantiate these seemingly different binding interactions among the G2 carbosilane
dendrimers 1–4 and the two single strand nucleotide sequences GEM91 and SREV, we next
processed the data collected during equilibrated MD simulations of the single molecular
species and the relevant complexes in the framework of the MM/PBSA theory. Specifically,
we assessed the effective free energy of binding ∆Gbind,eff , that is the contribution to binding
yielded by the dendrimer branches in constant and productive contact with the nucleic acid
fragment, as shown in Table 14.4. To estimate ∆Gbind,eff for each dendrimer/ODN complex,
all branches of dendrimers 1–4 involved in ODN binding (Neff , Table 14.4) were precisely
identified (see Figure 14.1) and their individual contribution towards the overall binding
energy estimated via a per residue deconvolution of the binding free energy. The first, inter-
esting finding of this analysis concerns a number of dendrimer branches efficiently involved
in binding the two ODNs. Indeed, in both ODN complexes the G2 carbosilane dendrimer 1
has the smallest number of branches in contact with the nucleic acid (Neff = 6), while the
remaining three dendrimers have more branches (8/9, Table 14.4) effectively involved in ODN
binding. Contextually, ∆Gbind,eff is larger (i.e., more negative and, hence, more favorable)
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GEM91 SREV
Neff ∆Gbind,eff ∆Gbind,eff/Neff Neff ∆Gbind,eff ∆Gbind,eff/Neff
1 6 −11.9± 1.4 −2.0± 0.2 1 6 −11.3± 0.8 −1.9± 0.1
2 9 −23.9± 2.1 −2.7± 0.2 2 9 −22.0± 2.0 −2.4± 0.2
3 8 −34.6± 2.9 −4.3± 0.4 3 8 −32.2± 4.2 −4.0± 0.5
4 8 −45.9± 3.6 −5.7± 0.5 4 8 −43.1± 4.3 −5.4± 0.5
Table 14.4: Predicted number of effective dendrimer branches Neff (–), effective free en-
ergy of binding ∆Gbind,eff (kcal mol−1), and normalized effective free energy of binding
∆Gbind,eff/Neff (kcal mol−1) for dendrimers 1–4 in complex with the two ODN sequences
GEM91 and SREV.
GEM91 SREV
Salt bridge H-bond pi-cation Salt bridge H-bond pi-cation
1 6 - - 1 6 - -
2 9 - - 2 9 - -
3 8 8 - 3 8 8 -
4 8 3 5 4 8 4 4
Table 14.5: The type and number of intermolecular interactions between dendrimers 1–4 and
the two ODN sequences GEM91 and SREV as detected in the corresponding equilibrated MD
trajectories
for dendrimers 2–4 with respect to dendrimer 1, in both series of complexes (Table 14.4).
Normalizing ∆Gbind,eff by Neff yields the performance of the different dendrimers in using
each active individual branch directly involved in a binding interaction (∆Gbind,eff/Neff , Ta-
ble 14.4). As we see, ∆Gbind,eff/Neff increases substantially in passing from dendrimer 1 to
dendrimer 4 for both ODN complexes, the difference between dendrimers leveling off between
dendrimers 3 and 4. Also, from data in Table 14.1 a small efficiency in binding GEM91 with
respect to SREV can be envisaged.
The differential efficacy in binding the ODNs shown by the four G2 carbosilane dendrimers
finds its molecular roots in the diverse number and type of interaction each dendrimer branch
is able to establish with the nucleic acid. As shown in Table 14.5, independently of their
structural details and their charge, all dendrimers exploit a conspicuous number of salt bridges
between the terminal, positively charged nitrogen of the dendrimer atoms and the negatively
charged oxygens of the ODN phosphate groups (see, for instance, Figure 14.10(a, b)).
However, the presence of a second N atom in the dendrimer branches as in dendrimers 3
and 4 allows for further intermolecular interactions, the nature and number of which depend
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(a) (b)
(c) (d)
Figure 14.10: Zoomed view of the different intermolecular interactions between the G2 car-
bosilane dendrimers 1–4 and the ODN GEM91, as detected in the equilibrate portion of the
corresponding MD trajectories. Dendrimers 1 (a), 2 (b), 3 (c), and 4 (d) are depicted as
transparent sticks and balls, the terminal residues involved in ODN binding colored by the
element. The GEM91 strand is portrayed as transparent sticks. Each non-covalent interaction
(salt-bridges, H-bonds, and pi-cation interactions) is highlighted by a dotted black line. Water
and ions are omitted for clarity.
109
on that atom being electrically neutral (3) or positively charged (4). Indeed, a number of
H-bonds are generated within each ODN/dendrimer complex in the case of 3 (Table 14.5
and Figure 14.10c), which justifies the higher efficacy of these dendrimer branches in ODN
binding and, consequently, the greater stabilization of the relevant complex with respect to
those made from 1 and 2 (Table 14.4). When this N atom bears a neat, positive charge as
in 4, beside the salt-bridges and some H-bonds, we detect the establishment of a number of
permanent pi-cation interactions involving this quaternary nitrogen and the aromatic rings
of the nucleic bases, as shown in Figure 14.10d. These interactions are quite strong and,
hence, contribute to the higher efficiency of per residue (as well as overall) ODN affinity of
G2 carbosilane dendrimer 4.
The free energy analysis described above allows for several, further comments. First, the
different lengths of the dendrimer branches between molecules 1 and 3 reflect in a considerably
higher efficiency of the latter dendrimer to bind both ODNs: thus, ∆Gbind,eff/Neff =−2.0 and
−1.9 kcal mol−1 for 1 in complex with GEM91 and SREV while ∆Gbind,eff/Neff = −4.3 and
−4.0 kcal mol−1 for 3 bound to the same two nucleotide sequences, respectively (Table 14.4).
At the same time, doubling the number of branching, and hence the number of positive
charges, in passing from 1 to 2 reflects only in a modest, although not negligible, increase
in ODN affinity. That is to say, the architecture of the dendrimer branches rather than the
dendrimer overall charge seems to be a fundamental parameter for effective ODN binding
in this series of G2 carbosilane dendrimers. Comparing now the performance of dendrimers
2 and 4, both with the overall charge +16, highlights the importance of another molecular
architecture parameter, that is the location of the charges within the molecular structure. In
fact, according to the present calculations, having two positive charges on the same branch
as in 4 (Figure 14.1) is far more efficient as concerns ODN binding than having two positive
charges on two vicinal branches, as in 2 (Figure 14.1). Indeed, the architecture of dendrimer
4 allows, aside from the ever-present salt bridges, the realization of other intermolecular
dendrimer/ODN contacts such as H-bonds and pi-cation interactions (Table 14.5) within
the supermolecular complex. These, in turn, make dendrimer 4 not only dramatically more
effective in binding the ODNs with respect to dendrimer 2 (∆Gbind,eff/Neff = −2.7 and
−2.4 kcal mol−1 for 2 in complex with GEM91 and SREV while ∆Gbind,eff/Neff = −5.7
and −5.4 kcal mol−1 for 4 in complex with the same ODNs, Table 14.4), but also make this
molecule the best binder of the entire series. Lastly, it is instructive to compare dendrimers
3 and 4. Indeed, these two molecules present the same molecular architecture but they
differ by the number of positive charges (+8 and +16, respectively). Thus, while the tertiary
nitrogen atoms characterizing the branches of 3 are involved in a plethora of permanent,
stabilizing H-bonds with the nucleic acid bases, making this dendrimer a good ODN binder,
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the inner quaternary nitrogens of 4 are engaged in several pi-cation interactions (Table 14.5),
which decidedly enhance the affinity of these dendrimer branches toward the nucleic acid
strand (∆Gbind,eff/Neff = −4.3 and −4.0 kcal mol−1 for 3 bound to GEM91 and SREV and
∆Gbind,eff/Neff = −5.7 and −5.4 kcal mol−1 for 4 in complex with the same ODNs).
14.5 Conclusions
Insufficient concentrations and very short residence time of the anti-retroviral agents at the
cellular and anatomical sites are among the major factors that contribute to the failure of
eradicating HIV from reservoirs and the development of multi-drug resistance against an-
tiretroviral agents. Gene therapy offers the promise of preventing progressive HIV infection
by sustained interference with viral replication in the absence of chronic chemotherapy. Ac-
cordingly, gene-targeting strategies are being developed with RNA-based agents, such as
ribozymes, antisense oligonucleotides, and small interfering RNA, just to name a few. Yet,
to date, gene therapy targeting HIV-1 has not fulfilled its promises and hopes. Nonetheless,
there is considerable motivation to be optimistic about its future for HIV-1 therapeutics as
analysis of unsuccessful anti-HIV-1 gene therapy studies is providing fundamental insights for
improvements. One of the major reasons of such failure resides in the fact that, to reach the
therapeutic goal of gene delivery, the use of nanocarriers able to reach the desired population
of cells avoiding all biological barriers is ineluctably required.
It is estimated that several hundreds of different nanovectors are in various stages of
pre-clinical and clinical development toward regulatory approval in the USA and worldwide.
These nano-sized molecular entities have the primary function of transporting the active
agent to the target site, performing the multiple biobarrier-avoidance tasks required along
the way. To perform these ambitious tasks, however, nanovectors must be carefully designed
and engineered to employ several, concurrent strategies to localize preferentially at the target
cells, and release its therapeutic payload.
G2 cationic carbosilane dendrimers 1–4 have been shown to hold great potential as gene
carriers for HIV-1 treatment both in vitro and in vivo. In particular, the characterization of
ODN binding properties of these dendrimers has highlighted a differential affinity for nucleic
acid strands notwithstanding a remarkable similarity in structure and overall charge content
of the members of this molecular series. Since the detailed knowledge of structure/activity
relationships governing the performance of these nano-objects is the ultimate tool for:
• understanding the reasons of their success/failure;
• designing new, more efficient, second generation nanovectors, in this work we aimed
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at unraveling a molecular rationale for the different ODN binding capacity of four G2
carbosilane dendrimers.
To the purpose, we performed a thorough in silico characterization of the structural and
energetical features of G2 carbosilane dendrimers 1–4, and their complexes with the two
single strands ODN GEM91 and SREV. Our results show that these four dendrimers are all
characterized by utterly similar shape and size, independently of their molecular architec-
ture or overall molecular charge, and so are the relevant complexes with the nucleic acids.
On the other hand, depending on the molecular architecture and/or the disposition of the
positive charges within the molecular scaffold, these molecules display a remarkably different
capacity of exploiting their charged groups for binding the negative ODNs in an efficient
and productive way. Accordingly, the different ODN binding affinity of dendrimers 1–4 has
been rationalized considering the normalized effective binding energy ∆Gbind,eff/Neff , i.e.,
the performance of each active individual dendrimer branch directly involved in a binding
interaction. We have thus shown that different combinations of charge localization/molecular
architecture reflect, upon dendrimer/ODN complex formation, in the intermolecular interac-
tion of different nature and strength; this, in turn, makes some molecules more efficient ODN
binders than others. Furthermore, this study conclusively shows that normalized effective
binding energy plays a dominant role among the plethora of critical molecular parameters
requiring optimization in the design of efficient nanovectors for gene therapy.
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Another brick in the wall. Validation of the σ1
receptor 3D model by computer-assisted design,
synthesis and activity of new σ1 ligands1
Because of the broad contributions of σ1 in maintaining cellular homeostasis, the receptor has
been identified as a therapeutic target for the treatment of cancer152 and neurodegenerative
diseases, including amyotrophic lateral sclerosis153, Alzheimer and Parkinson diseases154, and
for retinal neurodegeneration155. Several studies have also connected σ1 to the possible treat-
ment of drug addiction and toxicity related to derivatives of cocaine and amphetamine.156–159
Unfortunately, almost no information about the 3D structure of the receptor and a clear
description of the possible modes of interaction of the σ1 protein with its ligands have been
unveiled so far. With the work presented in this chapter, we validated the σ1 3D homology
model developed by our group; we assessed its reliability as a platform for σ1 ligand structure-
based drug design.
Firstly we designed 33 new σ1 ligands, exploiting the 3D σ1 homology model in our possess;
1The matherial presented in this chapter was published at: Laurini, E., Marson, D., Dal Col, V., Fer-
meglia, M., Mamolo, M. G., Zampieri, D., et al. (2012). Molecular Pharmaceutics, 9(11), 3107−3126.
doi:10.1021/mp300233y
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cpd. Ary R1 Ki(σ1)3DPh [nM] cpd. Ary R1 R2 Ki(σ1)3DPh [nM]
1a Ph H 228 1p pyridin-2-yl Bz - 810
1b 4-chlorophenyl H 32.5 1q pyridin-3-yl Bz - 1961
1c 4-methylphenyl H 116 1r pyridin-4-yl Bz - 785
1d Ph CH3 27.0 2a Ph H CH3 24.1
1e 4-chlorophenyl CH3 66.7 2b Ph H Ph 75.2
1f 4-methylphenyl CH3 43.7 2c Ph Cl CH3 1.04
1g Ph Bz 32 2d Ph Cl Ph 9.7
1h 4-chlorophenyl Bz 83 2e 4-chlorophenyl H CH3 0.26
1i 4-methylphenyl Bz 462 2f 4-chlorophenyl H Ph 37.1
1j pyridin-2-yl H 520 2g 4-chlorophenyl Cl CH3 20.4
1k pyridin-3-yl H 4433 2h 4-chlorophenyl Cl Ph 25.7
1l pyridin-4-yl H 1148 2i 4-methylphenyl H CH3 6.8
1m pyridin-2-yl CH3 1186 2j 4-methylphenyl H Ph 319
1n pyridin-3-yl CH3 2683 2k 4-methylphenyl Cl CH3 86.5
1o pyridin-4-yl CH3 3731 2l 4-methylphenyl Cl Ph 86.6
Table 15.1: 3D pharmacophore predicted σ1 Receptor Affinities Ki(σ1)3DPh of compounds
1a–r and 2a–l
using extensive molecular dynamics simulation-based free energy calculations I ranked the
molecules for σ1 receptor affinity. All compounds were then synthesized in our laboratory and
tested for σ1 binding activity in vitro; the agreement between in silico and in vitro results
confirms the reliability of the proposed σ1 3D model, at least in the a priori prediction of
the affinity of new σ1 ligands.
Applying a per residue free energy deconvolution and in silico alanine scanning muta-
genesis calculations, I analyzed the main interactions involved in receptor/ligand binding,
producing the fist description of the possible modes of interaction of the σ1 protein with
these ligands. The data obtained support the currently available biochemical data concern-
ing the σ1 receptor residues considered essential for σ1 ligand binding and activity.
15.1 3D pharmacophore-based design of new σ1 ligands
The initial step of the present work consisted of exploiting our 3D pharmacophore model
for the in silico design of new σ1 ligands.160 Accordingly, starting from compounds 1e and
2c161 (see Figure 15.1, top panels), we designed two new molecular series 1a–r and 2a–
l (Figure 15.1, bottom panels) with a wide range of σ1 receptor affinity values Ki(σ1), as
shown in Table 15.1.
Quite interestingly, compounds belonging to series 1 are generally endowed with a lower
affinity toward the σ1 receptor than those of series 2. This aspect can be explained by
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Figure 15.1: (Top) Chemical structure of compounds 1e and 2c. (Bottom) Molecular struc-
tures of compounds of series 1 and 2.
Figure 15.2: Pharmacophore mapping of 2d (A) and 1f (B). The 3D pharmacophore hypoth-
esis features are portrayed as meshed spheres, color-coded as follows: red, PI; light blue, HYAr;
pink, HY; light green, HBA.
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comparing, for instance, the mapping of two of the most active compounds of both series
(i.e., 1f Ki(σ1)3DPh = 43.7 nM) and 2d (Ki(σ1)3DPh = 9.7 nM) on the corresponding 3D
pharmacophore features, as shown in Figure 15.2.
The 3D pharmacophore model for σ1 ligands shown in Figure 15.1 is characterized by five
chemical features: one positive ionizable (PI) site, one hydrogen bond acceptor (HBA) group,
two hydrophobic aromatic (HYAr) moieties, and one further hydrophobic (HY) site. Thus,
when superposed on this pharmacophore model, compound 2d maps all the chemical fea-
tures with perfect overlap (Figure 15.2A): the phenyl ring matches the aromatic hydrophobic
function, the chlorine atom fills the hydrophobic group of the model, and the basic nitrogen
atom has the function of proton acceptor, while the carbonyl group matches the hydrogen
bond feature. On the other hand, the chemical groups on compound 1f, although suitable to
fulfill all chemical requirements of the 3D pharmacophore, cannot be perfectly superposed
to the corresponding pharmacophoric features due to a different molecular conformation and
steric rigidity characterizing this molecule (Figure 15.2B).
15.2 Assisted-ligand docking into the σ1 receptor 3D homol-
ogy model
The putative binding site and binding modes of all compounds 1a–r and 2a–l in the σ1
receptor 3D homology model structure were retrieved taking advantage of:
• the currently available preliminary information on sequence-structure relationships and
mutagenesis studies;
• the ligand-binding pharmacophore requirements;
• the docking poses and receptor affinity ranking of compounds 1e and 2c.161
To summarize briefly, a protein isoform missing residues 119–149 was found devoid of ligand
binding capacity, and the conversion of residues Asp126 and Glu172 to glycine led to a several-
fold reduction in ligand-binding function for the σ1 receptor.162 Moreover, our hydrophobicity
analysis identified, aside from the transmembrane (TM) domains, a third hydrophobic re-
gion matching the steroid binding domain-like II (SBDLII) region and centered on Asp188,
a residue specifically photolabeled by [125I]IACoc (3-iodo-4-azidoco-caine).163 This protein
region having been localized as a possible zone for ligand binding, a thorough search for a
sequence satisfying the 3D pharmacophoric requirements160 was performed and successfully
retrieved. Thus, all compounds 1a–r and 2a–l were docked into the putative binding site
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Figure 15.3: Details of the key interac-
tions detected in the equilibrated MD snap-
shots of 2e (A), 1g (B), and 1j (C) in
complex with the σ1 receptor 3D homol-
ogy model. The main protein residues in-
volved in ligand/receptor interactions are
Arg119 (red), Tyr120 (aquamarine), Trp121
(cyan), Asp126 (blue), Ile128 (forest green),
Thr151 (sienna), Val152 (gold), Val 171 (or-
ange), Glu172 (yellow), Tyr173 (magenta),
Ile178 (khaki), Leu182 (light green), and
Leu186 (coral). Compounds 2e, 1g, and 1j
are shown in atom-colored sticks and balls:
C, gray; O, red; N, blue; and Cl, green. H
atoms are not shown, but H-bonds and salt
bridges are indicated as black dotted and
continuous lines, respectively. In all images,
water molecules, ions, and counterions are
not shown for clarity.
of the σ1 receptor 3D model. For each compound, in the corresponding set of docked lig-
and conformations a solution was found that best reproduced the key 3D pharmacophore
requirements (see Figure 15.3). Each resulting receptor/ligand complex was then relaxed by
energy minimization and molecular dynamics (MD) simulations. Finally, the relevant values
of the free energy of binding ∆Gbind between all compounds and the σ1 receptor were eval-
uated by applying the well-known Molecular Mechanics/Poisson Boltzmann Surface Area
(MM/PBSA) computational ansatz, as listed in Table 15.2.
Figure 15.3 shows three MD snapshots extracted from the corresponding equilibrated
trajectories of 2e, 1g, and 1j in complex with the σ1 receptor, as an example. Among both
series of compounds, 2e is the molecule characterized by the highest MM/PBSA predicted
affinity toward the σ1 receptor, Ki(σ1)∆Gbind = 0.01 nM (see Table 15.2), in agreement with
the corresponding estimation from the 3D pharmacophore model (Ki(σ1)3DPh = 0.26 nM,
Table 15.1). From Figure 15.3A it is instructive to observe how, for 2e, an hydrogen bond
(HB) is established between the carbonyl oxygen of the ligand and the side-chain −OH group
of Thr151 on the receptor. This HB, which persists throughout the entire MD simulation
period, is characterized by an average dynamic length (ADL) of (1.82± 0.21)Å and yields a
substantial contribution to binding (vide infra for a quantitative discussion of these data). A
permanent salt bridge (SB), (ADL = (3.81± 0.10)Å) is detected between the −COO– group
of Asp126 on the receptor side and the piperidine −NH+ moiety of 2e. The 4-Cl-phenyl
117
compd. ∆H [kcal mol−1] T∆S [kcal mol−1 K−1] ∆Gbind [kcal mol−1] Ki(σ1)∆Gbind [nM]
1a −36.29± 0.19 −26.36± 0.34 −9.93± 0.39 53.0
1b −34.39± 0.21 −23.87± 0.32 −10.52± 0.38 19.6
1c −36.18± 0.17 −25.75± 0.31 −10.43± 0.35 22.8
1d −35.02± 0.18 −24.62± 0.35 −10.40± 0.39 24.0
1e −37.90± 0.18 −26.71± 0.30 −10.02± 0.35 6.32
1f −36.21± 0.20 −25.09± 0.31 −11.12± 0.37 7.12
1g −33.19± 0.16 −23.24± 0.35 −9.95± 0.38 51.2
1h −32.60± 0.20 −23.39± 0.36 −9.21± 0.41 178
1i −33.38± 0.19 −24.37± 0.33 −9.01± 0.38 250
1j −30.33± 0.18 −24.49± 0.35 −5.84± 0.39 52 600
1k −29.89± 0.21 −23.02± 0.31 −6.87± 0.37 9250
1l −30.69± 0.17 −22.43± 0.36 −8.26± 0.40 880
1m −29.88± 0.21 −23.35± 0.31 −6.53± 0.37 16 400
1n −29.24± 0.18 −22.65± 0.32 −7.75± 0.37 14 800
1o −28.87± 0.22 −22.27± 0.32 −6.60± 0.39 14 600
1p −31.89± 0.89 −23.03± 0.37 −8.86± 0.40 322
1q −30.92± 0.18 −23.67± 0.34 −7.25± 0.38 4870
1r −29.97± 0.20 −22.11± 0.33 −7.86± 0.39 1740
2a −38.31± 0.20 −25.81± 0.35 −12.50± 0.40 0.69
2b −39.01± 0.15 −26.19± 0.36 −12.82± 0.39 0.40
2c −38.81± 0.19 −25.54± 0.33 −11.31± 0.38 0.19
2d −38.39± 0.19 −24.91± 0.33 −13.48± 0.38 0.13
2e −48.83± 0.21 −25.71± 0.30 −15.12± 0.37 0.01
2f −37.76± 0.17 −25.97± 0.35 −11.79± 0.39 2.30
2g −38.33± 0.19 −26.38± 0.34 −11.95± 0.39 1.75
2h −37.04± 0.18 −25.11± 0.36 −11.93± 0.40 1.81
2i −38.61± 0.19 −26.09± 0.35 −12.52± 0.40 0.67
2j −33.95± 0.18 −24.35± 0.32 −9.60± 0.37 92.5
2k −34.61± 0.19 −25.03± 0.31 −9.58± 0.36 95.6
2l −34.49± 0.21 −24.62± 0.35 −9.87± 0.41 58.6
HAL −35.17± 0.19 −24.56± 0.38 −10.61± 0.42 16.8
PTZ −27.56± 0.22 −17.54± 0.39 −10.02± 0.45 45.5
Table 15.2: Enthalpy (∆H), entropy (T∆S), free energy of binding (∆Gbind), and correspond-
ing Ki(σ1)∆Gbind values for compounds 1a–r and 2a–l and the σ1 receptor homology model,
as estimated using the MM/PBSA approach. The Ki(σ1) values were obtained from the cor-
responding ∆Gbind values. The values of two σ1 ligand reference compounds, (+)-pentazocine
(PTZ) and haloperidol (HAL), are also reported for comparison.
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group of the compound is encased in a hydrophobic pocket, mainly lined by the side chains
of Val171 and Ile128. An outer hydrophobic region accommodates the second phenyl ring
of 2e, with the contribution of residues Leu182, Ile178, and Tyr120. Also, this phenyl ring
is further engaged in a parallel pi-pi stacking interaction with Tyr120. The synergistic effect
of all these stabilizing interactions is reflected in the highly negative (i.e., favorable) value
of ∆Gbind between 2e and the σ1 protein (−15.12 kcal mol−1, Table 15.2) and, hence, of the
predicted subnanomolar value of the corresponding Ki(σ1)∆Gbind .
For compound 1g, MM/PBSA calculations yield an intermediate affinity for the σ1
receptor—Ki(σ1)∆Gbind = 51.2 nM (see Table 15.2)—a value quite close to that predicted
by the 3D pharmacophore model (Ki(σ1)3DPh = 32 nM, Table 15.1). Figure 15.3B illustrates
how the stable HB and the SB outlined for 2e are still present, although the hydrogen
donor on the receptor side in this case is the −NH group of the backbone peptide bond
between Thr151 and Val152. Both these interactions, however, are somewhat weaker than
for 2e, as the corresponding ADL are (2.09± 0.12)Å and (4.53± 0.18)Å, respectively. The
hydrophobic pockets again enwrap two of the aromatic rings, residue Trp121 playing a role
in determining a T-stacked pi-pi interaction with one of the two aryl groups. However, the
conformation of the molecule is such that the last phenyl ring is not mapped by any suitable
pharmacophore feature of 1g; correspondingly, this interaction is lost within the receptor
binding site (Figure 15.3B). In line with this analysis, the presence of these less effective, al-
beit still favorable, interactions is reflected in the higher (less negative) value of the estimated
free energy of binding (∆Gbind = −9.95 kcal mol−1, Table 15.2).
According to both 3D pharmacophore modeling and MM/PBSA simulations, compound
1j is endowed with the lowest affinity toward the σ1 receptor, with values of Ki(σ1)3DPh =
520 nM and Ki(σ1)∆Gbind = 52 600 nM, respectively. In this case, the role exerted by Tyr120
and Thr151 in binding 1j is negligible, while the two hydrophobic pockets described above
are still able to accommodate the two aromatic moieties of this compound (Figure 15.3C).
More importantly, the carbonyl group is positioned far too distant from any possible proton
donor group on the receptor to set up any stabilizing HB bond. In agreement with these
considerations, a very low activity is predicted for this compound, with a corresponding
∆Gbind value of −5.84 kcal mol−1.
According to the present MM/PBSA analysis, the binding affinity of the two series of
compounds 1 and 2 toward the σ1 receptor is an enthalpy-driven process: indeed, panel A in
Figure 15.4 shows that for both molecular sets the unfavorable entropic contribution T∆S
to ligand binding is overwhelmed by the favorable enthalpic component ∆H, resulting in
an overall negative value of the free energy of binding ∆Gbind. It is also interesting to note
that the higher MM/PBSA average σ1 affinity value predicted for all compounds of series 2
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Figure 15.4: (A) Average MM/PBSA values of the enthalpy (∆H), entropy (T∆S), and free
energy of binding (∆Gbind) for compound series 1 and 2 in complex with the σ1 receptor. (B)
Average values of the enthalpic components of ∆Gbind (van der Waals term ∆EvdW , electrostatic
term ∆EELE , polar solvation term ∆GPB, and nonpolar solvation term ∆GNP ) for compound
series 1 and 2 in complex with the σ1 receptor. (C) Correlation between the σ1 affinity con-
stant Ki values for compounds 1a–r and 2a–l estimated using the 3D pharmacophore model
(Ki(σ1)3DPh) and the MM/PBSA methodology (Ki(σ1)∆Gbind).
originates solely from the difference in the enthalpic contributions between the two molecular
sets (∆∆H = ∆H(2) - ∆H(1) = −4.91 kcal mol−1), as the corresponding difference in the
entropic terms is significantly smaller (∆(T∆S) = T∆S(2) - T∆S(1) = 1.56 kcal mol−1 K−1).
The calculated ∆Gbind values are encouraging also in the light of the balance among
the energy terms contributing to them. As observed in many other drug/receptor complex
simulations including our own studies,135, 136, 164–166 the favorable contribution of the electro-
static interactions between the σ1 protein and compounds 1a–r and 2a–l (∆EELE) is more
than compensated by the electrostatic desolvation free energy upon complexation (∆GPB),
so that the total electrostatic term (∆EELE + ∆GPB) contributes unfavorably to the bind-
ing (see Figure 15.4B). Interestingly, several recent papers have demonstrated that (natural)
receptor−ligand pairs often show suboptimal electrostatic interactions that may be opti-
mized, leading to increased affinity.167–171 On the contrary, van der Waals (vdW) interactions
(∆EvdW ) contribute favorably to the binding affinity of 1a–r and 2a–l toward the receptor,
as does the nonpolar part of the solvation free energy (∆GNP ), again in agreement with
other studies mentioned above166–171 (Figure 15.4B). Therefore, for both 1 and 2 molecular
series, the favorable binding free energy for receptor/ligand complex formation stems pre-
dominantly from the nonpolar terms (∆E + ∆G ), while the polar vdW interactions provide
most of all the directional constraint for the complexation, that is, the relative positions of
the molecules.
The analysis of the entire MD simulation trajectories for all 33 compounds in complex
with the σ1 receptor 3D model further reveals that the overall conformation of the protein
backbone undergoes only minimal global conformational changes upon complex formation
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2e 1g 1j 2e/1g 2e/1j 1g/1j
0.9 1.6 2.1 2.5 4.2 3.5
Table 15.3: Average RMSDs of the binding site of the σ1 protein in complex with 2e, 1g, and
1j with respect to the unbound protein and to each alternative complex. All values are reported
in Å.
with the different compounds, while a rearrangement of the side chains of several residues
lining the receptor binding site is required for ligand binding. In its uncomplexed form, the σ1
model structure remained stable for the entire 10 ns MD trajectory, as testified by the small
root-mean-square deviation (RMSD) values of the backbone atom positions with respect to
those of the initial structure. The same parameter showed very low fluctuations during both
MD equilibration and data harvesting steps also for all receptor/ligand complexes, indicating
that the presence of a bound ligand does not result in large protein structural deviations. The
first part of Table 15.3 reports the average RMSDs of the binding site region of the σ1 receptor
(i.e., from residue 100 to residue 200) determined between average structures of the proteins
in the unbound and bound states for 2e, 1g, and 1j as an example: this region deviates by
very small amounts, confirming that the σ1 binding pocket does not experience a significantly
larger-than-average conformational change upon complex formations with ligands 1 and 2.
These aspects can be further inspected and quantified considering the superposition of
equilibrated snapshots extracted from the MD trajectory of the receptor in complex with
compounds 2e, 1g, and 1j reported in Figure 15.5 and the relevant RMSD values listed in
the rightmost three columns of Table 15.3. This evidence confirms that the putative binding
site of the σ1 receptor is able to accommodate all ligands of series 1 and 2 with no major
conformational readjustments, the difference in affinity toward the different compounds being
ascribable to a better/worse rearrangement of the binding pocket residue side chains.
In concluding this section it is interesting to note that the affinity values of all 33 com-
pounds toward the σ1 receptor predicted by the 3D pharmacophore model are in good agree-
ment with the corresponding values obtained from the MM/PBSA scoring, with a correlation
coefficient of R2 = 0.84, as shown in Figure 15.4C. The quality of the overall linear correlation
between these two Ki(σ1) data sets constitutes a first step toward the validation of the σ1
3D homology model and the location of its putative binding site.
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Figure 15.5: Superposition of equilibrated MD snapshots of the σ1 receptor in complex with
(A) 2e (blue) and 1g (green), (B) 2e (blue) and 1j (red), and (C) 1g (green) and 1j (red).
The images are zoomed views of the receptor binding site. The ligands are portrayed in sticks
and balls colored according to the protein in the corresponding complex. Water, ions, and
counterions are not shown for clarity.
15.3 Residue-based description of ligand binding to σ1: PRBFED
and computational alanine scanning
15.3.1 Per residue binding free energy decomposition
Insight into the origin of binding of σ1 to compounds 1 and 2 at an atomistic level may
be obtained by decomposing the total free energy of binding ∆Gbind in terms of contribu-
tions from structural subunits of both binding partners. The molecular Molecular Mechan-
ics/Generalized Born Surface Area (MM/GBSA), allows the decomposition of the electro-
static solvation free energy into atomic contributions in a straightforward manner. This, in
turn, permits an easy and rapid per residue binding free energy decomposition (PRBFED),
yielding the residue-based ∆HGB values required for the detailed study of the ligand/protein
interactions at each single amino acid level, including the backbone atoms. Therefore, we
proceeded in our study of the binding modes of compounds 1a–r and 2a–l to the σ1 receptor
by applying PRBFED to the analysis of those residues that, as qualitatively discussed above
(Figure 15.3), are predicted to be important for ligand binding to the protein.
Figure 15.6 illustrates the results of the PRBFED analysis obtained for compounds 2e, 1g,
and 1j, again taken as a proof of concept as they constitute examples of σ1 high affinity (2e),
intermediate affinity (1g), and very low affinity (1j) ligands. As can be seen from Figure 15.6,
in all cases three clusters of residues (I, II, and III) are identified, centered around Glu123,
Thr151, and Val177, respectively. In the case of 2e (Figure 15.6A), according to analysis of
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stabilizing electrostatic interactions. The stable hydrogen bond
detected between the −CO group of 2e and the side chain
−OH group of Thr151 is responsible for the favorable −1.31
kcal/mol contribution provided by the electrostatic inter-
actions. The PRBFED approach then confirms that residues
belonging to the two major clusters yield the required van der
Waals and hydrophobic interactions to favorably encase the
aromatic portions of the ligand: e.g., Arg119 (−1.58 kcal/mol),
Tyr120 (−2.16 kcal/mol), Trp121 (−1.76 kcal/mol), and
Ile128 (−3.15 kcal/mol) of cluster I, and Glu172 (−1.73 kcal/
mol), Tyr 173 (−1.91 kcal/mol), and Leu182 (−1.04 kcal/
mol) of cluster II, respectively.
Panel B in Figure 6 illustrates the PRBFED results for
compound 1g. The presence of weaker (i.e., longer) SB and HB
interactions detected along the 1g/σ1 MD trajectory (Figure
3C,D) is confirmed by the lower ΔHGB values of the residues
involved: −1.91 kcal/mol (SB) for Asp126 and −1.07 kcal/mol
(HB) for Val152, respectively. The minor entity of the
Figure 6. Per residue binding free energy decomposition for σ1 receptor in complex with 2e (A), 1g (B), and 1j (C). Only σ1 amino acids from
position 100 to 200 are shown, as for all the remaining protein residues the contribution to ligand binding is irrelevant.
Figure 7. Decomposition of ΔHGB on a per residue basis into contribution of the nonpolar (ΔEvdW + ΔGnp) and polar (ΔEele + ΔGnp) terms for
residues of the σ1 receptor in complex with 2e (A), 1g (B), and 1j (C). Only those residues for which |ΔHGB| ≥ 1 kcal/mol are shown in the
respective panels.
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Figure 15.6: Per residue binding free energy decomposition for σ1 receptor in complex with
2e (A), 1g (B), and 1j (C). Only σ1 amino acids from position 100 to 200 are shown, as for all
the remaining protein residues the contribution to ligand binding is irrelevant.
stabilizing electrostatic interactions. The stable hydrogen bond
detected between the −CO group of 2e and the side chain
−OH group of Thr151 is responsible for the favorable −1.31
kcal/mol contribution provided by the electrostatic inter-
actions. The PRBFED approach then confirms that residues
belonging to the two major clusters yield the required van der
Waals and hydrophobic interactions to favorably encase the
aromatic portions of the ligand: e.g., Arg119 (−1.58 kcal/mol),
Tyr120 (−2.16 kcal/mol), Trp121 (−1.76 kcal/mol), and
Ile128 (−3.15 kcal/mol) of cluster I, and Glu172 (−1.73 kcal/
mol), Tyr 173 (−1.91 kcal/mol), and Leu182 (−1.04 kcal/
mol) of cluster II, respectively.
Panel B in Figure 6 illustrates the PRBFED results for
compound 1g. The presence of weaker (i.e., longer) SB and HB
interactions detected along the 1g/σ1 MD trajectory (Figure
3C,D) is confirmed by the lower ΔHGB values of the residues
involved: −1.91 kcal/mol (SB) for Asp126 and −1.07 kcal/mol
(HB) for Val152, respectively. The minor entity of the
Figure 6. Per residue binding free energy decomposition for σ1 receptor in complex with 2e (A), 1g (B), and 1j (C). Only σ1 amino acids from
position 100 to 200 are shown, as for all the remaining protein residues the contribution to ligand binding is irrelevant.
Figure 7. Decomposition of ΔHGB on a per residue basis into contribution of the nonpolar (ΔEvdW + ΔGnp) and polar (ΔEele + ΔGnp) terms for
residues of th σ1 receptor in complex with 2e (A), 1g (B), and 1j (C). Only those residues for which |ΔHGB| ≥ 1 kcal/mol are shown in the
respective panels.
Molecular Pharmaceutics Article
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Figure 15.7: De ompos ion of ∆HGB on a per residue ba s int c ntrib tion of the nonpolar
(∆EvdW +∆GNP ) and polar (∆EELE+∆GNP ) terms for residues of the σ1 receptor in complex
with 2e (A), 1g (B), and 1j (C). Only those residues for which |∆HGB| ≥ 1 kcal mol−1 are shown
in the respective panels.
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the corresponding MD trajectory (Figure 15.3A,B) the side chain of Asp126 is engaged in
a fundamental salt bridge with the piperidine −NH+ moiety of the compound; indeed, this
residue is responsible for the −2.54 kcal mol−1 favorable contribution to binding, mostly pro-
vided by stabilizing electrostatic interactions. The stable hydrogen bond detected between
the −CO group of 2e and the side chain −OH group of Thr151 is responsible for the favorable
−1.31 kcal mol−1 contribution provided by the electrostatic interactions. The PRBFED ap-
proach then confirms that residues belonging to the two major clusters yield the required vdW
and hydrophobic interactions to favorably encase the aromatic portions of the ligand: e.g.,
Arg119 (−1.58 kcal mol−1), Tyr120 (−2.16 kcal mol−1), Trp121 (−1.76 kcal mol−1), and Ile128
(−3.15 kcal mol−1) of cluster I, and Glu172 (−1.73 kcal mol−1), Tyr 173 (−1.91 kcal mol−1),
and Leu182 (−1.04 kcal mol−1) of cluster II, respectively.
Panel B in Figure 15.6 illustrates the PRBFED results for compound 1g. The presence of
weaker (i.e., longer) SB and HB interactions detected along the 1g/σ1 MD trajectory (Fig-
ure 15.3C,D) is confirmed by the lower ∆HGB values of the residues involved:−1.91 kcal mol−1
(SB) for Asp126 and −1.07 kcal mol−1 (HB) for Val152, respectively. The minor entity of the
contributions to binding from residues belonging to clusters I and II (120–128 and 171–182)
supports the evidence that part of the hydrophobic and vdW interactions are lost in this
ligand/protein complex. Of note, the proposed T-stacked pi-pi interaction of Trp121 with one
of the two aryl groups of 1g is captured by the PRBFED analysis, according to which the
contribution afforded by this residue to binding is equal to −1.08 kcal mol−1.
In our predictions, compound 1j is the ligand characterized by the lowest affinity for the
σ1 receptor within both molecular series 1 and 2. The PRBFED results shown in panel C of
Figure 15.6 justify these calculations. While the presence of a salt bridge between the −NH+
moiety of 1j and the −COO– of Asp126 is preserved, providing a favorable contribution
to binding of −1.61 kcal mol−1, the absence of any H-bond between the −CO group of 1j
and any possible acceptor group on the receptor is responsible for the small contributions
to binding from residues of cluster II (e.g., Thr151, −0.81 kcal mol−1). Some residues of
clusters I and II are still able to provide some favorable contribution to complex formation,
although the reorientation of Glu172 side chain upon binding 1j is in part responsible for
the +1.41 kcal mol−1 unfavorable dispersion/electrostatic contribution to the binding made
by this amino acid.
To gain additional insights into the different contributions to the binding free energy
change, the per residue ∆HGB values can be further decomposed into the nonpolar terms
(i.e., the vdW energy ∆EvdW and the nonpolar term of the solvation free energy ∆GNP )
and the sum of the Coulombic interaction and the polar solvation free energy (∆EELE +
∆GGB). Figure 15.7 depicts the ∆HGB decomposition for the 2e/, 1g/, and 1j/σ1 complexes
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discussed above. The sum of electrostatic interactions in the gas phase and the change of the
polar part of the solvation free energy is shown instead of the separate contributions, since,
in most cases, the numbers are strongly anticorrelated.
Qualitatively, major differences are obvious among residues located in the binding site
in the case of high, intermediate, and low affinity ligands, respectively. For compound 2e
(Ki(σ1)∆Gbind = 0.01 nM), stabilizing vdW and nonpolar interactions, reinforced by favor-
able overall electrostatic/desolvation terms, prevail for almost all residues lining the σ1
binding pocket (Figure 15.7A). Interestingly, the overall stabilization of the salt bridge
of 2e with Asp126 (∆GGB = −2.54 kcal mol−1, see PRBFED analysis) is almost equiva-
lently contributed by the dispersive (∆EvdW + ∆GNP = −1.37 kcal mol−1) and electrostatic
(∆EELE + ∆GGB = −1.17 kcal mol−1) components, while the pharmacophoric H-bond in-
volving the side chain of Thr151 (∆GGB = −1.31 kcal mol−1) mainly gains from a favorable
electrostatic interaction (∆EELE + ∆GGB = −1.12 kcal mol−1 while ∆EvdW + ∆GNP =
−0.19 kcal mol−1). Figure 15.7A also confirms the dominant role played by the hydrophobic
(i.e., overall nonpolar) interactions in binding of 2e to σ1, well exemplified by the values
of ∆EvdW + ∆GNP for residues Arg119 (−1.38 kcal mol−1 and ∆HGB = −1.58 kcal mol−1),
Tyr120 (−1.98 kcal mol−1 and ∆HGB = −2.16 kcal mol−1), Trp121 (−1.52 kcal mol−1 and
∆HGB = −1.76 kcal mol−1), Ile128 (−2.83 kcal mol−1 and ∆HGB = −3.15 kcal mol−1), Glu172
(−1.67 kcal mol−1 and ∆HGB = −1.73 kcal mol−1), Tyr 173 (−2.31 kcal mol−1 and ∆HGB =
−1.91 kcal mol−1), and Leu182 (−1.15 kcal mol−1 and ∆HGB = −1.04 kcal mol−1).
In the case of compound 1g (Ki(σ1)∆Gbind = 51.2 nM), the dispersive forces benefit by a
lower synergistic interaction with the polar terms of ∆HGB with respect to the case of 2e
(Figure 15.7B). Notably, while the salt bridge between 1g and Asp126, although decreased
in strength (∆HGB = −1.91 kcal mol−1), shows a relative contribution from the different
∆HGB components which parallels that discussed for 2e (i.e., ∆EvdW + ∆GNP amounts to
approximately 74 % of the total ∆HGB), the other, distinctive pharmacophoric element (i.e.,
H-bond with Val152) not only is weaker but features contributions from the two main ∆HGB
components in a reverse trend with respect to 2e (∆EvdW + ∆GNP = −1.26 kcal mol−1 and
∆EELE + ∆GGB = −0.20 kcal mol−1, respectively). Of importance is the quantification of
the pi-pi stacking interaction between one aromatic moiety of 1g and the side chain of Trp121
(∆HGB = −1.08 kcal mol−1), for which the dispersive and the electrostatic terms show strong
contributions of opposite sign (∆EvdW + ∆GNP = −3.24 kcal mol−1 and ∆EELE + ∆GGB =
+2.16 kcal mol−1, respectively).
Lastly, for compound 1j (Ki(σ1)∆Gbind = 52 600 nM) both the number of useful contacts
with the amino acids belonging to the putative σ1 binding site and also the overall intensity of
the interactions between these residues and the ligand are highly diminished with respect to
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those characterizing compounds 2e and 1g discussed above. Also, at some specific positions
already identified during PRBFED analysis (e.g., Trp121 and Glu172), a gain in favorable
vdW interactions and the nonpolar part of solvation free energy is overcompensated by
unfavorable contributions from the ∆EELE + ∆GGB components of ∆HGB.
15.3.2 Computational alanine scanning mutagenesis
The MD simulations performed in the MM/PBSA framework of theory can be further em-
ployed to perform the so-called computational alanine scanning (CAS) mutagenesis,172 in
which the absolute binding free energy is calculated for the wild type protein, as well as
for several mutants in which one residue has been replaced by an alanine. Aside from yield-
ing information complementary to that obtained from a PRBFED analysis, the difference
in the binding free energy of the wild type and of the mutants estimated by CAS may be
directly compared with the results of an experimental alanine scanning (ASM) mutagenesis.
Undoubtedly, in the CAS approach it is questionable whether simply modifying a given side
chain to alanine in the corresponding MD simulation trajectory of the wild type system can
lead to a good representation of the conformational space of the mutant, since no eventual
conformation induced by the mutation is investigated. However, it is also questionable how
the binding free energy contribution of a given side chain in the wild type complexation may
be always representative of the change in the binding free energy upon mutation, since the
conformational modifications induced by the mutations are not included in the model either
and since, for instance, the modification of the solvation free energy of close side chains upon
mutation is not directly evaluated. Also, contrarily to the total free energy, the free energy
components are not state functions, and the values of these contributions are thus dependent
on the decomposition scheme adopted. Obviously, both CAS and the PRBFED methods can-
not be expected to provide results exactly comparable to experimental values obtained from
an experimental ASM; nonetheless, the application of both methodologies can give a good,
preliminary indication of which protein residues play a key role in ligand binding, ultimately
enabling the biochemist to avoid trial-and-error tests and perform targeted ASM experiments
with the obvious advantages of cost and time saving.
The CAS was applied to all compounds 1a–r and 2a–l; for the sake of brevity and in
keeping with the previous discussion, Table 15.4 gives the results of the CAS for compounds
2e, 1g, and 1j only. Note that, according to the definition adopted in this work, a negative
value of ∆∆Gbind corresponds to a residue for which the wild type (wt) side chain is more
favorable to the binding than an alanine side chain. From the values listed in Table 15.4, the
pivotal role exerted by Asp126 in ligand binding is clearly attested by the highly unfavorable
free energy of binding of the Ala126 σ1 mutant with respect to the wt protein. Also, Tyr173
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∆∆Gbind = ∆Gbind,wt −∆Gbind,mut
compd. ∆Gbind,wt D126A I128A T151A V152A E172A Y173A L182A
2e −15.12± 0.37 −3.69± 0.42 −2.27± 0.43 −0.67± 0.38 −0.56± 0.40 −2.04± 0.37 −1.79± 0.38 −1.11± 0.37
1g −9.95± 0.38 −3.25± 0.39 −1.35± 0.40 −0.71± 0.39 −0.45± 0.39 −1.19± 0.40 −2.03± 0.41 −0.79± 0.43
1j −5.84± 0.39 −2.82± 0.43 −0.12± 0.42 −0.57± 0.38 −0.39± 0.43 −0.21± 0.39 −1.27± 0.38 0.02± 0.44
Table 15.4: Computational alanine scanning mutagenesis results for the σ1 receptor in complex
with ligands 2e, 1g, and 1j. All values are inkcal mol−1.
is confirmed to play a substantial role in the complex stabilization for each compound. Inter-
estingly, residues Ile128 and Leu182 afford a significant contribution to the stabilization of
the protein/ligand complex for those ligands with high or intermediate affinity (2e and 1g)
but seem to be less critical for bind compounds endowed by a poor affinity for the receptor.
The importance of the hot spot residues detected by CAS can be verified by experimen-
tal binding assays of various σ1 mutants. For instance, in their seminal work Seth et al.
clearly demonstrated the obligatory nature of the fully conserved Asp126 and Glu172 for
the ligand binding function of the σ1 receptor via in vitro binding assays of the Asp126Gly
and Glu172Gly σ1 mutants to radiolabeled haloperidol.162 Also, other mutational studies
identified Tyr173 as a residue critical for the cholesterol binding activity of the protein.173
To summarize all the in silico work discussed above, we used MM/PBSA-based simula-
tions and analysis to design and rank 33 compounds for their affinity toward our 3D homology
model of the σ1 receptor. The Ki(σ1) values derived from the MM/PBSA calculations are
in agreement (R2 = 0.84) with those obtained using a 3D pharmacophore model, previously
shown to be reliable in reproducing and/or predicting the affinity of similar compounds to the
same receptor. Lastly, the combined application of a per residue free energy deconvolution
and computational alanine scanning mutagenesis allowed us to dissect the contribution of
each single residue belonging to the putative σ1 receptor binding pocket to ligand binding,
yielding fundamental information for further design and development of σ1 ligands. Further-
more, and perhaps most importantly in the perspective of the present manuscript, those σ1
residues experimentally found to be involved in ligand binding activity of the receptor were
also found critical in our 3D model, according to our PRBFED and CAS simulations.
15.4 Synthesis and activity of new σ1 ligands, and comparison
with in silico predictions
The two series of phenylmethanone (1a–r) and amide (2a–l) derivatives designed using the
molecular modeling methodology described so far were then synthesized.
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All molecules were subsequently subjected to in vitro binding assays, in order to as-
sess their experimental affinity toward the σ1 receptor. The Ki(σ1) values for all 33 com-
pounds were determined using a protocol based on the competitive displacement of [3H]-(+)-
pentazocine in a rat liver homogenate preparation.174, 175
With respect to compounds 1a–r, the results confirm the presence of a basic nitrogen
atom substituted with a small group (H, −CH3) as a fundamental factor to endow the com-
pound with σ1 affinity. Actually, the N-substitution with a benzyl group decreases the affinity
of the derivatives 1g–i toward the receptor with respect to the corresponding derivatives 1a–
f ; contrarily, the presence of a −CH3 group linked to the basic nitrogen atom in compounds
1e (Ki(σ1) = 30.3 nM) and 1f (Ki(σ1) = 36.4 nM) improves the σ1 affinity of this compound.
However, the simultaneous absence of a small substituent (e.g., chlorine or methyl group)
on the para position of the benzyl moiety decreases the σ1 receptor affinity of compound 1d
(Ki(σ1) = 75.5 nM) with respect to the corresponding para-substituted compounds 1e and
1f. Compound 1e, characterized by the presence of a chlorine atom on the para position of
the benzyl residue and of a methyl group linked to the basic nitrogen atom, explicates the
highest σ1 affinity. The para substitution with chlorine in compound 1b (Ki(σ1) = 42.3 nM)
maintains some level of σ1 affinity, inferior to that of the corresponding N-methyl derivative
1e, but superior to that of the analogues 1a (Ki(σ1) = 114 nM) and 1c (Ki(σ1) = 139 nM).
The replacement of the phenyl or substituted phenyl residues in compounds 1j–r with the
pyridine-2-yl, pyridine-3-yl, or pyridine-4yl moieties abolishes the σ1 affinity of the corre-
sponding compounds. In the derivative series 2a–l, the amide nitrogen atom is linked to
variously substituted benzyl residues and to a 4-methylpiperidin-1-yl spacer, substituted on
the benzene ring. The basic nitrogen atom that allows the ionic bond with a receptor acid
site belongs to the piperidine cycle. The experimental σ1 affinity of compound 2c is rather
high (Ki(σ1) = 1.87 nM). Compound 2c is substituted with chlorine on the para position
of the benzyl group linked to piperidine nitrogen atom. The most potent compound of the
series, however, is the acetamide derivative 2e, characterized by a Ki(σ1) value as low as
0.09 nM. Interestingly, the corresponding benzamide derivative 2f shows a much lower σ1
receptor affinity (Ki(σ1) = 23.2 nM). Actually, acetamide derivatives are endowed with σ1
affinity higher than that of corresponding benzamide derivatives, except for compound 2g.
The superior affinity of acetamide derivatives may be attributed to the electron donating
effect of the acetamide methyl group that may increase the electronegative character of the
carbonyl oxygen and further contribute to the σ1 binding affinity as hydrogen bond acceptor.
One of the main purposes of the entire work was a general validation of our originally
proposed 3D model of the σ1 receptor. Therefore, the direct comparison of the results stem-
ming from the experimental ligand binding assays and the corresponding values predicted by
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could be a somewhat expected result, the correlation between
the experimental Ki(σ1) values and those derived from the
application of the MM/PBSA ranking is even more gratifying:
indeed, Figure 8B shows how well the calculated Ki(σ1)ΔGbind
values reproduce the experimental ones (R2 = 0.89), with a
correct ranking order. To further confirm the capability of the
entire MM/PBSA computational procedure in ranking the
affinities of all 33 compounds toward the σ1 receptor, we
compared the values of the ΔGbind calculated by MM/PBSA
(Table 2) with those derived from the biological assays (Tables
5 and 6): we can observe that the average unsigned error
between these two data sets is 0.93 kcal/mol, and the
corresponding root-mean-square deviation is 1.19 kcal/mol.
Thus, the remarkable quality of all these correlations, coupled
with the correct ranking of the wide range of the σ1 affinity
values, constitutes a further, decisive validation of the putative
σ1 binding site and, overall, of the entire 3D homology model
of this intriguingly enigmatic receptor.
■ CONCLUSIONS
σ receptors were first postulated by Martin et al.35 based on the
actions of SKF 10,047 (N-allylnormetazocine) and related
benzomorphans. The name ‘‘σ’’ originated from the first letter
‘‘S’’ in SKF 10,047, which was thought to be the prototypic
ligand for these binding sites. Unfortunately, SKF 10,047 is now
recognized as a nonselective ligand, which contributed to the
turbulent early history surrounding these enigmatic receptors.
One distinguishing feature of the σ1 receptor is its promiscuity
in binding a wide range of different pharmacological agents,
although how binding of these various compounds translates
into function(s) through the σ1 receptor is currently not clear.
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Since the discovery of the σ1 receptor, many preclinical studies
have implicated the receptor in many important human
diseases, from maladies of the central nervous system to
cancer, just to name a few. Notwithstanding many pharmaco-
logic responses have been linked to the σ receptors, the
function of the σ1 protein is still a subject of intense study and
current debate. Importantly, until very recent times relatively
little information regarding the structure of the σ1 receptor or
its ligand binding site was available to the scientific community.
Cloning of the σ1 receptor revealed that the rat brain receptor
σ1 protein consists of 223 amino acids, which results in a
molecular weight of 23 kDa. Although human and animal σ1
receptors show a similarity of more than 95%, unfortunately
there is no resemblance of this receptor to other known
mammalian proteins.
Table 6. σ1 Receptor Affinities of Compounds 2a−la
compd Ary R1 R2 Ki(σ1) (nM) ΔGbind,exp (kcal/mol)b
2a phenyl H CH3 9.62 ± 1.81 −10.93
2b phenyl H phenyl 18.8 ± 2.2 −10.53
2c phenyl Cl CH3 1.87 ± 0.29 −11.90
2d phenyl Cl phenyl 24.3 ± 3.6 −10.38
2e 4-chlorophenyl H CH3 0.09 ± 0.03 −13.70
2f 4-chlorophenyl H phenyl 23.2 ± 3.2 −10.41
2g 4-chlorophenyl Cl CH3 14.6 ± 1.4 −10.68
2h 4-chlorophenyl Cl phenyl 10.7 ± 2.5 −10.87
2i 4-methylphenyl H CH3 14.2 ± 2.5 −10.70
2j 4-methylphenyl H phenyl 118 ± 28 −9.45
2k 4-methylphenyl Cl CH3 61.8 ± 7.6 −9.83
2l 4-methylphenyl Cl phenyl 66.6 ± 12.5 −9.78
(+)-pentazocine 15 ± 3 −10.67
haloperidol 5.7 ± 1 −11.24
aThe Ki(σ1) values for (+)-pentazocine and haloperidol as reference compounds are also reported, for comparison.
bThe ΔGbind,exp values were
obtained from the corresponding Ki(σ1) values using the relationship ΔGbind = −RT ln(1/Ki).
Figure 8. (A) Plot of the experimental vs 3D pharmacophore predicted Ki(σ1) values for the 33 compounds of series 1 and 2 (R
2 = 0.89). (B) Plot of
the experimental vs MM/PBSA predicted Ki(σ1) values for the 33 compounds of series 1 and 2 (R
2 = 0.89).
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Figure 15.8: (A) Plot of the experimental vs 3D pharmacophore predicted Ki(σ1) values for
the 33 compounds of series 1 and 2 (R2 = 0.89). (B) Plot of the experimental vs MM/PBSA
predict d Ki(σ1) values for the 33 compounds of series 1 and 2 (R2 = 0.89).
the application of the entire computational ansatz constitutes a fundamental and important
point of the entire discussion. Figure 15.8 illustrates the results of this direct comparison.
In detail, Figure 15.8A shows the remarkable agreement between the affinities for the σ1
recep or of c mpounds 1 and 2 predicted by the 3D pharmacophore model (Ki(σ1)3DPh)
and the corresponding experimental Ki(σ1) values, quantified by a correlation coefficient of
0.89. If this could be a somewhat expected result, the correlation between the experimental
Ki(σ1) values and those d rived from the application f the MM/PBSA ranking is ev more
gratifying: indeed, Figure 15.8B shows how well the calculated Ki(σ1)∆Gbind values reproduce
the experiment l nes (R2 = 0.89), with a correct ranking order. To further o firm the
capability of the entire MM/PBSA computational procedure in ranking the affinities of all
33 compounds toward the σ1 receptor, we compared the values of the ∆Gbind calculated by
MM/PBSA (Table 15.2) with those derived from the biological assays: we observe that the
average unsigned error between these two data sets is 0.93 kcal mol−1, and the correspond-
ing root-mean-square deviation is 1.19 kcal mol−1. Thus, the remarkable quality of all these
correlations, coupled with the correct ranking of the wide range of the σ1 affinity values,
constitutes a further, decisive validation of the putative σ1 binding site and, overall, of the
entire 3D homology model of this intriguingly enigmatic receptor.
15.5 Conclusions
σ receptors were first postulated by Martin et al.83 based on the actions of SKF 10,047
(N-allylnormetazocine) and related benzomorphans. The name “σ” originated from the first
letter “S” in SKF 10,047, which was thought to be the prototypic ligand for these binding
sites. Unfortunately, SKF 10,047 is now recognized as a nonselective ligand, which contributed
to the turbulent early history surrounding these enigmatic receptors. One distinguishing fea-
ture of the σ1 receptor is its promiscuity in binding a wide range of different pharmacological
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agents, although how binding of these various compounds translates into function(s) through
the σ1 receptor is currently not clear.175 Since the discovery of the σ1 receptor, many preclin-
ical studies have implicated the receptor in many important human diseases, from maladies
of the central nervous system to cancer, just to name a few. Notwithstanding many pharma-
cologic responses have been linked to the σ receptors, the function of the σ1 protein is still
a subject of intense study and current debate. Importantly, until very recent times relatively
little information regarding the structure of the σ1 receptor or its ligand binding site was
available to the scientific community. Cloning of the σ1 receptor revealed that the rat brain
receptor σ1 protein consists of 223 amino acids, which results in a molecular weight of 23 kDa.
Although human and animal σ1 receptors show a similarity of more than 95 %, unfortunately
there is no resemblance of this receptor to other known mammalian proteins.
Lately our group published for the first time a 3D model of the σ1 receptor protein as
obtained from a multistep computational recipe based on homology modeling techniques.176
The reliability of the proposed σ1 model and the validity of its putative ligand binding
site were assessed by a docking/MM/PBSA-based small-scale virtual screening of a series
of available σ1 ligands, and by the receptor model-based design of three new σ1 ligands,
featuring a wide range of activity (from 1.87 to 1578 nM). To definitely confirm the validity
of this σ1 3D model and its reliability as a platform for σ1-ligand structure-based drug
design, in the present work we expanded our study by designing 33 new σ1 ligands, with
affinity for the receptor spanning five orders of magnitude. All these compounds were then
ranked for receptor affinity by extensive molecular dynamics simulation-based free energy
calculations, and the main interactions/receptor residues involved in ligand binding were
thoroughly analyzed by applying per residue free energy deconvolution and in silico alanine
scanning mutagenesis. All compounds were subsequently synthesized in our laboratory and
then tested for σ1 binding activity in vitro.
Remarkably, the experimental affinity ranking for all 33 compounds toward the σ1 recep-
tor was found to be fully consistent with the corresponding predictions obtained from our in
silico procedure. Therefore, we are convinced that the computational methodology adopted
here can be generally employed to estimate the affinity of new σ1 ligands prior to their syn-
thesis, with an obvious optimization of time and resources. Furthermore, if we reconsider all
experimental affinity data, we can see that both sets of compounds 1 and 2 can be classi-
fied on the basis of their experimental activity as highly affine (Ki(σ1) ≤ 40.0 nM, +++),
moderately affine (40.0 < Ki(σ1) < 600 nM, ++), and poorly affine (Ki(σ1) ≥ 600 nM, +).
According to this classification, and looking at the in silico ranking shown it Table 15.2,
we can also conclude that all compounds classified as highly affine (+++) are characterized
by ∆Gbind values ≤ −11.00 kcal mol−1, those with a moderate affinity (++) have −11.00 <
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∆Gbind < −8.50 kcal mol−1, and finally the less affine ones have ∆Gbind ≥ −8.50 kcal mol−1.
Taking into account that the entire computational methodology is based on a protein struc-
ture obtained via homology modeling techniques, these ranking capacities and the related
results ultimately assess the reliability of the σ1 receptor 3D model in structure-based ligand
design.
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16
The Sigma enigma: in vitro/in silico site-directed
mutagenesis studies unveil σ1 receptor ligand
binding1
The σ1 receptor is an integral membrane protein that play critical roles in a wide variety of
cell functions. Unfortunately it shares no homology with other receptor systems; moreover it
has no unequivocally identified natural ligands. The only structural model of this receptor is
the 3D homology model developed by our group. In this chapter I will describe the exhaustive
in vitro/in silico investigation that we performed to analyze the molecular interactions of the
σ1 receptor with its prototypical agonist (+)-pentazocine (PTZ).
We developed 23 mutant σ1 isoforms, and their interactions with (+)-pentazocine were
determined experimentally. Once the effects of the mutations was correctly observed also in
silico, proving the reliability of our model, the rationalization of all the effects exerted by
all the mutant residues on the receptor-agonist interactions were performed. With this work,
we further validated our 3D homology model of the σ1 receptor as a trustworthy tool in the
1The matherial presented in this chapter was published at: Brune, S., Schepmann, D., Klempnauer, K.
H., Marson, D., Dal Col, V., Laurini, E., et al. (2014). Biochemistry, doi:10.1021/bi401575g
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Figure 16.1: Specific [3H]-(+)-pentazocine binding (SB) at a concentration of 40 nM to dif-
ferent alanine mutants of the human σ1 receptor (n ≥ 2). SB refers to the PTZ binding of the
wild-type (wt) receptor (100 %, first column). **p ≤ 0.001; *p ≤ 0.01. With respect to the red
lines, SB < 30 % indicates a strong influence of the particular amino acid on ligand binding,
30 % ≤ SB ≤ 70 % indicates a moderate influence on ligand binding, and SB > 70 % indicates
no influence on ligand binding.
study of this enigmatic protein, and also we gave a deep description of its putative ligand
binding site.
The model used in this work was an improvement of the previously developed model176
in our possess. I further optimized its structure with a long molecular dynamic simulation in
which the receptor was inserted in a lipid membrane (2:2:1 POPC:POPE:cholesterol), a very
good approximation of its physiological environment.
16.1 Mutants selection
On the basis of preliminary in silico information, 23 mutants of the σ1 receptor were cloned
and expressed and their interactions with PTZ were assessed experimentally (Figure 16.1).
As described below, all direct and indirect effects exerted by the mutant residues on the
receptor-agonist interactions could be reproduced in silico and rationalized at the molecular
level.
At first, we considered those σ1 residues to belong to the protein putative ligand binding
site. For this purpose, the interaction of PTZ with the wild-type (wt) σ1 receptor 3D model
was simulated using molecular dynamics (MD): the corresponding estimated drug-receptor
affinity (Kci ) value of 45 nM compares well with the experimentally measured Kei value of
15 nM.162 Specifically, the following interactions were found to be essential for PTZ binding
(Figure 16.2):
• a permanent salt bridge between the −NH+ moiety of PTZ and the −COO– group of
D126 [average dynamic length (ADL) of (3.93± 0.09)Å];
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Figure 16.2: Equilibrated MD snapshot of the wt σ1 receptor in complex with PTZ. The
image is a close-up of the receptor binding site. The ligand is shown with colored balls and
sticks (C, gray; N, blue; O, red). The protein residues mainly involved in the interaction with
PTZ are highlighted as labeled colored sticks. Salt bridges and H-bond interactions are shown
as solid and dotted black lines, respectively. The yellow shadow denotes the hydrophobic pocket
generated by the side chains of I128 and Y173.
• a stable hydrogen bond between the carboxylate group of E172 and the hydroxyl sub-
stituent of PTZ (ADL of (1.98± 0.04)Å);
• a T-stacking pi-pi interaction between the side chains of Y120 and W121 and the het-
eroaromatic condensed rings of PTZ;
• highly stabilizing van der Waals (vdW) and electrostatic interactions between R119,
I128, and Y173 and the aliphatic/aromatic portions of the ligand.
These receptor−ligand interactions were quantified via a per residue deconvolution of the free
energy of binding (Figure 16.3). Accordingly, the salt bridge and the hydrogen bond involving
D126 and E172 are responsible for stabilizing contributions of −2.89 and −1.83 kcal mol−1,
respectively. Substantial vdW and electrostatic interactions are further contributed by R119
(−0.98 kcal mol−1), Y120 (−1.49 kcal mol−1), W121 (−1.37 kcal mol−1), I128 (−2.04 kcal mol−1),
and Y173 (−1.95 kcal mol−1). T151 and V152 additionally contribute to the stabilization of
PTZ-σ1 binding with −0.36 and −0.38 kcal mol−1, respectively.
Interestingly, in a recent work, Chu at al. discussed the possibility of σ1 receptors existing
in a homo- or heterodimeric form when bound to a single ligand.177 Specifically, these authors
suggested that the observed σ1 binding and activity of the N-[3-(4-nitrophenyl)propyl]alkan-
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Figure 16.3: Per residue energy decomposition for the wt σ1 receptor in complex with PTZ.
Only σ1 amino acids from position 100 to 200 are shown, as for all remaining residues the
contribution to ligand binding is irrelevant. On the left, an expanded view of the first panel
showing those σ1 residues for which |∆Hbind| ≥ 0.5 kcal mol−1.
σ1 residue specific binding of PTZ [%] ∆Gbind [kcal mol−1] ∆∆Gbind [kcal mol−1]
wt 100 −10.02± 0.05 -
R119A 26± 3.5 −8.31± 0.05 -1.71
Y120A 62± 10 −9.34± 0.08 -0.68
W121A 76± 12 −8.48± 0.06 -1.54
I238A 1.1± 0.6 −7.55± 0.06 -2.47
Y173A 0.4± 0.4 −7.32± 0.11 -2.70
D126E 54± 3 −9.13± 0.07 -0.89
E172D 0± 0.1 −7.88± 0.06 -2.14
Table 16.1: In vitro/in silico site-directed mutagenesis of σ1 residues directly involved in PTZ
binding. ∆∆Gbind = ∆Gbind,wt − ∆Gbind,mutant; by this definition, a negative value of ∆∆Gbind
indicates a favorable contribution for the wt residue in that position and vice versa.
1-amine 4-NPPC12 might evoke a ligand binding model for the σ1 receptor that likely in-
volves a receptor dimer and/or oligomer. Undoubtedly, more conclusive studies are needed
to conclusively ascertain this interesting hypothesis and to discard specific ligand-dependent
oligomerization mechanisms. On the other hand, the monomeric 3D model of the σ1 receptor
discussed in this work has been comprehensively employed to predict and rationalize the
binding modes and affinities of a broad series of structurally unrelated σ1 ligands, including
PTZ, and the results of these in silico predictions were successfully validated against rele-
vant experimental data. Therefore, should a dimeric ligand-bound form of the σ1 receptor be
verified for different, known σ1 ligands,93, 161, 178, 179 the present monomeric σ1-ligand binding
model may eventually constitute a step along the dimerization pathway.
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16.2 R119, I128, and Y173 are essential residues for PTZ bind-
ing
The results of the site-directed mutations of those residues identified in silico as being crucial
for PTZ binding are listed in Table 16.1. We see that mutating residues R119, I128, and Y173
within the σ1 binding site to alanine leads to an almost complete loss of ligand binding, as
predicted from simulation. Indeed, residues I128 and Y173 afford a significant contribution
to the PTZ-σ1 complex (Figure 16.3), as their side chains generate a hydrophobic pocket
tailored to encase the methylbut-2-enyl moiety of PTZ. Accordingly, the favorable hydropho-
bic interactions exerted by these two residues in the binding of PTZ are lost upon alanine
substitution [for I128, specific binding, SB = 1 % and ∆∆Gbind = −2.47 kcal mol−1; for Y173,
SB = 0.4 % and ∆∆Gbind = −2.70 kcal mol−1 (Figure 16.1)]. On the other hand, the affinity
of the Y120A and W121 σ1 mutants for PTZ was only partly reduced (SB values of 62 and
76 %, respectively). Interestingly, the relevant modeling analysis reveals that, although each
of these two aromatic residues concurs in stabilizing PTZ binding mainly via pi-pi interactions
(Figure 16.3), the effect of mutating either of these two positions to alanine results in an
apt rearrangement of the alternative residue side chain within the binding site and, hence, in
a partial compensation of the receptor affinity loss [∆∆Gbind values of −0.68 kcal mol−1 for
Y120A and bind −1.54 kcal mol−1 for W121A (Table 16.1)].
16.3 D126 and E172 are strategically located within the σ1
binding site
The anionic amino acids D126 and E172 are known to be essential for ligand (i.e., haloperidol)
binding,162 and our combined study indeed confirms their role in binding PTZ (Figure 16.1
and Figure 16.3). To substantiate this prediction, however, we decided to swap these two
residues with each other instead of replacing them with alanine in the corresponding site-
directed mutagenesis experiments. Interestingly, the E172D σ1 mutant was totally devoid
of PTZ binding, while the D126E isoform preserved 54 % of the wt affinity. These results
clearly demonstrate the specific and strategic location of these two negative charges within
the σ1 binding site: while the elongation of the side chain from aspartate to glutamate at
position 126 is somewhat tolerated [∆∆Gbind = −0.89 kcal mol−1 (Table 16.1)], resulting
in a mild rearrangement of the protein binding pocket that preserves the main network
of interactions between the ligand and the protein, the corresponding reduction in chain
length in the E172D mutant fully abrogates the ability of the protein to bind the radioligand
[∆∆Gbind = −2.14 kcal mol−1 (Table 16.1)]. In detail, the substitution of D/E at position
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Figure 16.4: Comparison of the equilibrated MD snapshots of the wt σ1 receptor (blue) with
(a) D126E (goldenrod), (b) E172D (forest green), (c) D126A (red), and (d) E172A (firebrick)
mutants in complex with PTZ. All images are close-ups of the receptor binding site. The ligand
is shown as balls and sticks colored according to the respective protein complex. Hydrogen
atoms, water molecules, ions, and counterions were omitted for the sake of clarity.
126 leads to a longer, and hence less stable, salt bridge between the −NH+ group ion of
PTZ and the −COO– group of the E126 side chain (ADL of (4.85± 0.08)Å), leaving all
other ligand-receptor interactions almost unaltered (Figure 3a). Upon E172D substitution,
however, the missing H-bond between position 172 and the −OH group on PTZ leads to a
global readjustment of the protein binding site (Figure 16.4b), which ultimately leads to an
overall decrease in the favorable contributions to ligand binding.
To further corroborate this fundamental finding, we also performed in silico mutagenesis
of D126 and E172 to alanine. As expected, the prominent role exerted by D126 and E172
in binding PTZ is reflected in the highly unfavorable affinity predicted for the D126A and
E172A mutants [∆∆Gbind values of −3.01 and −2.02 kcal mol−1, respectively. The missing
critical salt bridge and H-bond interactions in which these residues are engaged in the wt
protein bound to PTZ result in a catastrophic loss of drug interaction when the residues
are mutated to alanine (Figure 16.4c and Figure 16.5). These predictions match the results
previously reported by Seth et al.162 for in vitro PTZ binding assays of the D126G and
E172G σ1 mutants; taken together, these results ultimately confirm the obligatory nature
of the highly conserved D126 and E172 residues for the ligand binding function of the σ1
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interactions almost unaltered (Figure 3a). Upon E172D
substitution, however, the missing H-bond between position
172 and the OH group on PTZ leads to a global readjustment of
the protein binding site (Figure 3b), which ultimately leads to an
overall decrease in the favorable contributions to ligand binding.
To further corroborate this fundamental finding, we also
performed in silico mutagenesis of D126 and E172 to alanine. As
expected, the prominent role exerted by D126 and E172 in
binding PTZ is reflected in the highly unfavorable affinity
predicted for the D126A and E172A mutants [ΔΔGbind values of
−3.01 and −2.02 kcal/mol, respectively (Table S3 of the
Supporting Information)]. Themissing critical salt bridge andH-
bond interactions in which these residues are engaged in the wt
protein bound to PTZ result in a catastrophic loss of drug
interaction when the residues are mutated to alanine (Figure 3c−
f). These predictions match the results previously reported by
Seth et al.19 for in vitro PTZ binding assays of the D126G and
E172G σ1 mutants; taken together, these results ultimately
confirm the obligatory nature of the highly conserved D126 and
E172 residues for the ligand binding function of the σ1 receptor.
Polar Residues Are Required in the SBDLI Domain To
Maintain the Binding Site Geometry. Next, we explored the
effect of mutations on residues belonging to the SBDLI and
SBDLII σ1 domains by performing a systematic substitution of
the polar (S and T) and aromatic (F and Y) amino acids of these
protein regions with alanine. The results are listed in Table 2.
Mutating the polar and aromatic amino acids of SBDLI (S101,
Y103, and F107) to alanine both in silico and in vitro led to a
considerable decrease in the level of PTZ binding [SB = 18−30%,
andΔΔGbind =−2.13 to−1.86 kcal/mol (Table 2, rows 1−3)]. A
sensible explanation of these results is that all three alanine-
mutated residues are in the proximity of the transmembrane
domain of the σ1 receptor (Figure 4a) and, during the long MD
simulation, they promote a substantial modification of both the
Figure 3. Comparison of the equilibrated MD snapshots of the wt σ1 receptor (blue) with (a) D126E (goldenrod), (b) E172D (forest green), (c)
D126A (red), and (d) E172A (firebrick) mutants in complex with PTZ. The images are close-ups of the receptor binding site. The ligand is shown as
balls and sticks colored according to the respective protein complex. In panels a−c, hydrogen atoms, water molecules, ions, and counterions were
omitted for the sake of clarity. (e) Comparison of σ1 residue contributions to PTZ binding for the wt and the E172Dmutant protein. (f) Expanded view
of panel e showing those σ1 residues for which |ΔHbind| ≥ |0.5 kcal/mol| in the wt receptor.
Table 2. In Vitro/in Silico Site-Directed Mutagenesis of σ1
Residues Belonging to the SBDLI and SBDLII Motifsa
σ1 residue domain
specific binding of
PTZ (%)
ΔGbind
(kcal/mol)
ΔΔGbindb
(kcal/mol)
S101A SBDLI 30 (27) −8.16 (0.08) −1.86
Y103A 22 (12) −7.89 (0.09) −2.13
F107A 18 (11) −8.05 (0.05) −1.97
T181A SBDLII 93 (7.5) −9.99 (0.11) −0.03
F184A 124 (18) −10.55 (0.07) 0.53
T189A 99 (1.1) −9.87 (0.07) −0.15
F191A 88 (14) −9.13 (0.10) −0.89
201Stop 1.0 (0.6) − −
209Stop 0.9 (0.5) − −
217Stop 37 (7.7) −8.80 (0.06) −1.22
aSpecific PTZ binding of different alanine mutants of the human σ1
receptor and in silico-estimated free energy of binding (ΔGbind) of the
same σ1 alanine mutants as generated by computational mutagenesis.
Errors are given in parentheses as standard errors of the mean.
bΔΔGbind = ΔGbind,wt − ΔGbind,mutant.
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Figure 16.5: Comparison of σ1 residue contributions to PTZ binding for the wt and the E172D
mutant protein. On e righ , the expanded view of the left panel, showing those σ1 residues
for which |∆Hbind| ≥ 0.5 kcal mol−1 in the wt receptor.
σ1 residue domain specific binding of PTZ [%] ∆Gbind [kcal mol−1] ∆∆Gbind [kcal mol−1]
S101A SBDLI 30± 27 −8.16± 0.08 −1.86
Y103A 22± 12 −7.89± 0.09 −2.13
F107A 18± 11 −8.05± 0.05 −1.97
T181A SBDLII 93± 7.5 −9.99± 0.11 −0. 3
F184A 124± 18 −10.55± 0.07 +0.53
T189A 99± 1.1 −9.87± 0.07 −0.15
F191A 88± 14 −9.13± 0.10 −0.89
201stop 1.0± 0.6 − −
209stop 0.9± 0.5 − −
217stop 37± 7.7 8.80± 0.06 −1.22
Table 16.2: In vitro/in silico site-directed mutagene is of σ1 residu s belonging to the SBDLI
and SBDLII motifs. ∆∆Gbind = ∆Gbind,wt − ∆Gbind,mutant; by this definition, a negative value
of ∆∆Gbind indicates a favorable cont ibu ion for the wt residue in that position and vice versa.
receptor.
16.4 Pol r residues are required in the SBDLI dom in to main-
tain the binding site geometry
Next, we explored the effect of mutations on residues belonging to the steroid binding domain-
like I (SBDLI) and steroid binding domain-like II (SBDLII) σ1 domains by performing a
systematic substitution of the polar (S and T) and aromatic (F and Y) amino acids of these
protein regions with alanine. The results are listed in Table 16.2. Mutating the polar and aro-
matic amino acids of SBDLI (S101, Y103, and F107) to alanine both in silico and in vitro led
to a considerable decrease in the level of PTZ binding [SB = 18–30 %, and ∆∆Gbind = −2.13
to −1.86 kcal mol−1 (Table 16.2)]. A sensible explanation of these results is that all three
alanine-mutated residues are in the proximity of the transmembrane domain of the σ1 receptor
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Figure 16.6: Close-up the residues be-
longing to the σ1 SBDLI and -II do-
mains, represented as forest and light green
sticks, respectively. The ligand is shown as
element-colored balls and sticks (C, gray;
N, blue; O, red) with its vdW surface col-
ored blue. The membrane phospholipids
are portrayed as semitransparent light yel-
low balls and sticks.
Figure 16.7: General secondary structure description of the σ1 receptor (amino acids 100–223)
during MD simulations of the wt-, Y103A-, and F184A-PTZ complexes. The y-axis gives the
percentage of specific secondary structure for each σ1 residue.
Figure 16.8: RMSD values of the
coordinates of the heavy atoms of
PTZ along the MD simulation com-
pared with those of the initial struc-
ture.
entire binding site and the surrounding protein regions. Taking
the PTZ−σ1(Y103A) complex as a proof of concept, we
observed a different rearrangement of the secondary structure
of this protein portion with respect to the PTZ−wt assembly
(Figure 4b, top and central panels), ultimately resulting in an
expansion of the receptor binding pocket from an average
dynamic volume (ADV) of 509 ± 5 Å3 to an ADV of 573 ± 7 Å3.
Accordingly, the ligand binds the receptor more loosely, as its
interactions with the protein residues lining the binding site
become weaker (Figure 4c). This effect is clearly seen in the
behavior of the rmsd of the heavy atom of PTZ during the MD
simulation (Figure 4d): after equilibration, the ligand assumes a
stable conformation in the wt binding pocket with an average
rmsd of 1.01 ± 0.06 Å, while a larger rmsd fluctuation (2.18 ±
0.35 Å) and a longer time to equilibrium are observed for the
Y103A mutant σ1−PTZ complex.
Residues in the SBDLII Domain Scarcely Contribute to
Ligand Binding. In stark contrast, analogous mutations in the
SBDLII domain barely influenced PTZ binding, if they did at all
[SB = 93−100%, andΔΔGbind =−0.59 to−0.03 kcal/mol (Table
2, rows 4−7)]. A comparison of the membrane-bound wt and
SDBLII mutated σ1 isoforms reveals that the presence of
mutations at the SBDLII domain does not lead to substantial
alteration of both the membrane and the protein binding site
and/or overall structure. Indeed, in the representative example of
the PTZ−σ1(F184A) complex, the fingerprint of the protein
secondary structure is conserved (Figure 4b, top and bottom
panels) and the average dynamic volume is essentially unchanged
(507 ± 7 Å3). Moreover, PTZ maintains a very stable
conformation in the binding site during the entire MD
simulation, as substantiated by the relevant rmsd [1.01 ± 0.07
Å (Figure 4c)]. Lastly, all ligand−receptor interactions detected
for the wt complex are maintained in this as well as in all other
Figure 4. (a) Close-up the residues belonging to the σ1 SBDLI and -II domains, represented as forest and light green sticks, respectively. The ligand is
shown as element-colored balls and sticks (C, gray; N, blue; O, red) with its van der Waals surface colored blue. The membrane phospholipids are
portrayed as semitransparent light yellow balls and sticks. (b) General secondary structure description of the σ1 receptor (amino acids 100−223) during
MD simulations of the wt−, Y103A−, and F184A−PTZ complexes. The y-axis gives the percentage of specific secondary structure for each σ1 residue.
(c) rmsd values of the coordinates of the heavy atoms of PTZ along the MD simulation compared with those of the initial structure. Comparison of the
equilibrated MD snapshots of the wt σ1 receptor (blue) with (d) Y103A (dark olive green) and (e) F184A (orange) mutants in complex with PTZ. The
images are close-ups of the receptor binding site. The ligand is shown as balls and sticks colored according to the respective protein complex. In panels d
and e, hydrogen atoms, water molecules, ions, and counterions were omitted for the sake of clarity.
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(Figure 16.6) and, during the long MD simulation, they promote a substantial modification of
both the entire binding site and the surrounding protein regions. Taking the PTZ-σ1(Y103A)
complex as a proof of concept, we observed a different rearrangement of the secondary struc-
ture of this protein portion with respect to the PTZ-wt assembly (Figure 16.7, top and central
panels), ultimately resulting in an expansion of the receptor binding pocket from an average
dynamic volume (ADV) of (509± 5)Å3 to an ADV of (573± 7)Å3. Accordingly, the ligand
binds the receptor more loosely, as its interactions with the protein residues lining the bind-
ing site become weaker. This effect is clearly seen in the behavior of the root-mean-square
deviation (RMSD) of the heavy atom of PTZ during the MD simulation (Figure 16.8): after
equilibration, the ligand assumes a stable conformation in the wt binding pocket with an
average RMSD of (1.01± 0.06)Å, while a larger RMSD fluctuation ((2.18± 0.35)Å) and a
longer time to equilibrium are observed for the Y103A mutant σ1-PTZ complex.
16.5 Residues in the SBDLII domain scarcely contribute to lig-
and binding
In stark contrast, analogous mutations in the SBDLII domain barely influenced PTZ binding,
if they did at all [SB = 93–100 %, and ∆∆Gbind = −0.59 to −0.03 kcal mol−1 (Table 16.2, rows
4–7)]. A comparison of the membrane-bound wt and SDBLII mutated σ1 isoforms reveals
that the presence of mutations at the SBDLII domain does not lead to substantial alteration
of both the membrane and the protein binding site and/or overall structure. Indeed, in
the representative example of the PTZ-σ1(F184A) complex, the fingerprint of the protein
secondary structure is conserved (Figure 16.7, top and bottom panels) and the ADV is
essentially unchanged ((507± 7)Å3). Moreover, PTZ maintains a very stable conformation
in the binding site during the entire MD simulation, as substantiated by the relevant RMSD
[(1.01± 0.07)Å (Figure 16.8)]. Lastly, all ligand-receptor interactions detected for the wt
complex are maintained in this as well as in all other SBDLII mutated complexes examined
with no significant differences in binding mode or strength. Remarkably, in a previous study,
SBDLII was postulated to be part of the σ1 ligand binding site.180 Our results clearly do
not support this hypothesis. It has been further proposed that SBDLII is responsible for
anchoring the σ1 receptors to the membrane and, in so doing, stabilizing the 3D structure of
the protein. Once again, our combined in vitro/in silico experiments point in the opposite
direction. Taken together, our findings lead to the conclusion that, while the SBDLI domain
is part of the binding site of the σ1 receptor and, as such, mutations at this domain lead
to a drastic decrease in receptor-ligand affinity, the SBDLII domain does not belong to the
σ1 ligand binding site. Accordingly, mutations in this protein domain exert only a marginal
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SBDLII mutated complexes examined with no significant
differences in bindingmode or strength (Figure 4e). Remarkably,
in a previous study, SBDLII was postulated to be part of the σ1
ligand binding site.25 Our results clearly do not support this
hypothesis. It has been further proposed that SBDLII is
responsible for anchoring the σ1 receptors to the membrane
and, in so doing, stabilizing the 3D structure of the protein. Once
again, our combined in vitro/in silico experiments point in the
opposite direction. Taken together, our findings lead to the
conclusion that, while the SBDLI domain is part of the binding
site of the σ1 receptor and, as such, mutations at this domain lead
to a drastic decrease in receptor−ligand affinity, the SBDLII
domain does not belong to the σ1 ligand binding site.
Accordingly, mutations in this protein domain exert only a
marginal effect on ligand binding, if any at all.
Even Small Deletions in the σ1 C-Terminal End
Abrogate Ligand Binding. As briefly mentioned above, σ1
ligand binding is abrogated when more than 15 amino acids are
removed from the C-terminal end of the protein.20 Thus, we
further investigated this aspect by deleting 7, 15, and 23 amino
acids from the C-terminal end of the σ1 receptor and determined
the affinity of the truncated receptors for PTZ. As expected,
elimination of 15 and 23 amino acids resulted in the loss of PTZ
binding ability (Figure 1c and Table 2). More interestingly, also,
the removal of only seven residues from the receptor C-terminal
end led to a considerable decrease in the level of PTZ binding
(SB = 37%). Again, these experiments were rationalized by the
corresponding in silico assays. While the major deletions resulted
in a partially unfolded structure of the receptor missing a large
portion of the ligand binding site, the affinity of the seven-
residue-truncated protein for PTZ remained low (Figure 5a), as
quantified by the ΔGbind value of −8.80 kcal/mol. The
corresponding ΔΔGbind of −1.22 kcal/mol nicely correlates
with the 63% decrease in affinity with respect to that of the wt
protein reported by in vitro mutagenesis. The seven deleted
amino acids are not directly involved in ligand binding; however,
the missing YLFGQDP sequence results in a structural
modification of the receptor that, like a domino effect, propagates
along the protein backbone to the binding site (Figure 5b). This
overall configuration rearrangement directly affects three σ1
residues most important for ligand binding: R119, D126, and
E172. Specifically, the interaction of D126 with PTZ becomes
less favorable by 1.54 kcal/mol with respect to the wt isoform,
while E172 decreases its contribution by −1.68 kcal/mol.
Distal Residues Also Shape the σ1 Binding Site. Lastly, to
determine whether other σ1 receptor residues could play a critical
role in binding PTZ, several alternative positions between the
SBDLI and -II protein domains were substituted with alanine. In
silico mutagenesis results suggested that the hydrophobic V145
and the aromatic F146 and Y147 residues, when mutated to
alanine, result in minor (if any) changes in the protein binding
site conformation (Table 3). These results are confirmed by the
corresponding in vitro experiments, showing that for these three
residues the SB values range between 57 and 121%. However, the
alanine mutants of the basic amino acid R175 and of the two
polar residues (S125 and T127) show a moderate (S125A and
T127A) to strong (R175A) influence on PTZ binding, as
revealed by the drastically less favorableΔΔGbind values of−1.45,
−1.24, and −2.02 kcal/mol, respectively (Table 3), and
supported by the corresponding SB values (49, 45, and 10%,
respectively). The S145A and T127A mutations transform the
environment in the proximity of the negatively charged D126
from polar to hydrophobic that, in turn, decreases the strength of
its salt bridge with PTZ (ADL values of 4.76 ± 0.07 and 4.69 ±
0.10 Å for S145A and T127A, respectively). The case of the
R175A mutant is more complex, as experiments detect a
drastically reduced affinity of this mutant σ1 isoform for PTZ (SB
= 10%). The calculated free energy of binding differs
considerably from that of the wt σ1 complex (ΔΔGbind = −2.02
kcal/mol), although this residue is not directly involved in PTZ
binding. Importantly, however, along the entireMD course R175
forms a stable, bifurcated H-bond with Y120 and R114. These
residues, in turn, stabilize the conformation of Y173 for
productive binding via another direct H-bond (Figure 6a). All
Figure 5. In silico mutagenesis of σ1 receptor residues via deletion of the seven-residue YLFGQDP sequence from the protein C-terminal domain. (a)
Comparison of the equilibrated MD snapshots of the wt (blue) and C-terminal seven-residue-truncated σ1 receptor (magenta) in complex with PTZ.
The image is a close-up of the receptor binding site. The ligand is shown as balls and sticks colored according to the respective protein complex.
Hydrogen atoms, water molecules, ions, and counterions were omitted for the sake of clarity. (b) Comparison of contributions of σ1 receptor residues to
PTZ binding for the wt and C-terminal seven-residue-truncated protein.
Table 3. In Vitro/in Silico Site-Directed Mutagenesis of σ1
Residues Belonging to the Region between the Protein SBDLI
and SBDLII Motifsa
σ1
residue
specific binding of PTZ
(%)
ΔGbind
(kcal/mol)
ΔΔGbindb
(kcal/mol)
wt 100 −10.02 (0.05) −
S125A 49 (1.5) −8.57 (0.09) −1.45
T127A 45 (2.3) −8.78 (0.11) −1.24
V145A 78 (14) −9.89 (0.07) −0.13
F146A 57 (0.3) −9.42 (0.09) −0.60
Y147A 121 (4.1) −8.80 (0.06) −1.22
R175A 10 (4.1) −8.00 (0.10) −2.02
aSpecific PTZ binding of different alanine mutants of the human σ1
receptor and in silico-estimated free energy of binding (ΔGbind) of the
same σ1 alanine mutants as generated by computational mutagenesis.
Errors are given in parentheses as standard errors of the mean.
bΔΔGbind = ΔGbind,wt − ΔGbind,mutant.
Biochemistry Article
dx.doi.org/10.1021/bi401575g | Biochemistry XXXX, XXX, XXX−XXXI
Figure 16.9: In ilico mutag nesis of σ1 receptor residues via deletion of the seven-residue
YLFGQDP sequence from the protein C-terminal domain. (a) Comparison of the equilibrated
MD snapshots of the wt (blue) and C-terminal seven-residue-truncated σ1 receptor (magenta)
in complex with PTZ. The image is a close-up of the receptor binding site. The ligand is
shown as balls and sticks colored according to the respective protein complex. Hydrogen atoms,
water molecules, ions, and counterions were omitted for the sake of clarity. (b) Comparison of
contributions of σ1 receptor residues to PTZ binding for the wt and C-terminal seven-residue-
truncated protein.
effect on ligand binding, if any at all.
16.6 Even small deletions in the σ1 C-terminal end abrogate
ligand binding
As briefly mentioned above, σ1 ligand binding is abrogated when more than 15 amino acids
are removed from the C-terminal end of the protein.181 Thus, we further investigated this
aspect by dele ing 7, 15, and 23 am o acids from the C-terminal end of the σ1 receptor and
d termined the affinity of the truncated receptors for PTZ. As expected, elimination of 15
and 23 amino acids resulted in the loss of PTZ binding ability (Figure 16.1 and Table 16.2).
More interestingly, also, the removal of only seven residues from the receptor C-terminal
end led to a considerable decrease in the level of PTZ binding (SB = 37 %). Again, these
experiments were rationalized by the corresponding in silico assays. While the major dele-
tions resulted in a partially unfolded structure of the receptor missing a large portion of the
ligand binding site, the affinity of the seven-residue-truncated protein for PTZ remained low
(Figure 16.9a), as quantified by the ∆Gbind value of −8.80 kcal mol−1. The cor sponding
∆∆Gbind of −1.22 kcal mol−1 nicely correlates with the 63 % decrease in affinity with respect
to that of the wt protein reported by in vitro mutagenesis. The seven deleted amino acids
re t directly involved in ligand binding; however, the missing YLFGQDP sequence results
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σ1 residue specific binding of PTZ [%] ∆Gbind [kcal mol−1] ∆∆Gbind [kcal mol−1]
wt 100 −10.02± 0.05 -
S125A 49± 1.5 −8.57± 0.09 -1.45
T127A 45± 2.3 −8.78± 0.1 -1.24
V145A 78± 14 −9.89± 0.07 -0.13
F146A 57± 0.3 −9.42± 0.09 -0.60
Y147A 121± 4.1 −8.80± 0.06 -1.22
R175A 10± 4.1 −8.00± 0.10 -2.02
Table 16.3: In vitro/in silico site-directed mutagenesis of σ1 residues belonging to the region
between the protein SBDLI and SBDLII motifs. ∆∆Gbind = ∆Gbind,wt − ∆Gbind,mutant; by this
definition, a negative value of ∆∆Gbind indicates a favorable contribution for the wt residue in
that position and vice versa.
in a structural modification of the receptor that, like a domino effect, propagates along the
protein backbone to the binding site (Figure 16.9b). This overall configuration rearrangement
directly affects three σ1 residues most important for ligand binding: R119, D126, and E172.
Specifically, the interaction of D126 with PTZ becomes less favorable by 1.54 kcal mol−1 with
respect to the wt isoform, while E172 decreases its contribution by 1.68 kcal mol−1.
16.7 Distal residues also shape the σ1 binding site
Lastly, to determine whether other σ1 receptor residues could play a critical role in binding
PTZ, several alternative positions between the SBDLI and -II protein domains were substi-
tuted with alanine. In silico mutagenesis results suggested that the hydrophobic V145 and
the aromatic F146 and Y147 residues, when mutated to alanine, result in minor (if any)
changes in the protein binding site conformation (Table 16.3). These results are confirmed by
the corresponding in vitro experiments, showing that for these three residues the SB values
range between 57 and 121 %. However, the alanine mutants of the basic amino acid R175 and
of the two polar residues (S125 and T127) show a moderate (S125A and T127A) to strong
(R175A) influence on PTZ binding, as revealed by the drastically less favorable ∆∆Gbind
values of −1.45, −1.24, and −2.02 kcal mol−1, respectively (Table 16.3), and supported by
the corresponding SB values (49 %, 45 %, and 10 %, respectively). The S145A and T127A
mutations transform the environment in the proximity of the negatively charged D126 from
polar to hydrophobic that, in turn, decreases the strength of its salt bridge with PTZ (ADL
values of (4.76± 0.07)Å and (4.69± 0.10)Å for S145A and T127A, respectively). The case
of the R175A mutant is more complex, as experiments detect a drastically reduced affinity
of this mutant σ1 isoform for PTZ (SB = 10 %). The calculated free energy of binding differs
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wt Y120 Y173 R175
R114 +0.02 −0.91 −0.88
Y120 - −0.26 −0.71
Y173 - - +0.02
R175 - - -∑∆Hbind - - −2.72
wt Y120 Y173 A175
R114 −0.01 −0.73 +0.02
Y120 - −0.03 −0.12
Y173 - - −0.02
A175 - - -∑∆Hbind - - −0.89
Table 16.4: Per residue free energy decomposition for wt and R175A mutant σ1 receptors in
complex with PTZ. All energy values are inkcal mol−1. Standard deviations range from ±0.01
to ±0.10.
Figure 16.10: Details of the residues involved in a structurally stabilizing interaction of the
(a) wt and (b) R175A mutant σ1 receptor in complex with PTZ as obtained from equilibrated
MD simulation snapshots. The protein backbone is shown as a transparent ribbon colored by
secondary type (orange, α- helices; cyan, β-sheets; light gray, coils). The main residues involved
in the interactions are shown as labeled green sticks. PTZ is shown as balls and sticks colored
by element (C, gray; O, red; N, blue). In all panels, hydrogen atoms, water molecules, ions, and
counterions were omitted for the sake of clarity.
considerably from that of the wt σ1 complex (∆∆Gbind = −2.02 kcal mol−1), although this
residue is not directly involved in PTZ binding. Importantly, however, along the entire MD
course R175 forms a stable, bifurcated H-bond with Y120 and R114. These residues, in turn,
stabilize the conformation of Y173 for productive binding via another direct H-bond (Fig-
ure 16.10). All these interactions translate into a −2.72 kcal mol−1 global favorable enthalpic
contribution of these four amino acids to ligand binding, as detailed in Table 16.4. As dis-
cussed above, both Y120 and Y173 play a major role not only in direct PTZ binding but also
in shaping the entire σ1 binding site. Thus, replacing R175 with alanine results in an almost
complete loss of the H-bond interaction network (Figure 16.10): the aromatic interaction
between Y120 and PTZ is lost, the entire binding site is enlarged, and the corresponding
complex stabilization energy decreases dramatically [0.89 kcal mol−1 (Table 16.4)].
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16.8 Conclusions
The combined in vitro/in silico mutagenesis study reported here confirms some previous
knowledge of the structural features of the σ1 receptor and its binding site but also, and
perhaps more importantly, qualifies and quantifies the role of several receptor residues that
figure prominently in receptor-ligand binding.
Specifically, among those residues belonging to the putative receptor binding pocket,
replacing I128 and Y173 with alanine almost abrogates PTZ binding, which is consistent with
a drastic reduction of stabilizing, hydrophobic interactions. The specific nature of the anionic
residue E172 is critical for PTZ binding in that not only its replacement with alanine but also
an exchange with a residue of a similar nature but with a smaller side chain (E172D) results in
the total failure of receptor ligand binding. The role of σ1 amino acids belonging to the SBDLI
and -II domains has been differentiated and rationalized: while a critical role in maintaining
the protein secondary structure of this protein portion with respect to the cellular membrane
has been verified for those residues belonging to the first domain, mutagenesis performed
on residues in the SDBLII region did not affect the affinity of the receptor for PTZ. The
removal of small sequences from the C-terminal part of the protein (e.g., seven residues)
resulted in a substantial decrease in ligand binding activity, as these deletions result in a
general reconfiguration of the receptor binding pocket, ultimately involving those residues
that constitute the PTZ main anchor points. Finally, this combined approach unveiled the
substantial role exerted by other σ1 residues in ligand binding; for instance, the series of
polar residues S125, T127, and R175 all serve to maintain the high affinity of the σ1 receptor
for PTZ, and their replacement with the small, apolar alanine results in a neat decrease in
receptor ligand binding activity.
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Smoothened receptor mutations dictate resistance
to vismodegib in basal cell carcinoma1
The smoothened receptor (SMO) regulates the Hedgehog (Hh) pathway, and the tumor sup-
pressor gene PTCH1 normally functions by repressing the activity of this receptor. Inac-
tivating PTCH1 mutations are frequent in basal cell carcinomas (BCCs) and in a subset
of medulloblastomas, resulting in a constitutive Hh pathway activity. When defects in this
pathway are detected, a treatment with vismodegib—a SMO inhibitor— results in impres-
sive tumor regression. BCC is the most frequent skin cancer, with an incidence increasing in
the last 30 years.182 A secondary mutation that interfere with drug binding, but keeps the
pathway active, has been reported in medulloblastoma patients, conferring drug resistance
to the unlucky patients.
In the work described in this chapter, we reported the molecular mechanisms of resistance
to vismodegib in two different BCC cases: a primary resistance with SMOG497W mutation,
and a secondary resistance with SMOD473Y mutation. Two patients enrolled in a phase II
trial with vismodegib for metastatic and locally advanced BCC (ClinicalTrials.gov Identifier:
1The matherial presented in this chapter was published at: Pricl, S., Cortelazzi, B., Dal Col, V., Marson,
D., Laurini, E., Fermeglia, M., et al. (2014). Molecular Oncology. doi:10.1016/j.molonc.2014.09.003
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NCT01367665) are reported and discussed, as examples of primary and acquired resistance
to the vismodegib, respectively. The in silico analysis, on which I collaborated, demonstrated
that:
• in SMOG497W (primary resistance) there is a partial obstruction of the protein drug
entry site, caused by a conformational rearrangement;
• in SMOD473Y (secondary resistance) there is a direct effect on the binding site geometry,
with a complete disruption of a binding-stabilizing hydrogen bond network.
Patient 1: a case of vismodegib primary resistance in BCCs
The first patient was an 82-years old woman presenting with a BCC metastatic to liver,
lung and bones. After histological confirmation of liver metastasis, she received radiation
therapy to lumbar (L2-L4) and cervical (C3) secondary lesions and she started vismodegib
150 mg/die. After two months of continuous treatment, CT scans showed disease progression
at all sites (primary resistance).
Patient 2: a case of vismodegib acquired resistance in BCCs
The second patient was a 78-years old man presenting with a large (12 cm), ulcerated lesion
of the supra-scapular skin on which a diagnosis of BCC was rendered. Because a surgical
approach would have led to substantial morbidity, this patient was started on a 150 mg/die
vismodegib regimen. The lesion dramatically reduced after the first month, and a complete
clinical response was obtained five months later. However, after eleven months on vismod-
egib, two subcutaneous nodules appeared in the area of the previous lesion. Both lesions
were surgically removed and the histology was consistent with recurrent BCC suggesting the
development of an acquired resistance.
Personal contribution
In this work particularly I focused on the use of steered molecular dynamic (SMD) to study
the entrance of vismodegib into the binding site of the mutated SMOG497W receptor. With
this approach, we were able to give a molecular explanation of the drug resistance conferred
by this mutation, that occur away from the drug-binding site. Also, this work was one of
the first in which I used the lipid membrane simulation protocol employing the lipid11 force
filed. The receptor structure was optimized inserted in an explicit membrane, a better model
of its physiological environment.
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treatment liver metastasis revealed the SMO missense muta-
tion GGG > TGG at exon 9, leading to the amino acid substitu-
tion G497W in the corresponding protein (Figure 1C). Primary
tumor and node metastasis also exhibited the same SMO
missense mutation GGG > TGG at exon 9. By contrast, in the
pre-treatment primary BCC of the second case (acquired resis-
tance, patient 2), no SMOmutations were detected (Figure 1D,
left panel); however the sample obtained from the recurrence
on vismodegib showed the missense mutation GAC > TAC at
exon 8, leading to the single amino acid substitution D473Y
(Figure 1D, right panel) confirming the acquired resistance to
the inhibitor.
3.5. SMOG497W: a distal mutation that obstructs
vismodegib entry to SMO binding site leading to primary
BCC resistance
To gain mechanistic insight regarding the resistance posed by
the mutant SMO proteins we performed a thorough in silico
analysis of the wild type and both clinically relevant SMO
mutant alleles (Figure 2).
As shown in Table 1, the MM/PBSA-derived IC50 for the
SMOG497W/vismodegib complex is 69 nM, a value slightly
higher than the experimental/calculated IC50 derived for the
wild-type (WT) receptor (3 and 2.5 nM, respectively). This
result indicates only a moderate direct effect of the mutation
G497Won the protein affinity for the inhibitor, in keepingwith
a distal position of G497W with respect to the protein drug
binding site.
However, in the presence of the mutant residue the entire
protein region undergoes a conformational rearrangement,
ultimately resulting in a partially obstructed drug entry site.
Our simulations of the binding process of vismodegib to
SMO indeed shows that the vismodegib link with the protein
binding pocket is substantially hindered in the presence of
the G497W mutation (Figure 3AeB and movies).
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.molonc.2014.09.003
This fundamentally implies that, in time, the effective vis-
modegib concentration within the SMOG497W binding site is
significantly lower than in the case of the WT receptor.
Accordingly to our simulation, other molecular mechanisms
are likely contributing to the resistance of SMOG497W to vismo-
degib. A direct comparison of the WT/mutated protein struc-
tures in the area surrounding position 497 revealed that, in
the presence of the tryptophan mutant residue, the entire re-
gion undergoes a conformational rearrangement, thus result-
ing in a narrowing of the protein drug entry site (Figure 3A).
For this reason, in the presence of the G497Wmutation vismo-
degib might be less able to reach the protein binding pocket
and, hence, less effective in its inhibitory activity. Further,
as we can see from Figure 3B and 3C, not only quite a higher
force (and hence energy) is required to vismodegib to reach
its binding site in the presence of the mutant residue
(Figure 3C) but also, and perhaps even more interestingly,
contrarily to the WT case, for SMOG497W the drug has not yet
reached its correct orientation within the protein binding
pocket after the same time lag (Figure 3B andmovies). In prac-
tical terms this fundamentally might imply that, in time, the
effective vismodegib concentration within the SMOG497W
binding site is significantly lower than in the case of the WT
receptor and this, is our opinion, constitutes a novel and effec-
tive mechanism of drug primary resistance.
Figure 1 e Pre-treatment BCC liver metastasis of the first case (patient 1, primary resistance) showed PTCH1 wild type gene (A) and the SMO
G49W mutation (C). Pre-treatment primary tumor and BCC recurrence of the second case (patient 2, acquired resistance) carried the nonsense
Q84Stop PTCH1 mutation (B) while the SMO D473Y mutation was observed only in the recurrence BCC sample (D).
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Figure 17.1: Pre-treatment BCC liver metastasis of the first case (patient 1, primary resis-
tance) showed PTCH1 wild type gene (A) and the SMO G49W mutation (C). Pre-treatment
primary tumor and BCC recurrence of the second case (patient 2, acquired resistance) carried
the nonsense Q84Stop PTCH1 mutation (B) while the SMO D473Y mutation was observed
only in the recurrence BCC sample (D).
17.1 PTCH1 is wild type in vismodegib primary resistance and
mutated in acquired resistance to SMO in BCC
To explore possible mechanisms of Hh pathway activation in these two BCC cases considered,
we first performed PTCH1 sequencing. In the pre-treatment BCC liver metastasis of the case
showing primary resistance (patient 1), no PTCH1 mutation as observed (Figure 17.1A). By
contrast, the pre-treatment primary biopsy of the case showing acquired resistance (patient
2) revealed the PTCH1 nonsense mutation CAG > TAG creating a premature STOP codon
(pQ84) in the exon 2 (Figur 17.1B). This PTCH1 mutation predicts translation to a avily
truncated protein, causing loss of function of the protein and preventing inhibition of SMO.
As expected, the same PTCH1 mutati n was also obs rved in the re urrence sample taken
during vismodegib (Figure 17.1B).
17.2 Two distinct missense SMO mutatio s characterize pri-
mary and secondary vismodegib resistance in BCCs
Next, we evaluated the SMO mutational status. In the case showing primary resistance (pa-
tient 1), the analysis of pretreatment liver metastasis revealed the SMO missense mutation
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Figure 17.2: Cross section of the 3D struc-
ture of the SMO receptor embedded in a
POPC/POPE (2:2) membrane model. Water
is shown as a light cyan surface, while Na+ and
Cl– ions are visible as green and purple spheres,
respectively. Lipids are portrayed as ball-and-
sticks, the polar heads of POPC and POPE
depicted in white and cyan, respectively, while
the corresponding hydrophobic tails are col-
ored green and salmon, respectively. The mem-
brane solvent accessible surface area is high-
lighted in transparent forest green. The SMO
receptor protein is shown as a red ribbon, the
inhibitor binding region being evidenced by a
yellow sphere.
GGG > TGG at exon 9, leading to the amino acid substitution G497W in the correspond-
ing protein (Figure 17.1C). Primary tumor and node metastasis also exhibited the same
SMO missense mutation GGG > TGG at exon 9. By contrast, in the pre-treatment primary
BCC of the second case (acquired resistance, patient 2), no SMO mutations were detected
(Figure 17.1D, left panel); however the sample obtained from the recurrence on vismodegib
showed the missense mutation GAC > TAC at exon 8, leading to the single amino acid
substitution D473Y (Figure 17.1D, right panel) confirming the acquired resistance to the
inhibitor.
17.3 SMOG497W: a distal mutation that obstructs vismodegib
entry to SMO binding site leading to primary BCC resis-
tance
To gain mechanistic insight regarding the resistance posed by the mutant SMO proteins we
performed a thorough in silico analysis of the wild type and both clinically relevant SMO
mutant alleles (Figure 17.2).
As shown in Table 17.1, the MM/PBSA-derived IC50 for the SMOG497W/vismodegib com-
plex is 69 nM, a value slightly higher than the experimental/calculated IC50 derived for the
wild-type (wt) receptor (3 and 2.5 nM, respectively). This result indicates only a moderate
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SMO complex ∆Gbind [kcal mol−1] ∆∆Gbind [kcal mol−1] IC50,calc [nM] IC50,exp [nM]
wt −11.75± 0.11 - 2.5 3
D473H −9.27± 0.10 -2.48 159 -
G497W −9.78± 0.10 -1.97 69 -
Table 17.1: In silico estimation of free energy of binding (∆Gbind) for wt, SMOD473H and
SMOG497W mutant receptors in complex with vismodegib.
Figure 17.3: Zoomed view of the
SMOG497W binding site in complex with
vismodegib. The receptor is shown as a
secondary-structure colored ribbon (orange,
α-helices; purple, β-sheets; gray, coils).
Vismodegib is portrayed as atom-colored
sticks-and-balls (red, O; blue, N; green, Cl;
S, sulfur; gray, C). Residue W497 is evi-
denced as dark red sticks. Hydrogen atoms,
water molecules, ions and counterions are
omitted for clarity.
direct effect of the mutation G497W on the protein affinity for the inhibitor, in keeping with
a distal position of G497W with respect to the protein drug binding site.
However, in the presence of the mutant residue the entire protein region undergoes a con-
formational rearrangement, ultimately resulting in a partially obstructed drug entry site. Our
simulations of the binding process of vismodegib to SMO indeed shows that the vismodegib
link with the protein binding pocket is substantially hindered in the presence of the G497W
mutation (Figure 17.3 and Figure 17.4).
This fundamentally implies that, in time, the effective vismodegib concentration within
the SMOG497W binding site is significantly lower than in the case of the wt receptor. Accord-
ingly to our simulation, other molecular mechanisms are likely contributing to the resistance
of SMOG497W to vismodegib. A direct comparison of the wt/mutated protein structures in
the area surrounding position 497 revealed that, in the presence of the tryptophan mutant
residue, the entire region undergoes a conformational rearrangement, thus resulting in a nar-
rowing of the protein drug entry site (Figure 17.3). For this reason, in the presence of the
G497W mutation vismodegib might be less able to reach the protein binding pocket and,
hence, less effective in its inhibitory activity. Further, as we can see from Figure 17.4 and
Figure 17.6, not only quite a higher force (and hence energy) is required to vismodegib to
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Figure 17.4: SMD snapshots of vismodegib entering the receptor binding pocket. The receptor
is shown as a secondary-structure colored ribbon (orange, α-helices; purple, β-sheets; gray, coils),
while vismodegib is highlighted by its green/red van der Waals surface. Hydrogen atoms, ions,
counterions and water molecules are omitted for clarity.
reach its binding site in the presence of the mutant residue (Figure 17.6) but also, and per-
haps even more interestingly, contrarily to the wt case, for SMOG497W the drug has not yet
reached its correct orientation within the protein binding pocket after the same time lag
(Figure 17.4). In practical terms this fundamentally might imply that, in time, the effective
vismodegib concentration within the SMOG497W binding site is significantly lower than in the
case of the wt receptor and this, is our opinion, constitutes a novel and effective mechanism
of drug primary resistance.
17.4 SMOD473Y: a binding site mutation that directly inter-
feres with vismodegib binding and leads to secondary BCC
resistance
When considering vismodegib in complex with SMOD473Y, the alternative mutant isoform of
SMO detected in the patient specimen with acquired BCC resistance, the calculated IC50
value is 159 nM. This translates into an almost two orders of magnitude decrease in protein
affinity to vismodegib with respect to the wt receptor (Table 17.1), clearly revealing a direct
effect of the mutated residue on vismodegib binding. Notably, D473 is involved with other
two residues (R400 and H470) in a pivotal network of hydrogen bonds that keeps the SMO
binding pocket in the proper shape and stabilizes vismodegib binding (Figure 17.5). The
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Figure 17.5: Zoomed views of the (a) wt and (b) SMOD473Y mutant binding sites in com-
plex with vismodegib. In both panels, the receptor secondary structure is outlined as a semi-
transparent ribbon (orange, α-helices; purple, β-sheets; gray, coils). Vismodegib is portrayed
as atom-colored sticks-and-balls (red, O; blue, N; green, Cl; S, sulfur; gray, C). The triad of
residues involved in the hydrogen-bond network are highlighted colored sticks: R300, dark ma-
genta; H470, olive drab; D/Y473, dark cyan. Y394 is also shown as dark red sticks. H-bonds
are evidenced as black lines.
Figure 17.6: Rupture force vs.
time during the entry process of
vismodegib within the wt (green)
and SMOG497W (red) binding site.
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Figure 17.7: Comparison of vismodegib binding energy contributions from wt and D473Y
SMO residues (a). Comparison between hydrogen bond network stabilization energies for SMO
residues belonging to the wt and SMOD473Y triad residues in the relevant vismodegib complexes
(b). X denotes either D or Y residue at position 473.
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aromatic side chain of the 473Y residue induces a considerable effect on the binding site
geometry and leads to the total disruption of the stabilizing hydrogen bond network; hence,
the inhibitor is shifted from its optimal position (Figure 17.5b). In details, in the presence of
the D473Y mutation, a considerable effect on the binding site geometry is induced, required
for the proper accommodation of the residue aromatic side chain, ultimately leading to the
total disruption of the stabilizing hydrogen bond network. The inhibitor is hence shifted from
its optimal position, the only surviving interaction with the receptor being an intermitted
hydrogen bond with Y394.
These evidences are substantiated by the corresponding per residue energy deconvolution
of the free energy of binding, as shown in Figure 17.7. As we see, all receptor residues mainly
involved in vismodegib binding undergo a severe reduction in the stabilizing contribution to
inhibitor binding in the presence of the mutation (Figure 17.7a). Analogously, upon disrup-
tion of the hydrogen bond network among the SMO triad residues, the relevant, favorable
contribution to receptor/inhibitor binding plummets drastically (Figure 17.7b).
17.5 Further discussion and conclusions
This study presents for the first time clinical, molecular and in silico evidence of primary
and acquired SMO mutation-mediated resistance to vismodegib in BCC. Indeed, the true-cut
based assessment of the SMO G497Wmissense mutation in the liver pre-treatment metastasis
of the first patient exhibiting a progression of disease after two months on vismodegib provides
a good example of primary resistance to the drug. To our knowledge, this SMO mutation has
never been previously described. However, its location in the most frequently mutated SMO
region in BCC (exons 8–10) where other SMO mutations have already shown a constitutive
ligand-independent signal transduction, argues in favor of its oncogenic role.183 Furthermore,
since the lack of a PTCH1 inactivating mutation reinforced this assumption, we sought to
explore the effects exerted by this mutation on the inhibitor binding to the mutated SMO
protein. By in silico experiments we demonstrated that in the presence of the W497 residue
the entire protein region undergoes a conformational rearrangement, which ultimately results
in a partial obstruction of the protein drug entry site. This obstruction, leading to a significant
decreasing of the effective vismodegib concentration within the SMOG497W binding site (lower
than that in the case of the wt receptor), gives a mechanistic explanation for a novel effective
drug resistance. In this respect, the presence of such a SMO mutation in BCC candidate
to vismodegib should definitely be assessed in a greater number of tumors with primary
resistance to the inhibitor. This would eventually allow defining SMOG497W as a possible
biomarker for drug resistance, ultimately resulting in the avoidance of unnecessary toxicity
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effects and costs limitation to non-responding patients.
Concerning the second patient, the presence of the PTCH1 inactivating mutation in the
pre-treatment primary lesion along with absence of SMO mutation could explain the complete
clinical response obtained after six months of continuous vismodegib treatment. Indeed, loss
of PTCH1 function by inactivating mutations relieves normal SMO inhibition leading to the
activation of Hh targets genes. By contrast, the secondary drug resistance observed after
eleven months is likely to be ascribable to the appearance of the missense SMO D473Y
substitution in the recurrence sample. Notably, another amino acid substitution of the same
SMO aspartic acid (D473H) was designated as the mechanism of vismodegib resistance in
medulloblastoma.82 More recently, the detrimental role of D473 in SMO function has been
found out by an elegant in vitro study where, by replacing this aspartic acid residue with
every other amino acid, all mutants were resistant to vismodegib.184 In keeping with these
findings, our analysis of the structural effects of the SMO D473Y clearly revealed a direct
and significant effect on the binding site geometry. The inhibitor is shifted from its optimal
position because the aromatic side chain of the 473Y residue causes the total disruption of
the stabilizing hydrogen bond network involving the D473 with other two residues (R400 and
H470). As for G497W, this SMO point mutation should also be confirmed in a greater series of
BCCs in order to definitely claim its role in secondary resistance to vismodegib. As a general
remark, we acknowledge that the presented evidences could be considered only reasonably
correlated to the resistance phenotype, and indeed our analysis requires further confirmation
through functional analysis. Under this perspective, in vitro and in vivo experiments are
under way in our laboratories to definitively assess the role of these two SMO mutations as
possible biomarkers for vismodegib resistance.
Similarly to medulloblastoma, our data further raise the issue of overcoming the resistance
due to mutation of the drug target. Under this perspective, efforts aimed at identifying second-
generation drugs showing potent activity against SMO mutants are mandatory. To this goal,
a panel of compounds has already been screened in vitro. Several promising antagonists able
to inhibit tumor growth mediated by drug-resistant SMOs were selected in murine allograft
model of medulloblastoma,184 that could be tested also in BCC.
Another strategy worth pursuing is the inhibition of the Hh pathway through other mech-
anisms, the activity of itraconazole or arsenic oxide in blocking vismodegib-resistant BCC
both in vitro and in vivo being prime examples.185, 186
A further alternative approach for facing vismodegib resistance could consist in exploring
other pathways interacting with Hh signaling in BCC and leading to an SMO-independent
stimulation of Gli1 such as EGFR,187 the atypical protein kinase C ι/λ,188 the protein kinase
A189 and, similarly to medulloblastoma, the PI3K pathway.184, 190
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Finally, a clinical point to be stressed is that our two cases of vismodegib resistance
occurred in patients who had not received previous radiation therapy. We cannot exclude
that Hh inhibitor resistance outbreak could be higher in patients having received a radiation
insult, as well as it is possible that alternative therapeutic schedules may alter resistance
mechanism development.190
In this work we discussed two different SMO mutations representing examples of primary
or secondary resistance respectively to vismodegib in two distinct BCC cases. The screening
for the reported SMO mutations and the search for new therapeutic strategies to overcome
related resistance mechanisms represent a priority in the treatment of patients with advanced
BCCs.
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Conclusions & future directions
Gene therapy holds great expectations for the treatment of maladies very different in nature.
With the right medicament it’s possible to tackle problems with a very precise and targeted
approach, limiting considerably the effects on non-damaged compartments. Possibles targets
are first and foremost different kind of cancers, many viral infections, such as HIV, and all
human disease that are caused by a genetic disfunction.
One of the most limiting factors on the use of nucleic acids in this, although promising,
approach is the difficulty of these molecules in reaching their site of action. To this regard,
dendrimers are one of the most interesting vehicles proposed. In continuous development
from 1978, this class of polymers has great potential as nanocarriers for different kind of
drugs, nucleic acids among others. Many of the key properties of dendrimers are strictly
linked to their particular structure, which in turn is affected by the chemical composition of
the molecule. To better understand their morphology and their interactions with other key
macromolecules (e.g., nucleic acids, proteins, lipid membranes) molecular simulations are a
fundamental tool that can give uniques informations.
In this regard, we saw the morphological characterization of two new families of den-
drimers, viologen and carbosilane. In particular a back-folding phenomena was observed for
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the viologen dendrimers of higher generations. To better understand the binding interac-
tions of the dendrimers with their partner, we enlightened the importance of a parameter
that can assess the performance of each active individual dendrimer branch directly involved
and interacting. With respect to carbosilane dendrimers, this parameter was the normalized
effective binding energy ∆Gbind,eff/Neff .
For the first time, steered molecular dynamics was used for the creation of the complexes
between the oligodeoxynucleotide and the carbosilane dendrimer, overtaking the lacking of
good docking procedures for this kind of molecules.
We changed then the point of view in the study of carrier-cargo binding and efficacy in
siRNA delivery. We studied the effects of different—in length and structure—overhangs in
the transfection capability of a G5-siRNA complex. A primary parameter was found to be
the flexibility of the overhangs, to achieve a good binding but also an optimal siRNA release.
A lipid membranes simulation protocol was also developed, and will be used to shed light
on dendrimer-membrane interactions, one of the most important property for dendrimers
efficacy and toxicology.
Many of the techniques examined in these works were also used in some side projects in
which our research group was involved. One of the main fields of work of our group is the
σ1 receptor, and the lipid membrane simulation protocol was used to refine our σ1 receptor
3D homology model recently developed. Furthermore, we used this optimized model of the
receptor to give a better description of its binding site. Also, in the study of two different
mutations of the smothered (SMO) receptor, we simulated the protein in a lipid membrane
to have a better representation of its physiological conditions. The steered molecular dynam-
ics technique was fundamental in the study of the SMOG497W mutation, giving a possible
explanation of the resistance to the drug vismodegib conferred by this mutation.
As we have seen, computer simulations today are an important tool in the hands of
researchers in different fields. The applicability of these techniques to different objects of
study also gives a big opportunity to the researcher to contribute in key aspects of different
projects. Increase in computational power and refinement of algorithms are making feasible
the study of different problems at an increasing precision level. In the near future our intention
is to use the lipid membrane model developed as a tool to study the interactions of dendrimer
with biological membranes.
Differentiate in the binding of similar dendrimers with their cargo is also a delicate task,
for which often the MM/PBSA approach is used. This method has some limitation in the
case of highly charged molecules like dendrimers and nucleic acids, and so it will be important
to implement other estimation of the free energy of binding, like Free Energy Perturbation
methods. Currently we are implementing these techniques in the “simpler” study of B-Raf
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ligands, with in mind the applicability of the methodology in the study of carrier-cargo
complexes.
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Acronyms
ADL average dynamic length. 117, 119, 134, 135, 138, 143
ADV average dynamic volume. 141
APL area per lipid. 53
ASM experimental alanine scanning. 126
BCC basal cell carcinoma. 22, 23, 147–150, 152, 154–156
CAS computational alanine scanning. 126, 127
CNV copy number variation. 49
COM center of mass. 61, 62, 91, 100, 102
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine. 14
DNA deoxyribonucleic acid. 46, 49
dsRNA double-stranded RNA. 6
EB ethidium bromide. 82, 84
EDA ethylenediamine-core. 96, 98–100
FDA US Food and Drug Administration. 4, 23
HB hydrogen bond. 117, 119, 124
HBA hydrogen bond acceptor. 116
Hh Hedgehog. 22, 23, 147, 149, 155, 156
HIV Human Immunodeficiency Virus. 4, 5, 16, 87
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HSA human serum albumin. 13, 91, 93
Hsp27 heat shock protein 27. 72, 73
HSV Herpes Simplex Virus. 16, 87
HY hydrophobic. 116
HYAr hydrophobic aromatic. 116
INT interface area. 105
LJ Lennard-Jones. 47
MD molecular dynamics. 29, 32, 33, 37, 44, 46, 47, 52, 55, 58, 65, 75, 78, 80, 83, 88, 91, 93,
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NPT constant pressure and temperature. 47, 52
NSAID nonsteroidal anti-inflammatory drug. 18
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PBC periodic boundary conditions. 45, 46
PEI polyethyleneimine. 8, 79
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PTGS post-transcriptional gene silencing. 6
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RISC RNA-Induced Silencing Complex. 6
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RNAi RNA interference. 5, 6, 82
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SB salt bridge. 117, 119, 124
SBDLI steroid binding domain-like I. 139, 141, 143, 145
SBDLII steroid binding domain-like II. 116, 139, 141
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siRNA small interfering RNA. 4–6, 8, 71–85
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